WO2014080730A1 - 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法 - Google Patents
糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法 Download PDFInfo
- Publication number
- WO2014080730A1 WO2014080730A1 PCT/JP2013/079408 JP2013079408W WO2014080730A1 WO 2014080730 A1 WO2014080730 A1 WO 2014080730A1 JP 2013079408 W JP2013079408 W JP 2013079408W WO 2014080730 A1 WO2014080730 A1 WO 2014080730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- glycosylated
- salt
- compound
- Prior art date
Links
- 125000005647 linker group Chemical group 0.000 title claims abstract description 315
- 150000001875 compounds Chemical class 0.000 title claims abstract description 211
- 239000013543 active substance Substances 0.000 title claims abstract description 207
- 150000003839 salts Chemical class 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title claims description 48
- 235000000346 sugar Nutrition 0.000 claims abstract description 329
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 125000004432 carbon atom Chemical group C* 0.000 claims description 360
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 264
- 229940024606 amino acid Drugs 0.000 claims description 230
- 235000001014 amino acid Nutrition 0.000 claims description 230
- 150000001413 amino acids Chemical class 0.000 claims description 225
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 186
- 229920001184 polypeptide Polymers 0.000 claims description 184
- 229910052799 carbon Inorganic materials 0.000 claims description 148
- 150000001721 carbon Chemical group 0.000 claims description 134
- -1 Boc group Chemical group 0.000 claims description 130
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 116
- 125000003277 amino group Chemical group 0.000 claims description 115
- 125000000217 alkyl group Chemical group 0.000 claims description 104
- 125000003118 aryl group Chemical group 0.000 claims description 93
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 91
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 76
- 125000000623 heterocyclic group Chemical group 0.000 claims description 74
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 53
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 125000002252 acyl group Chemical group 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 43
- 230000013595 glycosylation Effects 0.000 claims description 42
- 238000006206 glycosylation reaction Methods 0.000 claims description 42
- 239000011347 resin Substances 0.000 claims description 42
- 229920005989 resin Polymers 0.000 claims description 42
- 235000018102 proteins Nutrition 0.000 claims description 41
- 229910052757 nitrogen Inorganic materials 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 36
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 33
- 235000021310 complex sugar Nutrition 0.000 claims description 31
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 24
- 238000006467 substitution reaction Methods 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 21
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 230000018044 dehydration Effects 0.000 claims description 16
- 238000006297 dehydration reaction Methods 0.000 claims description 16
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 16
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical group ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 claims description 15
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 15
- 239000000460 chlorine Substances 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 13
- 229920001222 biopolymer Polymers 0.000 claims description 13
- 230000008878 coupling Effects 0.000 claims description 13
- 238000010168 coupling process Methods 0.000 claims description 13
- 238000005859 coupling reaction Methods 0.000 claims description 13
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 238000009833 condensation Methods 0.000 claims description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 9
- 230000005494 condensation Effects 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 9
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 8
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 235000008521 threonine Nutrition 0.000 claims description 6
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 5
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 claims description 3
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims description 3
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims description 3
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 3
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 3
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims description 3
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims description 3
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 claims description 3
- WEDKTMOIKOKBSH-UHFFFAOYSA-N 4,5-dihydrothiadiazole Chemical compound C1CN=NS1 WEDKTMOIKOKBSH-UHFFFAOYSA-N 0.000 claims description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 3
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 3
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims description 3
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000021615 conjugation Effects 0.000 claims description 3
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 claims description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 3
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 3
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 claims description 3
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims description 3
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 claims description 3
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 claims description 3
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 3
- 150000003852 triazoles Chemical class 0.000 claims description 3
- 238000002255 vaccination Methods 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 150
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 82
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 239000000126 substance Substances 0.000 description 47
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 45
- 238000003776 cleavage reaction Methods 0.000 description 45
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 44
- 230000007017 scission Effects 0.000 description 42
- 229940125904 compound 1 Drugs 0.000 description 35
- 239000007864 aqueous solution Substances 0.000 description 31
- 150000008163 sugars Chemical class 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 239000003814 drug Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 125000006239 protecting group Chemical group 0.000 description 28
- 229940079593 drug Drugs 0.000 description 27
- 239000000839 emulsion Substances 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 21
- 238000005406 washing Methods 0.000 description 21
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 20
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 20
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 20
- 235000009582 asparagine Nutrition 0.000 description 20
- 229960001230 asparagine Drugs 0.000 description 20
- 239000003480 eluent Substances 0.000 description 20
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 19
- 125000001424 substituent group Chemical group 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 18
- QLVGSBXIQFERFK-NBBYSTNSSA-N C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 Chemical class C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 QLVGSBXIQFERFK-NBBYSTNSSA-N 0.000 description 17
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 17
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 150000004985 diamines Chemical class 0.000 description 17
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 17
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 16
- 229960005486 vaccine Drugs 0.000 description 16
- 0 CN(*)C(*1)(*2)C12NC(*C(IC)=O)=O Chemical compound CN(*)C(*1)(*2)C12NC(*C(IC)=O)=O 0.000 description 15
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 12
- 229910052794 bromium Inorganic materials 0.000 description 12
- 150000001720 carbohydrates Chemical group 0.000 description 12
- 229910052731 fluorine Inorganic materials 0.000 description 12
- 239000011737 fluorine Substances 0.000 description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 11
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 11
- 150000008065 acid anhydrides Chemical class 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 10
- 210000000692 cap cell Anatomy 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical compound C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 9
- 239000008351 acetate buffer Substances 0.000 description 9
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 9
- 238000006482 condensation reaction Methods 0.000 description 9
- 238000003379 elimination reaction Methods 0.000 description 9
- 229910052740 iodine Inorganic materials 0.000 description 9
- 239000011630 iodine Substances 0.000 description 9
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 8
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 8
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical group ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 229950006780 n-acetylglucosamine Drugs 0.000 description 8
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 7
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 7
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 6
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000012317 TBTU Substances 0.000 description 6
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 6
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 5
- SFYDWLYPIXHPML-UHFFFAOYSA-N 3-nitro-1-(2,4,6-trimethylphenyl)sulfonyl-1,2,4-triazole Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)N1N=C([N+]([O-])=O)N=C1 SFYDWLYPIXHPML-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 5
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 4
- HXOYWJCDYVODON-UHFFFAOYSA-N 4-[4-(hydroxymethyl)-3-methoxyphenoxy]butanoic acid Chemical compound COC1=CC(OCCCC(O)=O)=CC=C1CO HXOYWJCDYVODON-UHFFFAOYSA-N 0.000 description 4
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 229940050176 methyl chloride Drugs 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 150000004053 quinones Chemical class 0.000 description 4
- 235000004400 serine Nutrition 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108010024976 Asparaginase Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102000051366 Glycosyltransferases Human genes 0.000 description 3
- 108700023372 Glycosyltransferases Proteins 0.000 description 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003118 drug derivative Substances 0.000 description 3
- 125000006575 electron-withdrawing group Chemical group 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000005561 phenanthryl group Chemical group 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000002110 toxicologic effect Effects 0.000 description 3
- 231100000027 toxicology Toxicity 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 2
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 2
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 2
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 2
- VUCNQOPCYRJCGQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenoxy]acetic acid Chemical compound OCC1=CC=C(OCC(O)=O)C=C1 VUCNQOPCYRJCGQ-UHFFFAOYSA-N 0.000 description 2
- LFXANAKASAMGLY-UHFFFAOYSA-N 2-imidazolidin-1-ylethanamine Chemical compound NCCN1CCNC1 LFXANAKASAMGLY-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- XXYNZSATHOXXBJ-UHFFFAOYSA-N 4-hydroxyisoindole-1,3-dione Chemical compound OC1=CC=CC2=C1C(=O)NC2=O XXYNZSATHOXXBJ-UHFFFAOYSA-N 0.000 description 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 102400000113 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 229930182847 D-glutamic acid Natural products 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZRWPUFFVAOMMNM-UHFFFAOYSA-N Patulin Chemical compound OC1OCC=C2OC(=O)C=C12 ZRWPUFFVAOMMNM-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 231100000674 Phytotoxicity Toxicity 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000016127 added sugars Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960001042 dexmethylphenidate Drugs 0.000 description 2
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- BGHSOEHUOOAYMY-JTZMCQEISA-N ghrelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)CN)C1=CC=CC=C1 BGHSOEHUOOAYMY-JTZMCQEISA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 150000002337 glycosamines Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 2
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 150000002704 mannoses Chemical class 0.000 description 2
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012434 nucleophilic reagent Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229960001634 ritodrine Drugs 0.000 description 2
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- WMSUFWLPZLCIHP-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 9h-fluoren-9-ylmethyl carbonate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)ON1C(=O)CCC1=O WMSUFWLPZLCIHP-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- CSMYOORPUGPKAP-IBGZPJMESA-N (2r)-3-(acetamidomethylsulfanyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CSCNC(=O)C)C(O)=O)C3=CC=CC=C3C2=C1 CSMYOORPUGPKAP-IBGZPJMESA-N 0.000 description 1
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- XXMYDXUIZKNHDT-QNGWXLTQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-QNGWXLTQSA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- KJYAFJQCGPUXJY-UMSFTDKQSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-(tritylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KJYAFJQCGPUXJY-UMSFTDKQSA-N 0.000 description 1
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 description 1
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 description 1
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 description 1
- UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- PNIWLNAGKUGXDO-LNCRCTFVSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r)-5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical group O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 PNIWLNAGKUGXDO-LNCRCTFVSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6r,7s)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 1
- VQHRZZISQVWPLK-UIRGBLDSSA-N (7s,9s)-7-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@H](O)C[C@H](O[C@@H]2C3=C(O)C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)O[C@H]1C VQHRZZISQVWPLK-UIRGBLDSSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- AMRUZIPWZWKBTL-UHFFFAOYSA-N 1-(2,5-dimethylpiperazin-1-yl)propan-2-amine Chemical compound CC(N)CN1CC(C)NCC1C AMRUZIPWZWKBTL-UHFFFAOYSA-N 0.000 description 1
- BJPWBQHXJAUDQL-UHFFFAOYSA-N 1-(2-aminoethyl)piperidin-3-ol Chemical compound NCCN1CCCC(O)C1 BJPWBQHXJAUDQL-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- NJEGACMQQWBZTP-UHFFFAOYSA-N 1-piperazin-1-ylpropan-2-amine Chemical compound CC(N)CN1CCNCC1 NJEGACMQQWBZTP-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- OFJBYLCQNJHFMI-UHFFFAOYSA-N 2,5-dihydro-1,2-oxazole Chemical compound C1ONC=C1 OFJBYLCQNJHFMI-UHFFFAOYSA-N 0.000 description 1
- BPWDBFGTCPZSQJ-UHFFFAOYSA-N 2-(1,4-diazepan-1-yl)ethanamine Chemical compound NCCN1CCCNCC1 BPWDBFGTCPZSQJ-UHFFFAOYSA-N 0.000 description 1
- ISADKHQORCWQLD-UHFFFAOYSA-N 2-(2-aminoethylamino)ethanethiol Chemical compound NCCNCCS ISADKHQORCWQLD-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- CYOIAXUAIXVWMU-UHFFFAOYSA-N 2-[2-aminoethyl(2-hydroxyethyl)amino]ethanol Chemical compound NCCN(CCO)CCO CYOIAXUAIXVWMU-UHFFFAOYSA-N 0.000 description 1
- LXAVCFDWHMZCJH-UHFFFAOYSA-N 2-[4-(hydroxymethyl)-3-methoxyphenoxy]butanoic acid Chemical compound CCC(C(O)=O)OC1=CC=C(CO)C(OC)=C1 LXAVCFDWHMZCJH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000004680 2-methylbutylcarbonyl group Chemical group CC(CC(=O)*)CC 0.000 description 1
- AFQWAHPEBNLBGZ-UHFFFAOYSA-N 2-n-(2-aminoethyl)benzene-1,2-diamine Chemical compound NCCNC1=CC=CC=C1N AFQWAHPEBNLBGZ-UHFFFAOYSA-N 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- FERWCFYKULABCE-UHFFFAOYSA-N 3-(2-aminoethoxymethyl)-2,5,9-trimethylfuro[3,2-g]chromen-7-one Chemical compound O1C(=O)C=C(C)C2=C1C(C)=C1OC(C)=C(COCCN)C1=C2 FERWCFYKULABCE-UHFFFAOYSA-N 0.000 description 1
- KTLIZDDPOZZHCD-UHFFFAOYSA-N 3-(2-aminoethylamino)propan-1-ol Chemical compound NCCNCCCO KTLIZDDPOZZHCD-UHFFFAOYSA-N 0.000 description 1
- KENXEMKVFFJZFQ-UHFFFAOYSA-N 3-hydroxypyrido[3,2-d]triazin-4-one Chemical compound C1=CN=C2C(=O)N(O)N=NC2=C1 KENXEMKVFFJZFQ-UHFFFAOYSA-N 0.000 description 1
- LRZCBJYTBUZEFK-UHFFFAOYSA-N 3-n-(2-aminoethyl)benzene-1,3-diamine Chemical compound NCCNC1=CC=CC(N)=C1 LRZCBJYTBUZEFK-UHFFFAOYSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- KMMBJDNXKWZSLX-UHFFFAOYSA-N 4-(2-aminoethyl)piperazin-2-one Chemical compound NCCN1CCNC(=O)C1 KMMBJDNXKWZSLX-UHFFFAOYSA-N 0.000 description 1
- FCTDPDWTVUINMD-UHFFFAOYSA-N 4-(2-aminoethylamino)benzoic acid Chemical compound NCCNC1=CC=C(C(O)=O)C=C1 FCTDPDWTVUINMD-UHFFFAOYSA-N 0.000 description 1
- BFTCOOLIWWXDEJ-UHFFFAOYSA-N 4-(2-aminoethylamino)phenol Chemical compound NCCNC1=CC=C(O)C=C1 BFTCOOLIWWXDEJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- TVARKMCEMIFLIP-UHFFFAOYSA-N 4-n-(2-aminoethyl)benzene-1,4-diamine Chemical compound NCCNC1=CC=C(N)C=C1 TVARKMCEMIFLIP-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- WIRXLUOGFMRKEE-UHFFFAOYSA-N 6-[4-(hydroxymethyl)-3-methoxyphenoxy]hexanoic acid Chemical compound COC1=CC(OCCCCCC(O)=O)=CC=C1CO WIRXLUOGFMRKEE-UHFFFAOYSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- XFTWUNOVBCHBJR-UHFFFAOYSA-N Aspergillomarasmine A Chemical group OC(=O)C(N)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O XFTWUNOVBCHBJR-UHFFFAOYSA-N 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- ABFNTRQPWNXUHA-VEVJRHMJSA-N C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(CC(N)=O)CCCC(=O)NCCCC(=O)N1)=O)[C@H](O)C)C1=CC=CC=C1 Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(CC(N)=O)CCCC(=O)NCCCC(=O)N1)=O)[C@H](O)C)C1=CC=CC=C1 ABFNTRQPWNXUHA-VEVJRHMJSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- SCPSTYYXFAKZCS-UHFFFAOYSA-N C1(=C(C(=CC(=C1)C)C)S(=O)(=O)N1N=C(N=C1)[N+](=O)[O-])C.C1(=C(C(=CC(=C1)C)C)S(=O)(=O)N1N=C(N=C1)[N+](=O)[O-])C Chemical compound C1(=C(C(=CC(=C1)C)C)S(=O)(=O)N1N=C(N=C1)[N+](=O)[O-])C.C1(=C(C(=CC(=C1)C)C)S(=O)(=O)N1N=C(N=C1)[N+](=O)[O-])C SCPSTYYXFAKZCS-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 102400000242 Dynorphin A(1-17) Human genes 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- XRHVZWWRFMCBAZ-UHFFFAOYSA-L Endothal-disodium Chemical compound [Na+].[Na+].C1CC2C(C([O-])=O)C(C(=O)[O-])C1O2 XRHVZWWRFMCBAZ-UHFFFAOYSA-L 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229930182473 O-glycoside Natural products 0.000 description 1
- OODJOWAYQOSBKJ-UHFFFAOYSA-N O=C(C1=C2C(CCCC3)C3=C3C1CCCC3)OC2=O Chemical compound O=C(C1=C2C(CCCC3)C3=C3C1CCCC3)OC2=O OODJOWAYQOSBKJ-UHFFFAOYSA-N 0.000 description 1
- DZJRPRNTIZUPQW-UHFFFAOYSA-N O=C(C1=C2C(CCCC3)C3C3C1CCCC3)OC2=O Chemical compound O=C(C1=C2C(CCCC3)C3C3C1CCCC3)OC2=O DZJRPRNTIZUPQW-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 108700036316 PTR 3173 Proteins 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710170513 Retinoic acid receptor responder protein 2 Proteins 0.000 description 1
- 102100033914 Retinoic acid receptor responder protein 2 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000004189 Salinomycin Substances 0.000 description 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010001957 Ularitide Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 102400001279 Urodilatin Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000004188 Virginiamycin Substances 0.000 description 1
- 108010080702 Virginiamycin Proteins 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 125000004062 acenaphthenyl group Chemical group C1(CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960000959 amineptine Drugs 0.000 description 1
- ONNOFKFOZAJDHT-UHFFFAOYSA-N amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003036 amisulpride Drugs 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229950004267 amotosalen Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 1
- 229950006334 apramycin Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229960002403 atosiban Drugs 0.000 description 1
- 108700007535 atosiban Proteins 0.000 description 1
- VWXRQYYUEIYXCZ-OBIMUBPZSA-N atosiban Chemical compound C1=CC(OCC)=CC=C1C[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)CSSCCC(=O)N1 VWXRQYYUEIYXCZ-OBIMUBPZSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 108010033394 biphalin Proteins 0.000 description 1
- DESSEGDLRYOPTJ-VRANXALZSA-N biphalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NNC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 DESSEGDLRYOPTJ-VRANXALZSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 238000005864 bromoacetylation reaction Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960003362 carbutamide Drugs 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- PUAQLLVFLMYYJJ-ZETCQYMHSA-N cathinone Chemical compound C[C@H](N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-ZETCQYMHSA-N 0.000 description 1
- 229950002698 cathinone Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 108700005721 conestat alfa Proteins 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- LINOMUASTDIRTM-QGRHZQQGSA-N deoxynivalenol Chemical compound C([C@@]12[C@@]3(C[C@@H](O)[C@H]1O[C@@H]1C=C(C([C@@H](O)[C@@]13CO)=O)C)C)O2 LINOMUASTDIRTM-QGRHZQQGSA-N 0.000 description 1
- 229930002954 deoxynivalenol Natural products 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108010051768 des-n-octanoyl ghrelin Proteins 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012414 factor viia Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- 229960003704 framycetin Drugs 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003008 fumonisin Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229950003053 icofungipen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- PVTHJAPFENJVNC-MHRBZPPQSA-N kasugamycin Chemical compound N[C@H]1C[C@H](NC(=N)C(O)=O)[C@@H](C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H]1O PVTHJAPFENJVNC-MHRBZPPQSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 229940042470 lyme disease vaccine Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- DTSDBGVDESRKKD-UHFFFAOYSA-N n'-(2-aminoethyl)propane-1,3-diamine Chemical compound NCCCNCCN DTSDBGVDESRKKD-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004676 n-butylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229930183344 ochratoxin Natural products 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 229940045258 pancrelipase Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- RKOUGZGFAYMUIO-RITPCOANSA-N pdl 118 Chemical compound N[C@H]1CC(=C)C[C@H]1C(O)=O RKOUGZGFAYMUIO-RITPCOANSA-N 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
- 229960003209 phenmetrazine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950000615 sabarubicin Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960001548 salinomycin Drugs 0.000 description 1
- 235000019378 salinomycin Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
- 229960002758 sermorelin Drugs 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000468 sulfalene Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N sulfamethopyrazine Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- AUHHYELHRWCWEZ-UHFFFAOYSA-N tetrachlorophthalic anhydride Chemical compound ClC1=C(Cl)C(Cl)=C2C(=O)OC(=O)C2=C1Cl AUHHYELHRWCWEZ-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 tetrodotoxin Drugs 0.000 description 1
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- MBMQEIFVQACCCH-UHFFFAOYSA-N trans-Zearalenon Natural products O=C1OC(C)CCCC(=O)CCCC=CC2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-UHFFFAOYSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- IUCCYQIEZNQWRS-DWWHXVEHSA-N ularitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 IUCCYQIEZNQWRS-DWWHXVEHSA-N 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 229950001272 viomycin Drugs 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229960003842 virginiamycin Drugs 0.000 description 1
- 235000019373 virginiamycin Nutrition 0.000 description 1
- LINOMUASTDIRTM-UHFFFAOYSA-N vomitoxin hydrate Natural products OCC12C(O)C(=O)C(C)=CC1OC1C(O)CC2(C)C11CO1 LINOMUASTDIRTM-UHFFFAOYSA-N 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a glycosylated linker, a compound comprising a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof, and a method for producing them.
- a physiologically active substance is to be administered to a living body as a drug, there are those that cannot be (sufficiently) sterilized by filter because of its low water solubility. In addition, there are those that are difficult to administer to a living body by dissolving a physiologically active substance in an aqueous solution or an emulsion prepared from the aqueous solution.
- a carrier-drug conjugate (so-called drug derivative) is known in which a carrier having high water solubility is covalently bonded to a drug.
- Known carriers include hydrophilic amino acid sequences and polyethylene glycol (PEG).
- the three-dimensional structure of such a drug derivative is different from that of the original drug, and therefore has different pharmacokinetic, immunogenic, toxicological or pharmacological properties, etc. compared to the original drug. Indicates. For example, when a drug derivative is used as a vaccine, it is known that its antigenicity generally decreases as compared to an unmodified drug.
- Non-patent Document 1 a drug to which PEG is added as a carrier (PEGylation) has biodegradation resistance. Therefore, if the PEGylated drug is continuously administered in the living body, it accumulates in the living body and may cause phytotoxicity to the living body (Patent Document 1). Furthermore, PEG has a molecular weight distribution (polydisperse nature). Therefore, when a drug is PEGylated, the attachment position or molecular weight of the added PEG is different, and thus many monomer isoforms having different activities (proteins with different structures) are generated. These generated isoforms may compete with each other for binding of a drug to a receptor molecule (Non-patent Document 1).
- a carrier-linker-drug conjugate in which a drug and a carrier are bonded via a linker moiety has also been developed. It is designed so that at the target location (such as in the blood), the bond between the carrier-linker moiety and the drug is cleaved and the drug itself is released. Light or enzymatic cleavage has been used as a trigger to break such bonds. However, it is difficult to irradiate a target site in a living body, and there is a concern about damage to the living body due to light. In the case of enzymatic cleavage, it is known that the amount of enzyme varies greatly between individuals and administration sites. Therefore, there arises a problem that variations in the effects of drug treatment occur.
- Patent Document 2 does not pay attention to the biodegradability of the carrier. Furthermore, no mention is made of the water solubility of the carrier-linker-drug conjugate.
- An object of the present invention is to provide a compound containing a carrier linker moiety and a physiologically active substance moiety or a salt thereof, wherein the carrier is biodegradable and water-soluble.
- the present inventors have adopted a sugar chain as a carrier and focused on the structure of a carrier-linker having a specific structure. Or a salt thereof.
- the object of the present invention is to A compound comprising a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof,
- the compound is represented by the following formula (A): R 1 -X (A) here, R 1 means a glycosylated linker moiety;
- R 1 is represented by the following formula (I): [In the formula (I), R 2 and R 3 are each independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms, or an aryl group having 5 to 16 carbon atoms (provided that both R 2 and R 3 are R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered heterocycle, At least one hydrogen atom in the alkyl group, the aryl group, or the heterocyclic ring is substituted with a sugar chain, a glycosylated amino acid, or a glycosylated polypeptide;
- Each R 4 is independently a hydrogen atom, an alkyl group having
- R 5A and R 5B each independently represent a hydrogen atom, a halogen atom, , Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substitution Or an unsubstituted phenyl group or a benzyl group, R 5C and R 5D are a carbon atom to which R 5C is bonded, a carbon atom to which R 5D is bonded, a cycloalkyl having 4 to 16 carbon atoms, a cycloalkenyl having 5 to 16 carbon atoms, a carbon atom having 7 to Forming 13 bicyclyls
- X means a physiologically active substance moiety;
- the physiologically active substance has at least one amino group, hydroxy group, thiol group, or carboxy group,
- the bond of X to R 1 is a bond in the at least one amino group, hydroxy group, thiol group, or carboxy group. This is accomplished by providing a compound or salt thereof.
- the compound of the present invention or a salt thereof is R 1 is represented by the following formula (I): [In the formula (I), R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered heterocycle,
- the heterocyclic ring is aziridine, azetidine, pyrroline, pyrrole, imidazole, imidazoline, pyrazole, pyrazoline, isoxazoline, thiazoline, isothiazoline, thiadiazoline, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, Selected from the group consisting of thiadiazolidine, piperazine, piperidine, morpholine, thiomorpholine, thiazine, tetrazole, triazole, triazolidine, tetrazolidine, azepane, diazepane, a
- Each R 4 is independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms; Y is And here, R 5A and R 5B together with the carbon atom to which R 5A is bonded, the carbon atom to which R 5B is bonded, are aryl having 5 to 16 carbon atoms, cycloalkenyl having 5 to 16 carbon atoms, and 7 to 13 carbon atoms.
- R 5A and R 5B each independently represent a hydrogen atom, a halogen atom, , Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substitution Or an unsubstituted phenyl group or a benzyl group, R 5C and R 5D are a carbon atom to which R 5C is bonded, a carbon atom to which R 5D is bonded, a cycloalkyl having 4 to 16 carbon atoms, a cycloalkenyl having 5 to 16 carbon atoms, a carbon atom having 7 to Forming 13 bicyclyls
- R 1 is represented by the following formula (II): [In the formula (II), Each R 4 is independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms; Y is And here, R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form an aryl having 5 to 16 carbon atoms, or R 5A and R 5B are Is also a hydrogen atom, R 5C and R 5D , together with the carbon atom to which R 5C is bonded, the carbon atom to which R 5D is bonded, form cyclohexyl or norbornyl; R 6 is a sugar chain, a glycosylated amino acid or a glycosylated polypeptide; A wavy line shows the coupling
- the compound of the present invention or a salt thereof is The physiologically active substance has a peptide portion
- the bond of X to R 1 is (1) an amide bond in the N-terminal amino group of the peptide portion of the physiologically active substance, (2) an ester bond in a hydroxy group present on the side chain of a serine residue, threonine residue or tyrosine residue of the peptide part of the physiologically active substance (provided that the peptide part of the physiologically active substance is a serine residue , Only if it has a threonine or tyrosine residue) (3) An acid anhydride bond in the carboxy group present in the side chain of the aspartic acid residue or glutamic acid residue of the peptide part of the physiologically active substance (provided that the peptide part of the physiologically active substance is an aspartic acid residue Or only if it has glutamic acid residues), (4) An amide bond in the amino group present in the side chain of the lysine residue,
- R 1 is represented by the following formula (III): [In the formula (III), Each R 4 is independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms; Y is And here, R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form an aryl having 5 to 16 carbon atoms, or R 5A and R 5B are Is also a hydrogen atom, R 5C and R 5D , together with the carbon atom to which R 5C is bonded, the carbon atom to which R 5D is bonded, form cyclohexyl or norbornyl; R 7 is —S—CH 2 —CONH-sugar chain or —CONH-sugar chain; R 8 is a hydrogen atom, a carbamate protecting group such as an acyl group having 1 to 16
- R 1 is represented by the following formula (IV): [In the formula (IV), Each R 4 is independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms; R 7 is —S—CH 2 —CONH-sugar chain or —CONH-sugar chain; R 8 is a hydrogen atom, a carbamate protecting group such as an acyl group having 1 to 16 carbon atoms, Fmoc group, Boc group, Z group, Troc group, or Alloc group, sugar chain, amino acid, polypeptide, glycosylated amino acid Or a glycosylated polypeptide, R 9 is independently hydrogen atom, halogen, cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl having 1 to 3 carbon atoms.
- R 4 is independently a hydrogen atom, an al
- the physiologically active substance has at least one amino group;
- the bond of X to R 1 is a bond in the at least one amino group; It is preferable.
- the compound of the present invention or a salt thereof is It is preferable that all four R 4 in the formula (I), (II), (III) or (IV) is a hydrogen atom.
- the compound of the present invention or a salt thereof is At least one R 9 in the formula (IV) is halogen; It is preferable.
- the compound of the present invention or a salt thereof is The four R 9 in the formula (IV) are all chlorine. It is preferable.
- the compound of the present invention or a salt thereof is in the “glycosylated amino acid or glycosylated polypeptide”, the sugar chain is bound to Asn or Cys in the amino acid or polypeptide. It is preferable.
- the compound of the present invention or a salt thereof is in the “glycosylated amino acid or glycosylated polypeptide”, the sugar chain is bound to the amino acid or polypeptide without a linker. It is preferable.
- the compound of the present invention or a salt thereof is
- the sugar chain in the “sugar chain, glycosylated amino acid or glycosylated polypeptide” consists of four or more sugar residues. It is preferable.
- the compound of the present invention or a salt thereof is
- the sugar chain in the “sugar chain, glycosylated amino acid or glycosylated polypeptide” is a two-chain complex sugar chain, a three-chain complex sugar chain, or a four-chain complex sugar chain. It is preferable.
- the compound of the present invention or a salt thereof is
- the sugar chain is a double-stranded complex type sugar chain selected from the group consisting of a dicialo sugar chain, a monosialo saccharide chain, an asialog saccharide chain, a diglucnac saccharide chain, and a dimannose saccharide chain. It is preferable.
- the compound of the present invention or a salt thereof is
- the sugar chain in the “sugar chain, glycosylated amino acid or glycosylated polypeptide” is represented by the following formula: [Wherein R 10 and R 11 are the same or different, Indicates. Ac represents an acetyl group. ] Is a sugar chain represented by It is preferable.
- the compound of the present invention or a salt thereof is
- the physiologically active substance is a low molecular weight physiologically active substance or a biopolymer, It is preferable.
- the compound of the present invention or a salt thereof is The biopolymer is selected from the group consisting of proteins, polypeptides, polynucleotides, and peptide nucleic acids. It is preferable.
- the compound of the present invention or a salt thereof is Compared to unmodified physiologically active substances, it has improved water solubility, It is preferable.
- the compound of the present invention or a salt thereof is The improved water solubility is 10 to 1,000,000 times in molar concentration compared to the “unmodified physiologically active substance”. It is preferable.
- the compound of the present invention or a salt thereof is The glycosylated linker moiety is autocatalytically cleaved depending on pH and / or temperature; It is preferable.
- any combination of one or more features of the present invention described above is also a compound of the present invention or a salt thereof.
- the present invention provides: The sugar chain in the compound or salt thereof is substantially uniform. A composition is provided.
- composition of the present invention is preferably a pharmaceutical composition.
- the present invention provides: (I) the compound or a salt thereof, and (II) a pharmacologically acceptable carrier, A pharmaceutical composition is provided.
- the pharmaceutical composition of the present invention in one aspect, The physiologically active substance exerts its activity promptly after administration to a subject, It is preferable.
- the pharmaceutical composition of the present invention in one aspect, Used for vaccination, It is preferable.
- any combination of one or more features of the present invention described above is also a (pharmaceutical) composition of the present invention.
- the present invention provides: A method for producing a compound comprising a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof,
- the physiologically active substance includes a peptide portion having at least one amino group, hydroxy group, thiol group, or carboxy group
- the following steps (A) synthesizing the peptide moiety on a resin by a solid phase synthesis method; (B) attaching a linker moiety represented by the following formula (I ′) to the “amino group, hydroxy group, thiol group, or carboxy group” in the peptide moiety synthesized in step (a);
- R 2 and R 3 are each independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms, or an aryl group having 5 to 16 carbon atoms (provided that both R 2 and R 3 are R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered
- R 5A and R 5B each independently represent a hydrogen atom, a halogen atom, , Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substitution Or an unsubstituted phenyl group or a benzyl group, R 5C and R 5D are a carbon atom to which R 5C is bonded, a carbon atom to which R 5D is bonded, a cycloalkyl having 4 to 16 carbon atoms, a cycloalkenyl having 5 to 16 carbon atoms, a carbon atom having 7 to Forming 13 bicyclyls
- step (C) the alkyl group, the aryl group in R 2 or R 3 of the linker moiety bonded to the “amino group, hydroxy group, thiol group, or carboxy group” of the peptide moiety according to step (b), Or replacing at least one hydrogen atom in the heterocycle with a sugar chain, a glycosylated amino acid or a glycosylated polypeptide.
- a manufacturing method is provided.
- the present invention in still another aspect, A method for producing a compound comprising a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof,
- the physiologically active substance includes a peptide portion having at least one amino group, hydroxy group, thiol group, or carboxy group
- a sugar chain addition linker represented by the following formula (I ′′) is bonded to the “amino group, hydroxy group, thiol group, or carboxy group” in the peptide moiety by dehydration condensation.
- R 2 and R 3 are each independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms, or an aryl group having 5 to 16 carbon atoms (provided that both R 2 and R 3 are R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered heterocycle, At least one hydrogen atom in the alkyl group, the aryl group, or the heterocyclic ring is substituted with a sugar chain, a glycosylated amino acid, or a glycosylated polypeptide;
- Each R 4 is independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms;
- Y is And here, R 5A and R 5B together with the carbon atom to which R 5A is bonded, the carbon atom to which R 5B is bonded, are aryl having 5 to 16 carbon atoms, cycloalkenyl having 5 to 16 carbon atoms,
- R 5A and R 5B each independently represent a hydrogen atom, a halogen atom, , Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substitution Or an unsubstituted phenyl group or a benzyl group, R 5C and R 5D are a carbon atom to which R 5C is bonded, a carbon atom to which R 5D is bonded, a cycloalkyl having 4 to 16 carbon atoms, a cycloalkenyl having 5 to 16 carbon atoms, a carbon atom having 7 to 13 bicyclyl, 9 to
- an arbitrary combination of one or more features of the present invention described above is also a method for producing the compound of the present invention or a salt thereof.
- the present invention provides: Provided is a compound or a salt thereof obtainable by any one of the above production methods.
- the present invention provides: A compound or a salt thereof obtained by any one of the above production methods is provided.
- any combination of one or more features of the present invention described above is also a compound of the present invention or a salt thereof.
- the present invention provides: A glycosylated linker that may be used for conjugation with a physiologically active substance having at least one amino group, hydroxy group, thiol group, or carboxy group
- the sugar chain addition linker is represented by the following formula (B): R 1 -L (B) here, R 1 means a glycosylated linker moiety;
- R 1 is represented by the following formula (I): [In the formula (I), R 2 and R 3 are each independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms, or an aryl group having 5 to 16 carbon atoms (provided that both R 2 and R 3 are R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered heterocycle, At least one hydrogen atom in the alkyl group, the aryl group, or the heterocyclic ring is substituted with a sugar chain, a glycosylated amino acid, or a glycosylated polypeptide;
- Each R 4
- R 5A and R 5B each independently represent a hydrogen atom, a halogen atom, , Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substitution Or an unsubstituted phenyl group or a benzyl group, R 5C and R 5D are a carbon atom to which R 5C is bonded, a carbon atom to which R 5D is bonded, a cycloalkyl having 4 to 16 carbon atoms, a cycloalkenyl having 5 to 16 carbon atoms, a carbon atom having 7 to Forming 13 bicyclyls
- any combination of one or more features of the present invention described above is also a glycosylated linker of the present invention.
- a compound containing a sugar chain-added linker moiety and a physiologically active substance moiety or a salt thereof has a hydroxy group and a highly polar sugar chain, so compared with an unmodified physiologically active substance, Has improved water solubility.
- the carrier is a sugar chain having biodegradable properties, there is little phytotoxicity when administered to a living body.
- FIG. 1 Changes in abundance of glycosylated (Asn (asialo)) linker-chemerin 9 conjugate (compound 1) and unmodified chemerin 9 (compound 3) dissolved in PBS over time at 37 ° C. and pH 7.4
- the vertical axis represents absorbance at a wavelength of 220 nm, and the horizontal axis represents retention time (minutes).
- the 1 peak indicated by the arrow represents a glycosylated (Asn (asialo) type) linker-chemerin 9 conjugate (Compound 1).
- the 3 peaks indicated by the arrows represent unmodified chemerin 9.
- the expression “Relativation Concentration of 1” described on the vertical axis means the relative concentration of dissolved glycosylated (Asn (Asialo) type) linker-chemerin 9 conjugate (Compound 1).
- a physiologically active substance derivative having a glycosylated linker moiety is used in the same meaning as the “compound containing a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof” of the present invention.
- conjugate means a substance (for example, a carrier or a carrier linker (such as a glycosyl linker)) bonded to a drug (such as a physiologically active substance).
- the sugar chain addition linker of the present invention is obtained by adding a sugar chain as a carrier to the linker.
- the glycosylated linker of the present invention may have two or more identical or different sugar chains.
- the physiologically active substance moiety (X) and the glycosylated linker moiety (R 1 ) bind to each other, whereby the glycosylated linker moiety represented by the formula (A) “R 1 -X” and the physiological Compounds or salts thereof containing the active substance moiety can be formed.
- the physiologically active substance can be bonded to the glycosylated linker moiety by changing (modifying) a part of its structure. However, once the glycosylated linker moiety is cleaved, the physiologically active substance is released.
- the structure of the released physiologically active substance is preferably the same as the compound structure before binding (before modification) to the glycosylated linker moiety.
- a physiologically active substance that is not bonded to a glycosylated linker is referred to as an “unmodified physiologically active substance”.
- the unmodified physiologically active substance preferably has the pharmacokinetic, immunogenic, toxicological or pharmacological characteristics inherent to the physiologically active substance itself, but the characteristics are altered, modified, etc. Also good.
- the “compound containing a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof” of the present invention releases an unmodified physiologically active substance by cleaving the glycosylated linker moiety under a predetermined condition. It is preferable to do.
- glycosylated linker of the present invention preferably does not adversely affect the pharmacokinetic, immunogenic, toxicological or pharmacological properties of the physiologically active substance that becomes a binding partner.
- the “physiologically active substance” means a substance that brings about some action / influence directly or indirectly on the physiological activity of a living body, although not limited thereto.
- the physiologically active substance may be intended for use in vitro and in vivo.
- the physiologically active substance may be one that does not exhibit its function in vivo.
- the physiologically active substance may be used synonymously with a drug.
- the physiologically active substance may include not only those useful as vaccines or pharmaceuticals, but also substances that do not directly act on or influence physiological activities of living bodies, such as diagnostic agents.
- the physiologically active substance may include not only naturally derived substances but also those obtained by deleting, modifying or substituting a part thereof (also referred to as derivatives).
- the physiologically active substance in the present invention includes, for example, a substance fused with a reporter protein such as GFP (green fluorescent protein) or a fluorescent dye such as fluorescein.
- a reporter protein such as GFP (green fluorescent protein) or a fluorescent dye such as fluorescein.
- the physiologically active substance in the present invention has at least one amino group, hydroxy group, thiol group, or carboxy group.
- the physiologically active substance in the present invention is preferably a low molecular weight physiologically active substance or biopolymer having at least one amino group, hydroxy group, thiol group, or carboxy group.
- biopolymer may mean a high molecular organic compound among physiologically active substances.
- the “low molecular biologically active substance” may mean a low molecular organic compound among the physiologically active substances.
- the biopolymer may be, for example, a polymer compound such as protein, nucleic acid or polysaccharide or a part thereof, but may be artificially synthesized.
- the low molecular weight physiologically active substance may be, for example, a substance capable of interacting with a biopolymer in a living body or may be artificially synthesized.
- the biopolymer and the low-molecular physiologically active substance may refer to the same thing depending on the case.
- the biopolymer in the present invention is a protein, polypeptide, polynucleotide, or peptide nucleic acid having at least one amino group, hydroxy group, thiol group, or carboxy group, or of the structure thereof.
- some include proteins, polypeptides, polynucleotides, or peptide nucleic acids.
- a portion derived from a protein or polypeptide is also referred to as a “peptide portion”.
- the “protein” is not particularly limited as long as a plurality of amino acids are bonded by an amide bond, and includes known proteins, novel proteins, or modifications thereof.
- the “variant” is a compound obtained by partially modifying a protein naturally or artificially. Such modifications include, for example, alkylation, acylation (eg, acetylation), amidation (eg, C-terminal amidation of a protein), carboxylation, ester formation of one or more amino acid residues of a protein. , Disulfide bond formation, glycosylation, lipidation, phosphorylation, hydroxylation, dehydration condensation or label component conjugation.
- examples of the variant include those obtained by deleting, substituting, or fusing a part of the structure of a known protein or a novel protein.
- the biopolymer as a physiologically active substance is a protein
- the protein is not limited.
- those skilled in the art such as solid phase synthesis, liquid phase synthesis, cell synthesis, and methods for separating and extracting naturally occurring substances can be used. May be synthesized using known methods.
- polypeptide and “peptide” are used in the same meaning as protein in principle. However, polypeptides and peptides may be used to indicate a relatively short amino acid chain that is not part of a protein structure or a higher order structure (ie, a protein fragment).
- the polypeptide or peptide in the present invention includes, for example, a dipeptide in which two amino acids are bonded, a tripeptide in which three amino acids are bonded, a tetrapeptide in which four amino acids are bonded, and an oligo in which the number of amino acids is usually 10 or less. Peptides may also be included.
- amino acid is used in its broadest sense, and is a natural amino acid such as serine (Ser), asparagine (Asn), valine (Val), leucine (Leu), isoleucine (Ile), alanine.
- Al tyrosine
- Tyr glycine
- Gly lysine
- Lys lysine
- Arg arginine
- His histidine
- aspartic acid Aspartic acid
- Glu glutamic acid
- Glu glutamine
- Gln glutamine
- Thr threonine
- Non-natural amino acids such as cysteine (Cys), methionine (Met), phenylalanine (Phe), tryptophan (Trp), proline (Pro) as well as amino acid variants and derivatives are also included.
- amino acids in the present specification, for example, L-amino acids; D-amino acids; chemically modified amino acids such as amino acid variants and amino acid derivatives; norleucine, ⁇ -alanine, It should be understood that ornithine and other amino acids that are not constituents of proteins in vivo; and chemically synthesized compounds having amino acid properties known to those skilled in the art.
- non-natural amino acids include ⁇ -methylamino acids ( ⁇ -methylalanine etc.), D-amino acids (D-aspartic acid, D-glutamic acid etc.), histidine-like amino acids (2-amino-histidine, ⁇ -hydroxy-histidine) , Homohistidine, ⁇ -fluoromethyl-histidine, ⁇ -methyl-histidine, etc.), amino acids with extra methylene in the side chain (“homo” amino acids), and carboxylic acid functional amino acids in the side chain are replaced with sulfonic acid groups Amino acids such as cysteic acid.
- ⁇ -methylamino acids ⁇ -methylalanine etc.
- D-amino acids D-aspartic acid, D-glutamic acid etc.
- histidine-like amino acids (2-amino-histidine, ⁇ -hydroxy-histidine)
- polynucleotide includes, but is not limited to, single-stranded or double-stranded DNA or RNA having a 2-2000 nucleotide sequence; single-stranded or double-stranded siRNA, miRNA or nucleic acid ( DNA or RNA) aptamers; or compounds in which they are chemically modified. Such modifications further include, but are not limited to, charge, polarizability, hydrogen bonding, electrostatic interaction, or fluxionality to all or part of the polynucleotide. Modifications with other chemical groups are mentioned.
- a polynucleotide may be an oligonucleotide having a size of 20 base pairs or less.
- the “peptide nucleic acid” means a modified nucleic acid obtained by converting a sugar phosphate skeleton of a nucleic acid (DNA or RNA) into an N- (2-aminoethyl) glycine skeleton, although not limited thereto.
- the peptide nucleic acid may be further modified by methods known to those skilled in the art.
- the biopolymer in the present invention is not limited to the following, but in one embodiment, for example, adrenocorticotropic hormone (ACTH), oxytocin, adenosine deaminase, agarsidase, ⁇ 1 antitrypsin, ⁇ 1 protease inhibitor, alteplase, amylin, simulin , Anistreplase, ancrodose serine protease, antithrombin III, antitrypsin, aprotinin, asparaginase, atosiban, biphalin, bivalirudin, bone morphogenetic protein, pancreatic trypsin inhibitor, cadherin fragment, calcitonin (eg salmon derived), collagenase, Complement C1 esterase inhibitor, conotoxin, cytokine receptor fragment, DNase, dynorphin A, endorphin, et Nfuvirtide, enkephalin, erythropoiet
- vaccine cancer vaccine, HIV antigen, hepatitis A vaccine, hepatitis B Vaccine (HBs antigen etc.), influenza vaccine, Lyme disease vaccine etc., vascular endothelial growth factor (VEGF), chemerin), HER2 protein (human epidermal growth factor receptor), epidermal growth factor (EGF), vasoactive Sex intestinal peptide, vasopressin, ziconotide, lectin, cholinesterase, amylase, or pepsin, or variants thereof.
- VEGF vascular endothelial growth factor
- chemerin chemerin
- HER2 protein human epidermal growth factor receptor
- EGF epidermal growth factor
- vasoactive Sex intestinal peptide vasopressin
- ziconotide lectin
- cholinesterase cholinesterase
- amylase or pepsin, or variants thereof.
- the low molecular weight physiologically active substance in the present invention includes, for example, a central nervous system active agent, anti-infective agent, anti-allergic agent, immunity having at least one amino group, hydroxy group, thiol group, or carboxy group.
- a central nervous system active agent for example, a central nervous system active agent, anti-infective agent, anti-allergic agent, immunity having at least one amino group, hydroxy group, thiol group, or carboxy group.
- the low molecular weight physiologically active substance in the present invention is not limited, but as one aspect, for example, acarbose, alaprocrat, alendronate, amantadine, amikacin, amineptin, aminoglutethimide, amisulpride, amlodipine, amotosalen, amoxapine, Amoxicillin, amphetamine, amphotericin B, ampicillin, amplenavir, amrinone, anilellidine, apraclonidine, apramycin, articaine, atenolol, atomoxetine, abizaphone, baclofen, benazepril, benserazide, benzocaine, betaxolol, brenacarin bromolbromine , Cathinone, carbutamide, cephalexin, clinafloxacin, ciprofloxacin Deferoxamine, delavirdine, desipramine, daunorubi
- the physiologically active substance moiety in the present invention is a glycosylated linker moiety or a linker moiety (linker moiety to which no sugar chain is added) in at least one amino group, hydroxy group, thiol group, or carboxy group possessed by the physiologically active substance. Combine with.
- the amino group is preferably a primary amino group or a secondary amino group.
- the “glycosylated amino acid” is an amino acid to which a sugar chain is bound, and the sugar chain and the amino acid may be bound without a linker, or may be bound via a linker. May be.
- the binding site between the sugar chain and the amino acid but it is preferable that the amino acid is bound to the reducing end of the sugar chain.
- the type of amino acid to which the sugar chain is bound and any of natural amino acids, unnatural amino acids, and D-amino acids can be used.
- the glycosylated amino acid has the same or similar structure as that present as a glycopeptide (glycoprotein) in the living body
- the glycosylated amino acid is a glycosylated Asn such as an N-linked sugar chain.
- Glycosylated Ser such as O-linked sugar chain and glycosylated Thr are preferable.
- the amino acid of the glycosylated amino acid has two or more carboxy groups in the molecule such as aspartic acid or glutamic acid.
- An amino acid having two or more amino groups in a molecule such as lysine, arginine, asparagine, histidine, or tryptophan; an amino acid having a hydroxy group in a molecule such as serine, threonine, or tyrosine; Amino acids having a thiol group; amino acids having an amide group in the molecule such as asparagine and glutamine are preferred.
- the amino acid of the glycosylated amino acid is preferably aspartic acid, glutamic acid, lysine, arginine, serine, threonine, cysteine, asparagine, or glutamine, and more preferably cysteine or asparagine.
- linkers used in the art can be used.
- a is an integer and is not limited as long as the desired linker function is not inhibited, but preferably represents an integer of 0 to 4); C 1-10 polymethylene; —CH 2 —R—; Wherein R is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted carbocyclic group, substituted or unsubstituted heterocyclic (A group formed by elimination of one hydrogen atom from a group selected from the group containing a cyclic group.) -(CO)-(CH 2 ) a- (CO)- (In the formula, a is an integer and is not limited as long as the desired linker function is not inhibited, but preferably represents an integer of 0 to 4); C 1-10 polymethylene; —CH 2 —R—; Wherein
- the hydrogen atom on the amino group of the side chain of asparagine is at the reducing end portion of the sugar chain. May be substituted.
- the leaving group present at the reducing end of the sugar chain is not limited, and may be, for example, chlorine, bromine or fluorine.
- the hydrogen atom on the thiol group of the side chain of cysteine is reduced in the sugar chain via the linker. It may be bonded to the terminal (for example, when the linker is —CH 2 —CONH—, the reducing terminal of the sugar chain is bonded to the nitrogen atom in the linker).
- the leaving group of the linker bonded to the reducing end of the sugar chain is not limited, and may be, for example, chlorine, bromine or fluorine.
- glycosylated polypeptide is not particularly limited as long as it is a compound in which at least one sugar chain is added to a protein (or polypeptide or peptide).
- Glycosylated polypeptides are used interchangeably herein with “glycoprotein” or “glycopeptide”.
- the glycosylated polypeptide may be a polypeptide containing the aforementioned glycosylated amino acid.
- the binding mode between the sugar chain and the amino acid, the type of amino acid constituting the polypeptide, and the like may be defined similarly to the glycosylated amino acid in the present invention.
- the amino acid (residue) in the polypeptide that binds to the sugar chain is not limited to the N-terminus or C-terminus of the polypeptide, and if appropriate, any of the amino acids (residues) that constitute the polypeptide. Also good.
- the amino acid residue in the glycosylated polypeptide of the present invention may preferably be 2 to 100 amino acid residues, more preferably 2 to 10 amino acid residues.
- amino acids other than the amino acid at the portion where the sugar chain and the polypeptide are bonded may be selected relatively freely.
- the amino acid at the portion where the sugar chain and the polypeptide bind is, for example, asparagine, cysteine, glutamine or lysine, while the amino acid other than the amino acid at the portion where the sugar chain and the polypeptide bind (for example, The person skilled in the art understands that the addition) the amino acids bound to the linker moiety is not particularly limited.
- the glycosylated amino acid or the amino acid constituting the glycosylated polypeptide in the present invention is preferably composed of amino acids present in the living body.
- sugar chain refers to a compound in which two or more unit sugars (monosaccharides and / or derivatives thereof) are connected, and one unit sugar (monosaccharide and / or derivatives thereof).
- a compound comprising Examples of such sugar chains include, but are not limited to, monosaccharides and polysaccharides contained in the living body (glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine, sialic acid, or those As well as a sugar chain or the like derived from a complex biomolecule such as a degraded polysaccharide, glycoprotein, proteoglycan, glycosaminoglycan, or glycolipid.
- each unit sugar may be bound by dehydration condensation by a glycosidic bond.
- the sugar chain may be linear or branched.
- sugar chain includes sugar chain derivatives.
- sugars constituting the sugar chain are sugars having a carboxy group (for example, aldonic acids in which the C1-position is oxidized to become carboxylic acids (for example, D-glucose having oxidized D-glucose).
- Gluconic acid uronic acid having terminal C atom converted to carboxylic acid (D-glucuronic acid in which D-glucose is oxidized)), amino group or amino group derivative (for example, acetylated amino group)
- Sugars for example, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine, etc.
- sugars having both amino group and carboxy group for example, N-acetylneuraminic acid (sialic acid), N-acetylmura
- Glycans such as minic acid, deoxylated sugars (eg, 2-deoxy-D-ribose), sulfated sugars containing sulfate groups, phosphorylated sugars containing phosphate groups, and the like. It is, but is not limited thereto.
- the sugar chain in the present invention may be a sugar chain that exists as a complex carbohydrate (glycoprotein (or glycopolypeptide), proteoglycan, glycolipid, etc.) in vivo.
- a complex carbohydrate glycoprotein (or glycopolypeptide), proteoglycan, glycolipid, etc.
- it may be a carbohydrate that does not exist as a complex carbohydrate in vivo.
- a sugar chain that exists as a complex carbohydrate in a living body is preferable from the viewpoint of administering the compound of the present invention or a salt thereof to the living body.
- sugar chains include, but are not limited to, N-linked sugar chains and O-linked sugar chains that are sugar chains bound to proteins as glycoproteins in vivo.
- N-linked sugar chains In glycoproteins with O-linked sugar chains bound, N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), xylose, or fucose is bound to Ser or Thr of the peptide via an O-glycoside bond.
- a sugar chain is added to this.
- the N-linked sugar chain include a high mannose (high mannose) type, a complex (complex) type, and a hybrid (hybrid) type, and a complex type is preferable.
- the sugar chain in the “glycosylated amino acid or glycosylated polypeptide” of the present invention is a saccharide comprising 4 or more, for example, 5 or more, 7 or more, particularly 9 or more, 11 or more saccharides.
- a chain is preferred. The inventor surprisingly found that the greater the number of sugars constituting the sugar chain to be added, the better the water solubility of the compound of the present invention or a salt thereof, while not affecting the half-life thereof. discovered.
- the sugar chain in the glycosylated amino acid or glycosylated polypeptide of the present invention is a double-chain complex type (that is, a two-branch complex type in which the sugar chain is bifurcated).
- the complex type sugar chain includes two or more kinds of monosaccharides, and has a basic structure shown below and a lactosamine structure represented by Gal ⁇ 1-4GlcNAc.
- the double-stranded complex type sugar chain refers to one in which a single-chain sugar chain consisting of 0 to 3 sugars is bonded to two mannoses at the ends of the basic structure.
- the double-stranded complex type sugar chain for example, the following disialo sugar chain: Monosialo sugar chain shown below: The following asialo sugar chains: The following diglucnac sugar chains: The following dimannose sugar chains: Etc. are preferred.
- the complex sugar chain of the present invention includes the above-described double-chain complex sugar chain, a three-chain complex sugar chain (three-branch complex sugar chain), and four chains.
- the complex type sugar chain (four-branch type complex sugar chain) may also be included.
- Tetrasialo sugar chain shown below: Can be mentioned.
- examples of the three-chain complex sugar chain and the four-chain complex sugar chain include sugar chains that have lost one or more sugars from the non-reducing end of these trisialo sugar chains or tetrasialo sugar chains. it can.
- the sugar chain in the present invention may be a high mannose type sugar chain.
- the high mannose type sugar chain used in the present invention is a sugar chain in which two or more mannoses are further bonded to the basic structure of the complex type sugar chain described above.
- a sugar chain containing 5 to 9 mannose is preferable like a mammalian high mannose sugar chain, but may be a sugar chain containing more mannose like a high mannose sugar chain of yeast.
- the high mannose type sugar chain preferably used in the present invention, for example,
- the sugar chain in the present invention may be a sugar chain having a linear structure.
- sugar chains include oligohyaluronic acid.
- the oligohyaluronic acid in the present invention is not limited, but N-acetylglucosamine and glucuronic acid are alternately 4 to 32 sugars, preferably 4 to 16 sugars, more preferably 4 to 8 sugars, and sugars bonded on a straight chain. It can be a chain.
- oligohyaluronic acids used in the present invention particularly preferred are sugars having 2 units (4 sugars) or more and 8 units (16 sugars) or less when the unit consisting of N-acetylglucosamine and glucuronic acid is 1 unit.
- a chain more preferably 2 units (4 sugars) to 4 units (8 sugars), most preferably 2 units (4 sugars).
- hyaluronic acid preferably used in the present invention, for example, The tetrasaccharide oligohyaluronic acid shown below: The following octasaccharide oligohyaluronic acid: Etc.
- examples of the complex type sugar chain in the present invention include those with various sugars (for example, fucose).
- various sugars for example, fucose
- at least one fucose is added to N-acetylglucosamine at the non-reducing end of a sugar chain (double-chain complex sugar chain, three-chain complex sugar chain, four-chain complex sugar chain, etc.). It's okay.
- fucose-containing complex sugar chain the following fucose-containing complex sugar chain: Can be mentioned. Furthermore, the sugar chain which lost one or more sugars from the non-reducing end of these fucose-containing complex sugar chains can also be mentioned.
- the complex sugar chain of the present invention can also typically include a sugar chain having a polylactosamine structure or a sialylpolylactosamine structure represented by the following formula.
- n is an integer of 2 to 3.
- n is an integer of 2 to 3.
- a sugar chain in which one or more sugars are lost from the non-reducing end of the sugar chain having the polylactosamine structure or the sialylpolylactosamine structure can also be mentioned.
- a double-chain complex sugar chain in the present invention, includes, in addition to those specifically shown in the chemical formula in this specification, those having a bonding mode different from the examples shown in the chemical formula. It is preferably used as a sugar chain in the invention.
- sugar chains include those in which sialic acid and galactose are bonded by an ( ⁇ 2 ⁇ 3) bond in a dicialo sugar chain or a monosialo sugar chain.
- the hydroxy group and / or carboxy group of each sugar residue constituting the sugar chain may be protected by a protecting group.
- the protecting group is, for example, a protecting group known to those skilled in the art introduced for the purpose of protecting the hydroxy group and / or carboxy group of the sugar residue by a chemical reaction.
- an alkyl group methyl group, ethyl group, etc.
- benzyl group acyl group (acetyl group, benzoyl group, pivaloyl group, etc.), tert-butyldimethylsilyl group, tert -Butyldiphenylsilyl group, phenacyl group, allyl group and the like
- tert-butyldimethylsilyl group tert -Butyldiphenylsilyl group
- phenacyl group allyl group and the like
- sugar chains are, for example, bound to proteins in the human body.
- Sugar chains existing as glycoproteins for example, sugar chains described in “FEBS LETTERS Vol. 50, No. 3, Feb. 1975” and sugar chains having the same structure (types of constituent sugars and their binding modes) Are the same sugar chains) or sugar chains in which one or more sugars are lost from the non-reducing end thereof, as listed in Tables 1 to 4 below.
- the structure of the sugar chain in the sugar chain, glycosylated amino acid or glycosylated polypeptide of the present invention is substantially uniform.
- the structure of the sugar chain in the sugar chain, glycosylated amino acid or glycosylated polypeptide is substantially uniform between the compound of the present invention or a salt thereof and the sugar chain of the glycosylated linker of the present invention.
- glycosylation sites in the amino acid and / or polypeptide types of sugars constituting the sugar chain, binding order, and sugar It means that the bonding mode between them is substantially the same.
- substantially the same means that the sugar chain structure is at least 90% or more, preferably 95% or more, more preferably 99% or more.
- the structure of the glycosylated amino acid and / or glycosylated polypeptide of the present invention is substantially uniform.
- the structure of the glycosylated amino acid and / or glycosylated polypeptide is substantially uniform when the compound of the present invention or a salt thereof or the glycosylated linker of the present invention is added. And / or the type, structure, etc. of the glycosylated polypeptide are substantially the same.
- “substantially the same” means that the structures of glycosylated amino acids and / or glycosylated polypeptides of at least 90% or more, preferably 95% or more, more preferably 99% or more are uniform.
- Sugars contained in the sugar chain addition linker of the present invention when two or more sugar chains are present that is, when a plurality of sugar chains are present in the same compound
- composition or pharmaceutical composition of the present invention Even when there are a plurality of compounds or salts thereof including a chain addition linker moiety and a physiologically active substance moiety (that is, when a plurality of compounds or salts thereof are present), all sugar chains, glycosylated amino acids and / or sugars
- the structures of all sugar chains in the chain-added polypeptide are substantially uniform. In these cases, it is further preferred that the structures of all glycosylated amino acids and / or glycosylated polypeptides are substantially uniform.
- a glycosylated amino acid and a glycosylated polypeptide having a uniform sugar chain have a constant quality, and are particularly preferable in the fields of pharmaceutical production and assay.
- the uniform sugar chain ratio can be measured, for example, by a method using HPLC, capillary electrophoresis, NMR, mass spectrometry or the like.
- the physiologically active substance that binds to the glycosylated linker or linker (having a structure to which no sugar chain is bound) in the present invention is bound in the same binding mode.
- a glycosylated amino acid or glycosylated polypeptide having a substantially uniform amino acid sequence and / or sugar chain is a solid phase synthesis, a liquid phase synthesis, a cell synthesis, or a naturally occurring one. It can be produced by incorporating a glycosylation step into a peptide production method known to those skilled in the art, such as a separation and extraction method.
- a glycosylation step into a peptide production method known to those skilled in the art, such as a separation and extraction method.
- WO 2010/021126, WO 2004/005330, WO 2009/153960, JP 2001 Reference may be made to -302695, pamphlet of International Publication No. 2005/095331, JP 2009-242372, Biochimica et Biophysica Acta 1526 (2001) pages 242-248, and the like.
- the glycosylated polypeptide used in the present invention includes a sugar chain in which an amino acid-free sugar chain is bound to an amino acid or an amino acid on the polypeptide directly or via a linker.
- the glycosylated polypeptide is bound via a linker, it may also be included such as.
- glycosylated amino acid or glycosylated polypeptide of the present invention by glycosyltransferase, the glycosylated amino acid or sugar chain having a desired sugar chain structure is transferred. Additional polypeptides may be obtained efficiently.
- a glycosylated amino acid or a glycosylated polypeptide having a desired sugar chain structure containing fucose can be obtained by transferring fucose using a glycosyltransferase (eg, fucose transferase).
- a glycosylated amino acid or glycosylated polypeptide having a desired glycosylated structure with a different binding mode can be obtained.
- fucose commercially available fucose or chemically synthesized can be used.
- fucose transferase commercially available ones, naturally-derived ones, and ones produced by gene recombination can be used, and can be appropriately selected depending on the type of fucose to be transferred. Specific examples include Fucoyltransferase® V (Human, Recombinant, plasma-derived, serum-derived, milk-derived, liver-derived), which is an enzyme that transfers fucose to N-acetylglucosamine on the non-reducing end side of the sugar chain asparagine. it can. Further, fucose may be transferred by using fucose hydrolase and shifting the equilibrium by adjusting pH or the like.
- Fucoyltransferase® V Human, Recombinant, plasma-derived, serum-derived, milk-derived, liver-derived
- fucose may be transferred by using fucose hydrolase and shifting the equilibrium by adjusting pH or the like.
- sugar chain addition linker In the present invention, the sugar chain addition linker, the sugar chain addition linker part, the linker, or each substituent in the linker part will be further described below:
- R 2 and R 3 are each independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms, or an aryl group having 5 to 16 carbon atoms (provided that both R 2 and R 3 are Or R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered heterocyclic ring. In a preferred but non-limiting embodiment, R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered heterocycle.
- the 3-7 membered heterocycle contains up to the maximum number of double bonds
- R 2 and R 3 may each have an additional heteroatom selected from the group comprising a sulfur atom, an oxygen atom and a nitrogen atom in addition to the adjacent nitrogen atom.
- the heteroatom is preferably selected from the group consisting of a sulfur atom, an oxygen atom and a nitrogen atom.
- the 3- to 7-membered heterocyclic ring includes aziridine, azetidine, pyrroline (2-pyrroline, 3-pyrroline, etc.), pyrrole, imidazole, imidazoline, pyrazole, pyrazoline, isoxazoline (3-isoxazoline, 4 -Isoxazoline, etc.), thiazoline (such as 4-thiazoline), isothiazoline, thiadiazoline, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, piperazine, piperidine, morpholine, thiomorpholine, thiazine, It is preferably selected from the group comprising tetrazole, triazole, triazolidine, tetrazolidine, azepane, diazepane, azepine and homopiperazine.
- the 3- to 7-membered heterocyclic ring may have one or more substituents at substitutable positions.
- substituents include, but are not limited to, alkyl having 1 to 16 carbon atoms, alkenyl having 2 to 16 carbon atoms, alkynyl having 2 to 16 carbon atoms, aryl having 5 to 16 carbon atoms, and cycloalkyl having 3 to 8 carbon atoms.
- a 1 is alkylene having 1 to 4 carbon atoms
- a 2 is alkyl having 1 to 4 carbon atoms
- n is an integer of 0 to 3] (for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec -Butoxy, tert-butoxy, ethoxyethoxy, methoxyethoxyethoxy, etc.), phenoxy, halogenov Noxy (eg o-, m- or p-chlorophenoxy, o-, m- or p-bromophenoxy, etc.), alkylthio having 1 to 4 carbon
- unsubstituted or substituted amino ie, alkanoylamino having 1 to 6 carbon atoms (for example, acetylamino, propionylamino, etc.), alkylamino having 1 to 16 carbon atoms (for example, methylamino, ethylamino, n -Propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, tert-butylamino, pentylamino, hexylamino, heptylamino, octylamino, nonylamino, decylamino, undecylamino, dodecylamino, tridecyl Amino, tetradecylamino, pentadecylamino, hexadecylamino and the like, wherein these alkyl groups
- R 2 and / or R 3 is an alkyl group having 1 to 16 carbon atoms
- the alkyl group having 1 to 16 carbon atoms is a substituted or unsubstituted, linear or branched aliphatic hydrocarbon group. It may be.
- alkyl group having 1 to 16 carbon atoms examples include methyl group, ethyl group, n-propyl group, n-butyl group, n-pentyl group, n-hexyl group, n-heptyl group, n-octyl group, n -Nonyl group, n-decyl group, n-undecyl group, n-dodecyl group, n-tridecyl group, n-tetradecyl group, n-pentadecyl group, n-hexadecyl group can be mentioned.
- C 1-16 alkyl group which is a branched aliphatic hydrocarbon group
- examples of the “C 1-16 alkyl group” which is a branched aliphatic hydrocarbon group include an isobutyl group, an isodecyl group, a 2-ethylhexyl group, a 2-octyl-dodecyl group, a neopentyl group, or a tert- A butyl group can be mentioned.
- Examples of one or more substituents in the linear or branched aliphatic hydrocarbon group are each independently an alkoxy group having 1 to 10 carbon atoms (eg, methoxy, ethoxy, propoxy, butoxy, etc.) , Amino group, hydroxy group, thiol group, carboxy group, or halogen atom (for example, fluorine, chlorine, bromine, iodine).
- R 2 and / or R 3 is an alkyl group having 1 to 16 carbon atoms, it is preferably a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms. In a more preferred embodiment, it may be a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms.
- R 2 and / or R 3 is an aryl group having 5 to 16 carbon atoms
- the aryl group having 5 to 16 carbon atoms may be a substituted or unsubstituted aryl group.
- substituent in the case where one or more hydrogen atoms of the aryl group are substituted include independently an alkyl group having 1 to 4 carbon atoms and an alkoxy group having 1 to 4 carbon atoms (for example, methoxy, Ethoxy, propoxy, butoxy, etc.), amino group, hydroxy group, thiol group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), halogenated alkyl group having 1 to 4 carbon atoms (eg, methyl chloride group) Can be mentioned.
- substituted or unsubstituted aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthranyl, phenanthryl, anthryl, o-tolyl, m-tolyl, p-tolyl, xylyl A group, an ethylphenyl group or a benzyl group.
- R 2 and / or R 3 is an aryl group having 5 to 16 carbon atoms, it is preferably a substituted or unsubstituted aryl group having 5 to 10 carbon atoms. In a more preferred embodiment, it may be a substituted or unsubstituted aryl group having 5 to 8 carbon atoms, such as a phenyl group, o-tolyl group, m-tolyl group, p-tolyl group or benzyl group.
- Each R 4 is independently a hydrogen atom, an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms.
- R 4 is an alkyl group having 1 to 16 carbon atoms, it may be the same as the alkyl group having 1 to 16 carbon atoms described above in connection with R 2 and / or R 3 .
- R 4 when one or more of R 4 is an alkyl group having 1 to 16 carbon atoms, it is preferably a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms. In a more preferred embodiment, it may be a substituted or unsubstituted alkyl group having 1 to 5 carbon atoms, such as a methyl group, an ethyl group, or a propyl group.
- R 4 is an aryl group having 5 to 16 carbon atoms, it may be the same as the aryl group having 5 to 16 carbon atoms described above in connection with R 2 and / or R 3 .
- R 4 when one or more of R 4 is an aryl group having 5 to 16 carbon atoms, it is preferably a substituted or unsubstituted aryl group having 5 to 10 carbon atoms. In a more preferred embodiment, it may be a substituted or unsubstituted aryl group having 5 to 8 carbon atoms, such as a phenyl group, o-tolyl group, m-tolyl group, p-tolyl group or benzyl group.
- All of R 4 may be the same, or the three R 4 may be the same.
- both of the two said R 4 adjacent different carbon atoms, both of the same two bonded to a carbon atom of the R 4 or two opposing different carbon atom bonded, the R 4 to its binding Both may be the same.
- At least one of the four R 4 is a hydrogen atom, more preferably at least two of the four R 4 are hydrogen atoms, and more preferably, at least any of the four R 4 Three are hydrogen atoms, and most preferably, all four R 4 are hydrogen atoms.
- R 5A and R 5B together with the carbon atom to which R 5A is bonded, the carbon atom to which R 5B is bonded, are aryl having 5 to 16 carbon atoms, cycloalkenyl having 5 to 16 carbon atoms, and 7 to 13 carbon atoms.
- R 5A and R 5B each independently represent a hydrogen atom, a halogen atom, , Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substitution Or an unsubstituted phenyl group or a benzyl group, R 5C and R 5D are a carbon atom to which R 5C is bonded, a carbon atom to which R 5D is bonded, a cycloalkyl having 4 to 16 carbon atoms, a cycloalkenyl having 5 to 16 carbon atoms, a carbon atom having 7 to It may form 13 bicyclyl
- Y is And here, R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form an aryl having 5 to 16 carbon atoms, or R 5A and R 5B are Is also a hydrogen atom, R 5C and R 5D may be combined with the carbon atom to which R 5C is bonded or the carbon atom to which R 5D is bonded to form cyclohexyl or norbornyl.
- R 5A and R 5B together with the carbon atom to which R 5A is bonded, the carbon atom to which R 5B is bonded, are aryl having 5 to 16 carbon atoms, cycloalkenyl having 5 to 16 carbon atoms, and 7 to 13 carbon atoms.
- R 5A and R 5B each independently represent a hydrogen atom, a halogen atom, , Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substitution Or an unsubstituted phenyl group and a benzyl group.
- R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form an aryl having 5 to 16 carbon atoms
- the aryl having 5 to 16 carbon atoms is R It may be the same as the aryl group having 5 to 16 carbon atoms described above with respect to 2 and / or R 3 .
- R 5A and R 5B when R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form an aryl having 5 to 16 carbon atoms, they are substituted or unsubstituted, An aryl having 5 to 10 carbon atoms is preferred. In a further preferred embodiment, it may be substituted or unsubstituted aryl having 5 to 8 carbon atoms, such as phenyl, o-tolyl, m-tolyl, p-tolyl or benzyl.
- the cycloalkenyl having 5 to 16 carbon atoms is Substituted or unsubstituted cycloalkenyl.
- unsubstituted cycloalkenyl include, but are not limited to, those having an unsaturated bond such as one or more double bonds in cycloalkyl having 4 to 16 carbon atoms described later in relation to R 5C and R 5D Is mentioned.
- Examples include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, cycloundecenyl, cyclododecenyl, cyclotridecenyl, cyclotetradecenyl, cyclopentadecenyl, or cyclohexadecenyl.
- substituents when one or more hydrogen atoms of cycloalkenyl are substituted include each independently an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms (for example, a methoxy group) Ethoxy group, propoxy group, butoxy group, etc.), amino group, hydroxy group, thiol group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), or halogenated alkyl group having 1 to 4 carbon atoms ( For example, a methyl chloride group) can be mentioned.
- R 5A and R 5B together with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B are bonded form a cycloalkenyl having 5 to 16 carbon atoms a substituted or unsubstituted
- the cycloalkenyl having 5 to 10 carbon atoms is preferable. In a further preferred embodiment, it may be substituted or unsubstituted cycloalkenyl having 5 to 8 carbon atoms, such as cyclohexenyl.
- each ring of bicyclyl may contain a 3-6 membered ring.
- Examples of the substituent when one or more hydrogen atoms of biscyclyl are substituted include independently an alkyl group having 1 to 4 carbon atoms and an alkoxy group having 1 to 4 carbon atoms (for example, methoxy, ethoxy , Propoxy, butoxy, etc.), amino group, hydroxy group, thiol group, carbonyl group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), or halogenated alkyl group having 1 to 4 carbon atoms (eg, chloride) Methyl group).
- Examples of C 7-13 bicyclyl include, but are not limited to, azulenyl and naphthyl.
- R 5A and R 5B when R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form a bicyclyl having 7 to 13 carbon atoms, they are substituted or unsubstituted, It may be bicyclyl having 7 to 10 carbon atoms, such as naphthyl.
- the tricyclyl group having 9 to 14 carbon atoms is substituted Or it may be unsubstituted tricyclyl.
- unsubstituted tricyclyl include, but are not limited to, one or more unsaturated bonds such as a double bond, and optionally one or more heteroatoms.
- each ring of tricyclyl may contain 3 to 6 members.
- Examples of the substituent when one or more hydrogen atoms of tricyclyl are substituted include independently an alkyl group having 1 to 4 carbon atoms and an alkoxy group having 1 to 4 carbon atoms (for example, methoxy, ethoxy , Propoxy, butoxy, etc.), amino group, hydroxy group, thiol group, carbonyl group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), or halogenated alkyl group having 1 to 4 carbon atoms (eg, chloride) Methyl group).
- an alkyl group having 1 to 4 carbon atoms and an alkoxy group having 1 to 4 carbon atoms for example, methoxy, ethoxy , Propoxy, butoxy, etc.
- amino group eg, hydroxy group, thiol group, carbonyl group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), or halogen
- tricyclyl having 9 to 14 carbon atoms examples include, but are not limited to, anthracenyl, phenanthryl, acenaphthenyl, acenaphthylenyl, fluorenyl, derivatives thereof such as hydrogenated products thereof.
- R 5A and R 5B when R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form a tricyclyl group having 9 to 14 carbon atoms, they are substituted or unsubstituted, Tricyclyl having 12 to 14 carbon atoms is preferable. In a further preferred embodiment, it may be a substituted or unsubstituted tricyclyl having 14 carbon atoms, such as phenanthryl.
- the quinone having 6 to 14 carbon atoms is substituted Or it may be an unsubstituted quinone.
- unsubstituted quinone include, but are not limited to, benzoquinone, anthraquinone, and naphthoquinone.
- quinones include isomers such as o-benzoquinone and p-benzoquinone.
- Examples of the substituent when one or more hydrogen atoms of quinone are substituted include independently an alkyl group having 1 to 4 carbon atoms and an alkoxy group having 1 to 4 carbon atoms (for example, methoxy, ethoxy , Propoxy, butoxy, etc.), amino group, hydroxy group, thiol group, carbonyl group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), or halogenated alkyl group having 1 to 4 carbon atoms (eg, chloride) Methyl group).
- an alkyl group having 1 to 4 carbon atoms and an alkoxy group having 1 to 4 carbon atoms for example, methoxy, ethoxy , Propoxy, butoxy, etc.
- amino group eg, hydroxy group, thiol group, carbonyl group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), or halogenated
- R 5A and R 5B when R 5A and R 5B are combined with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded to form a quinone having 6 to 14 carbon atoms, they are substituted or unsubstituted, A quinone having 6 to 10 carbon atoms is preferable. In a further preferred embodiment, it may be a substituted or unsubstituted quinone having 6 carbon atoms, such as benzoquinone.
- the 5- to 10-membered heterocyclic ring is substituted Or it may be an unsubstituted heterocyclic ring.
- unsubstituted heterocycle include, but are not limited to, heteroatoms that may contain up to the maximum number of double bonds and are selected from the group comprising nitrogen, sulfur, oxygen, and nitrogen atoms You may have one or more.
- a bicyclic or tricyclic system having one or more heteroatoms in this case, a bicyclic or tricyclic heterocyclic ring having one or more heteroatoms is
- it may be a bicyclyl having 7 to 13 carbon atoms or a tricyclyl having 9 to 14 carbon atoms as described above).
- heterocycles include, but are not limited to, pyrazole rings, pyrrole rings, furan rings, thiophene rings, imidazole rings, thiazole rings, isothiazole rings, oxazole rings, isoxazole rings, pyridine rings, pyrazine rings, pyrimidine rings or pyridazines.
- a ring can be mentioned.
- substituent when one or more hydrogen atoms of the heterocyclic ring are substituted include each independently an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms (for example, methoxy, Ethoxy, propoxy, butoxy, etc.), amino group, hydroxy group, thiol group, carbonyl group, carboxy group, halogen atom (for example, fluorine, chlorine, bromine, iodine), or halogenated alkyl group having 1 to 4 carbon atoms (for example, Methyl chloride group).
- R 5A and R 5B together with the carbon atom to which R 5A is bonded and the carbon atom to which R 5B is bonded form a 5- to 10-membered heterocyclic ring they are substituted or unsubstituted, A 5- to 8-membered heterocyclic ring is preferred. In a further preferred embodiment, it may be a substituted or unsubstituted 5- to 7-membered heterocycle, such as a pyridine ring.
- R 5A and R 5B are each independently a hydrogen atom, halogen, Cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl group having 1 to 3 carbon atoms, hydroxy group, carboxy group, amino group, substituted or It may be an unsubstituted phenyl group or a benzyl group.
- Examples of the substituted phenyl group include, but are not limited to, an o-tolyl group, an m-tolyl group, or a p-tolyl group.
- the acyl group having 1 to 3 carbon atoms is preferably a formyl group or an acetyl group.
- R 5A and R 5B are each independently A hydrogen atom, a methyl group, an ethyl group, a propyl group, and a phenyl group.
- R 5A and R 5B are each a hydrogen atom, a methyl group or a phenyl group.
- unsubstituted cycloalkyl examples include, but are not limited to, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentadecyl, or Mention may be made of cyclohexadecyl.
- Examples of the substituent in the case where one or more hydrogen atoms of cycloalkyl are substituted include each independently an alkyl group having 1 to 4 carbon atoms or an alkoxy group having 1 to 4 carbon atoms (for example, methoxy, Ethoxy, propoxy, butoxy, etc.), amino group, hydroxy group, thiol group, carboxy group, halogen atom (eg, fluorine, chlorine, bromine, iodine), or halogenated alkyl group having 1 to 4 carbon atoms (eg, methyl chloride group) ).
- a substituted or unsubstituted And is preferably a cycloalkyl having 4 to 10 carbon atoms. In a further preferred embodiment, it may be substituted or unsubstituted cycloalkyl having 4 to 8 carbon atoms, such as cyclopentyl, cyclohexyl, cycloheptyl.
- R 5C and R 5D together with the carbon atom to which R 5C is bonded and the carbon atom to which R 5D is bonded form a cycloalkenyl having 5 to 16 carbon atoms the cycloalkenyl having 5 to 16 carbon atoms is , R 5A and / or R 5B may be the same as the C 5-16 cycloalkenyl described above.
- R 5C and R 5D together with the carbon atom to which R 5C is bonded and the carbon atom to which R 5D is bonded form a cycloalkenyl having 5 to 16 carbon atoms, a substituted or unsubstituted And preferably a cycloalkenyl having 5 to 10 carbon atoms. In a further preferred embodiment, it may be substituted or unsubstituted cycloalkenyl having 5 to 8 carbon atoms, such as cyclohexenyl.
- R 5C and R 5D are combined with the carbon atom to which R 5C is bonded and the carbon atom to which R 5D is bonded to form a bicyclyl having 7 to 13 carbon atoms
- the bicyclyl having 7 to 13 carbon atoms is R It may be similar to the 7-13 carbon bicyclyl described above in connection with 5A and / or R 5B .
- R 5C and R 5D together with the carbon atom to which R 5C is bonded and the carbon atom to which R 5D is bonded form a bicyclyl having 7 to 13 carbon atoms a substituted or unsubstituted, Bicyclyl having 7 to 10 carbon atoms is preferable. In a more preferred embodiment, it may be substituted or unsubstituted bicyclyl having 7 to 9 carbon atoms, such as norbornyl, hexachloronorbornyl.
- R 5C and R 5D are combined with the carbon atom to which R 5C is bonded and the carbon atom to which R 5D is bonded to form a tricyclyl having 9 to 14 carbon atoms
- the tricyclyl having 9 to 14 carbon atoms is R It may be similar to the 9-14 carbon tricyclyl described above with respect to 5A and / or R 5B .
- R 5C and R 5D together with the carbon atom to which R 5C is bonded and the carbon atom to which R 5D is bonded form a tricyclyl group having 9 to 14 carbon atoms they are substituted or unsubstituted
- Tricyclyl having 12 to 14 carbon atoms is preferable.
- it may be a substituted or unsubstituted tricyclyl having 14 carbon atoms, such as tetradecahydrophenanthryl.
- the 5- to 10-membered heterocyclic ring is R It may be similar to the 5-10 membered heterocycle described above in connection with 5A and / or R 5B .
- R 5C , R 5D together with the carbon atom to which R 5C is bonded, the carbon atom to which R 5D is bonded, form a 5- to 10-membered heterocyclic ring, a substituted or unsubstituted, It is preferably a 5- to 8-membered heterocyclic ring. In a further preferred embodiment, it may be a substituted or unsubstituted 5- to 7-membered heterocycle, such as epoxycyclohexyl.
- R 8 represents a hydrogen atom, a carbamate protecting group such as an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group, or an amino acid, polypeptide, sugar chain, sugar chain An added amino acid or glycosylated polypeptide.
- R 8 may be a hydrogen atom, an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group.
- R 8A is a protecting group such as an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group.
- R 8 ′ is a protecting group such as an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group.
- R 8 , R 8A or R 8 ′ is an acyl group having 1 to 16 carbon atoms
- the acyl group having 1 to 16 carbon atoms may be a substituted or unsubstituted acyl group.
- substituted or unsubstituted acyl groups include, but are not limited to, formyl group, acetyl group, methylcarbonyl group, ethylcarbonyl group, n-propylcarbonyl group, iso-propylcarbonyl group, n-butylcarbonyl group, iso -Butylcarbonyl group, sec-butylcarbonyl group, tert-butylcarbonyl group, n-pentylcarbonyl group, iso-pentylcarbonyl group, neopentylcarbonyl group, 2-methylbutylcarbonyl group, benzoyl group, 1-naphthoyl group, 2 -Naphthoyl group,
- R 8 , R 8A or R 8 ′ is an acyl group having 1 to 16 carbon atoms, it may be a formyl group or an acetyl group, respectively.
- R 8 when R 8 is present, R 8 is an acyl group having 1 to 16 carbon atoms, an Fmoc group in order to stabilize the compound of the present invention or a salt thereof under acidic conditions (eg, pH 1 to pH 6). , Boc group, Z group, Troc group, or Alloc group.
- R 9 is independently hydrogen atom, halogen, cyano group, alkyl group having 1 to 4 carbon atoms, alkoxy group having 1 to 4 carbon atoms, nitro group, mesyl group, tosyl group, acyl having 1 to 3 carbon atoms. Group, hydroxy group, carboxy group or amino group.
- R 9 is halogen, it is preferably fluorine, chlorine, bromine or iodine.
- R 9 When one or more of R 9 is an acyl group having 1 to 3 carbon atoms, it may be a substituted or unsubstituted acyl group. Examples of the unsubstituted acyl group include, but are not limited to, a formyl group, an acetyl group, and a propionyl group. In one preferred embodiment, when one or more of R 9 is an acyl group having 1 to 3 carbon atoms, it may be a formyl group or an acetyl group.
- R 9 When one or more of R 9 is an alkyl group having 1 to 4 carbon atoms, it may be a substituted or unsubstituted alkyl group. Examples of the unsubstituted alkyl group include a methyl group, an ethyl group, a propyl group, and a butyl group. In one preferred embodiment, when one or more of R 9 is an alkyl group having 1 to 4 carbon atoms, it may be a methyl group or an ethyl group.
- R 9 When one or more of R 9 is an alkoxy group having 1 to 4 carbon atoms, it may be a substituted or unsubstituted alkoxy group. Examples of the unsubstituted alkoxy group include a methoxy group, an ethoxy group, an n-propoxy group, and an n-butoxy group. In one preferred embodiment, when one or more of R 9 is an alkoxy group having 1 to 4 carbon atoms, it may be a methoxy group or an ethoxy group.
- R 9 is The inventor has surprisingly discovered that an electron withdrawing group is preferred. Therefore, in a preferred embodiment, when it is desired to rapidly cleave the glycosylated linker moiety from the compound of the present invention or a salt thereof to rapidly release the physiologically active substance, at least one of the above-mentioned R 9 is used.
- R 5A and R 5B are carbon atoms to which R 5A is bonded, and carbons to which R 5B is bonded.
- aryl having 5 to 16 carbon atoms cycloalkenyl having 5 to 16 carbon atoms, bicyclyl having 7 to 13 carbon atoms, tricyclyl having 9 to 14 carbon atoms, quinone having 6 to 14 carbon atoms, or 5
- R 5C and R 5D together with the carbon atom to which R 5C is bonded, the carbon atom to which R 5D is bonded, and a cycloalkyl having 4 to 16 carbon atoms
- At least one hydrogen atom present is independently substituted with a halogen, a cyano group, a nitro group, a mesyl group (methanesulfonyl group), a tosyl group (p-toluenesulfonyl group) or an acyl group having 1 to 3 carbon atoms. It's okay.
- the electron-withdrawing group is preferably halogen, and more preferably chlorine.
- the compound of the present invention or a salt thereof, or the glycosylated linker of the present invention has a physiological activity for which pharmacological activity or the like is desired to be exhibited immediately after reaching the target environment (for example, in blood). Substances can be used.
- glycosylated linker moiety in the present invention, when a hydrogen atom is substituted with a glycosylated amino acid or a glycosylated polypeptide, it is substituted with the amino acid moiety in the glycosylated amino acid, or the glycosylated chain is added. Substitution is preferably made at the amino acid moiety constituting the polypeptide in the polypeptide. These substitutions are not limited as long as they are binding modes known to those skilled in the art.
- the sugar chain, glycosylated amino acid and / or glycosylated polypeptide in the present invention is bound to a nitrogen atom, a carbon atom and / or a sulfur atom, etc. present in the glycosylated linker moiety. Bonding is achieved by replacing at least one hydrogen atom.
- glycosylated linker moiety in the present invention is represented by the formula (I):
- R 2 or R 3 is a hydrogen atom (both R 2 and R 3 are not hydrogen atoms at the same time)
- the glycosylated amino acid or glycosylated polypeptide is substituted at the part of such hydrogen atom.
- R 2 and / or R 3 is an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms, or R 2 and R 3 are nitrogen atoms to which they are bonded.
- the glycosylated amino acid or glycosylated polypeptide may be substituted.
- R 2 is a methyl group
- at least one hydrogen atom in the methyl group (—CH 3 ) may be substituted with a glycosylated amino acid or a glycosylated polypeptide.
- R 2 and R 3 together with the nitrogen atom to which they are bonded form piperazine
- the hydrogen atom bonded to the nitrogen atom on the ring structure of the piperazine is added to the sugar chain It may be substituted with an amino acid or glycosylated polypeptide.
- At least one hydrogen atom bonded to the nitrogen group present in the alkyl group, the aryl group, or the heterocyclic ring is substituted with a sugar chain, a glycosylated amino acid, or a glycosylated polypeptide.
- at least one hydrogen atom bonded to the nitrogen group present in the alkyl group, the aryl group, or the heterocyclic ring is substituted with a glycosylated amino acid or a glycosylated polypeptide, and more
- the substitution is a bond at an amino acid or polypeptide portion in the “glycosylated amino acid or glycosylated polypeptide”.
- glycosylated linker moiety in the present invention is represented by the formula (II):
- the sugar chain, glycosylated amino acid or glycosylated polypeptide of R 6 is bonded to the nitrogen atom on the ring structure of piperazine in the above formula (II).
- R 6 is preferably a glycosylated amino acid or a glycosylated polypeptide, and in such a case, but not limited thereto, the bond to the nitrogen atom of R 6 is the “glycosylated amino acid or sugar It is preferably a bond at the amino acid or polypeptide portion in the “chain added polypeptide”.
- the glycosylated linker moiety in the present invention is represented by the formula (III) or the formula (IV):
- the glycosylated linker moiety in the present invention represented by the formula (III) or the formula (IV) is Contains sugar chain structure.
- R 8 is a sugar chain, a sugar chain-added amino acid or a sugar chain-added polypeptide, and R in the formula (III) or the formula (IV) It may be bonded to the nitrogen atom to which 8 is bonded.
- R 8 is bonded to R 8 which is a protective group such as a hydrogen atom or an acyl group having 1 to 16 carbon atoms, Fmoc group, Boc group, Z group, Troc group, or Alloc group.
- substitution may be made with a sugar chain, a glycosylated amino acid or a glycosylated polypeptide using the nucleophilicity of the amino group derived from the nitrogen atom.
- the substituted R 8 is a glycosylated amino acid or glycosylated polypeptide, the substitution is in the amino acid or polypeptide portion of the “glycosylated amino acid or glycosylated polypeptide”. A bond is preferred.
- R 8 which is a protecting group such as a hydrogen atom or an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group is substituted with an amino acid or a polypeptide.
- a sugar chain may be further added to the substituted amino acid or polypeptide by a method well known to those skilled in the art.
- the glycosylated amino acid in the present invention is converted into a sugar chain by a dehydration condensation reaction between the —OH moiety in the carboxy group present in the main chain of the amino acid and the hydrogen atom derived from the glycosylated linker moiety. It may be attached to an additional linker moiety.
- the amino acid is serine, threonine or tyrosine
- the glycosylated amino acid may be bound by a dehydration condensation reaction between a hydroxy group present in the side chain of the amino acid and the hydrogen atom.
- the glycosylated amino acid is bound by a dehydration condensation reaction between the —OH moiety in the carboxy group present in the side chain of the amino acid and the hydrogen atom. You can do it.
- the glycosylated polypeptide of the present invention comprises a dehydration condensation reaction between the —OH moiety in the carboxy group of the C-terminal amino acid constituting the polypeptide and the aforementioned hydrogen atom derived from the glycosylated linker moiety. May be combined.
- the glycosylated polypeptide has a hydroxy group present in the side chain of the amino acid residue when the amino acid residue constituting the polypeptide includes a serine residue, a threonine residue, or a tyrosine residue. You may couple
- the glycosylated polypeptide is a carboxy group present in the side chain of the amino acid residue when the amino acid residue constituting the polypeptide includes an aspartic acid residue or a glutamic acid residue. Bonding may be performed by a dehydration condensation reaction between the —OH moiety and the hydrogen atom.
- R 7 may be bonded to any part of the sugar chain (for example, the reducing end) via a —S—CH 2 —CONH— moiety or a —CONH— moiety.
- the sugar chain is bonded to the nitrogen atom of —S—CH 2 —CONH— or —CONH—.
- R 7 is —S—CH 2 —CONH—sugar chain
- —CH 2 —CONH— represents a linker, and preferably, the sulfur atom may be derived from cysteine.
- R 7 is —CONH-sugar chain, preferably —CONH— may be derived from asparagine.
- the glycosylated linker of the present invention can be bonded to at least one amino group, hydroxy group, thiol group, or carboxy group of a physiologically active substance.
- the form of the binding is not limited as long as it is known to those skilled in the art, but when the physiologically active substance has an amino group, it is bound by an amide bond, and when the physiologically active substance has a hydroxy group, an ester bond.
- the physiologically active substance has a thiol group
- it is preferably bound by a thioester bond
- the physiologically active substance has a carboxy group
- it is preferably bound by an acid anhydride bond.
- the mode of binding is the same.
- the physiologically active substance is a polynucleotide or includes a polynucleotide as a part thereof
- the glycosylated linker of the present invention and an amide bond or ester are not limited, but are limited thereto. You may combine by a coupling
- the glycosylation linker of the present invention is bound by an amide bond through an amino group or a carboxy group, which is not limited thereto. May be.
- the physiologically active substance is a protein or polypeptide, or includes a peptide portion as a part thereof, the amino active, hydroxy group, thiol group, or carboxy group of the present invention is not limited, You may couple
- the physiologically active substance in the present invention is a protein or polypeptide, (I) having an amino group derived from an amino acid at the N-terminus, (II) includes a serine residue, threonine residue or tyrosine residue having a hydroxy group in the side chain, (III) containing an aspartic acid residue or a glutamic acid residue having a carboxy group in the side chain, (IV) contains a lysine residue, asparagine residue, arginine residue, histidine residue or tryptophan residue having an amino group in the side chain, (V) includes a cysteine residue having a thiol group in the side chain, or (VI) It preferably has a carboxy group derived from an amino acid at the C-terminus.
- the aspartic acid may be D-aspartic acid.
- the glutamic acid may be D-glutamic acid.
- Other artificial amino acids may be employed as well.
- the binding between the physiologically active substance moiety and the glycosylated linker moiety is (1) an amide bond in the N-terminal amino group of the physiologically active substance, (2) An ester bond in a hydroxy group present in the side chain of a serine residue, threonine residue or tyrosine residue of the physiologically active substance (provided that the physiologically active substance is a serine residue, threonine residue or tyrosine residue) Only if you have (3) Acid anhydride bond in the carboxy group (specifically, —OH moiety in the —COOH group) present in the side chain of the aspartic acid residue or glutamic acid residue of the physiologically active substance (however, the physiological activity Only if the substance has aspartic acid or glutamic acid residues) (4) Amide bond in the amino group present in the side
- the mode of binding between the physiologically active substance part and the glycosylated linker moiety is the same as the mode of binding described above when the physiologically active substance is a protein or polypeptide. May be.
- the compound of the present invention or a salt thereof has been found to increase in water solubility while the half-life does not change as the number of sugar chains added to the linker moiety increases. Presence is believed not to interfere with cleavage of the linker moiety from the compound of the invention or salt thereof. Therefore, in the present invention, when the glycosylated linker moiety and the physiologically active substance moiety are linked via an amide bond, the mechanism by which the glycosylated linker is cleaved by cleaving the amide bond is Although it is not intended to be restrained by this, it was considered to be based on what is reported in the pamphlet of International Publication No. 2009/095479.
- the release rate of the physiologically active substance generated by the cleavage of the glycosylated linker moiety in the compound of the present invention or a salt thereof has a positive correlation in vivo / in vitro. .
- the cleavage of the glycosylated linker moiety in the present invention is characterized by having a positive correlation in vivo / in vitro.
- the compound of the present invention or a salt thereof, and the glycosylated linker of the present invention have a sugar chain, so that they can be easily used in an in vivo environment (body fluid such as blood, lymph, etc.). Can be dissolved.
- glycosylation linker may be represented by the formula (B) “R 1 -L” in which a glycosylation linker moiety (R 1 ) and a leaving group L are bonded. Can exist stably.
- the glycosylated linker of the present invention may be intended to bind to a physiologically active substance having at least one amino group, hydroxy group, thiol group, or carboxy group.
- the glycosylated linker of the present invention is represented by the following formula (B): R 1 -L (B) here, R 1 means a glycosylated linker moiety, the definition of which is as described above, L means a leaving group.
- R 1 means a glycosylated linker moiety, the definition of which is as described above, L means a leaving group.
- at least one hydrogen atom bonded to a nitrogen atom present in the alkyl group, the aryl group, or the heterocyclic ring is substituted with a glycosylated amino acid or a glycosylated polypeptide. More preferably, the substitution is a linkage at an amino acid or polypeptide portion in the “glycosylated amino acid or glycosylated polypeptide”.
- L represents a group capable of binding to a sugar chain addition linker moiety (R 1 ).
- the aspect of the leaving group L and the elimination reaction are not particularly limited as long as they are known to those skilled in the art.
- a leaving group as disclosed in International Publication No. 2009/095479 may be used.
- the L is not limited, but in one embodiment, chlorine, bromine, fluorine, nitrophenoxy, imidazolyl, N-hydroxysuccinimidyl, N-hydroxybenzotriazolyl, N-hydroxyazobenzotriazolyl, pentafluoro It may be phenoxy, 2-thiooxo-thiazolidinyl or N-hydroxysulfosuccinimidyl.
- the glycosylated linker of the present invention can be stored stably under low temperature conditions (for example, ⁇ 80 ° C. to 4 ° C., preferably ⁇ 80 ° C. to ⁇ 30 ° C.). Furthermore, the leaving group L can be removed from the sugar chain-added linker by elimination reaction, and can be bound to the physiologically active substance in the above-described manner.
- the sugar chain addition linker of the present invention is a compound or a salt thereof containing a sugar chain addition linker moiety and a physiologically active substance moiety. After collection, it may be reused.
- the synthesized or recovered sugar chain addition linker of the present invention is a sugar chain addition linker represented by the formula (I ′′)
- the free carboxylic acid in the sugar chain addition linker and the physiologically active substance have at least By dehydrating and condensing one amino group, hydroxy group, thiol group, or carboxy group, the glycosylated linker of the present invention and a physiologically active substance are bound to produce the compound of the present invention or a salt thereof. Also good.
- linker moiety in the present invention, it is also possible to synthesize only the linker moiety in the present invention, and then bind the sugar chain, glycosylated amino acid and / or glycosylated polypeptide to the linker moiety to produce a glycosylated linker moiety.
- a physiologically active substance such as a protein or polypeptide obtained by extraction from a living body, expression, chemical synthesis, or the like may be bound to the produced glycosylated linker.
- the bioactive substance moiety having at least one amino group, hydroxy group, thiol group, or carboxy group in the cleaved glycosylation linker The portion bonded to has an —OH group.
- the glycosylation linker immediately after cleavage from the compound comprising the glycosylation linker moiety and the physiologically active substance moiety of the present invention or a salt thereof is a sugar chain represented by the formula (I ′′) in the present specification. It may be an additional linker.
- the “linker” (having a structure in which no sugar chain is bonded) in the sugar chain-added linker can be produced in a state where no sugar chain is bonded.
- the production method, production conditions, and the like are not limited.
- a free carboxy group derived from a dicarboxylic acid anhydride for example, phthalic acid anhydride
- a diamine for example, N- (2- Aminoethyl) piperazine
- the dicarboxylic acid anhydride and diamine are not limited, but may be the same as the dicarboxylic acid anhydride and diamine that can be used in a unit that forms a glycosyl linker described below.
- a sugar chain addition linker using a unit for forming a sugar chain addition linker which will be described later, is used. You may synthesize
- the method for binding the linker moiety to the physiologically active substance, reaction conditions and the like are not limited.
- the production method and production conditions described in International Publication No. 2009/095479 are appropriately taken into consideration. Those skilled in the art will appreciate that this may be done.
- the compound containing a glycosylated linker moiety of the present invention and a physiologically active substance moiety or a salt thereof may be synthesized using a liquid phase synthesis method or a solid phase synthesis method.
- a compound containing a glycosylated linker moiety of the present invention and a physiologically active substance moiety or a salt thereof is (A) fixing a physiologically active substance to an appropriate resin; (B) attaching a linker by an amide bond, an ester bond, a thioester bond, or an acid anhydride bond in at least one amino group, hydroxy group, thiol group, or carboxy group of the physiologically active substance; (C) Then, it may be synthesized by a process comprising a step of binding a sugar chain, a glycosylated amino acid and / or a glycosylated polypeptide to a linker.
- step (B ′) At least one free amino group, hydroxy group, thiol group, or carboxy group of the physiologically active substance, and a first linker moiety (dicarboxylic anhydride (eg, phthalic anhydride)) Condensation by an amide bond, an ester bond, a thioester bond or an acid anhydride bond, and further, a free carboxy group in the first linker moiety is linked to a second linker moiety (diamine (eg N- (2-aminoethyl) piperazine A physiologically active substance having a desired linker moiety may be obtained by condensing the free amino group in)).
- a first linker moiety (dicarboxylic anhydride (eg, phthalic anhydride)) Condensation by an amide bond, an ester bond, a thioester bond or an acid anhydride bond, and further, a free carboxy group in the first linker moiety is linked to a second link
- a person skilled in the art can synthesize a physiologically active substance having a desired linker moiety by appropriately selecting reaction conditions, a compound constituting a part of the linker to be reacted, etc., and condensing the physiologically active substance continuously. it can.
- the step (A) precedes the step (B) or the step (B ′).
- the protein or polypeptide may be synthesized on an appropriate resin by solid phase synthesis.
- the method for synthesizing a protein or polypeptide by the solid phase synthesis method is not limited as long as it is a method well known to those skilled in the art.
- the method for producing a compound of the present invention or a salt thereof, which is combined with a protein or polypeptide synthesis method by a solid phase synthesis method may be performed, for example, as follows.
- the hydroxy group of a resin (resin) having a hydroxy group is esterified with the carboxy group of an amino acid whose amino group is protected with a fat-soluble protecting group.
- the amino group of the amino acid is protected with a fat-soluble protecting group, self-condensation between amino acids is prevented, and an esterification reaction occurs between the hydroxy group of the resin and the carboxy group of the amino acid.
- step (1) removing the lipophilic protecting group of the ester obtained in step (1) to form a free amino group; (3) an amidation reaction between the free amino group and a carboxy group of another amino acid whose amino group is protected with a fat-soluble protecting group; (4) After step (3), the lipophilic protecting group is eliminated to form a free amino group, (5)
- a polypeptide in which a desired number of amino acids are linked can be obtained by repeating the steps (3) and (4) as necessary.
- the polypeptide obtained in step (5) has one end bonded to the resin and the other end having a free amino group. Therefore, (6) A linker having the target structure is bonded to an amide bond, an ester bond, a thioester bond or an acid anhydride bond at the free amino group of the polypeptide bonded to the resin, (7) replacing at least one hydrogen atom in a predetermined substituent of the linker moiety with a sugar chain, a glycosylated amino acid and / or a glycosylated polypeptide; (8) The ester bond formed in step (1) is cleaved with an acid.
- a desired linker moiety-polypeptide compound comprising a sugar chain, a glycosylated amino acid and / or a glycosylated polypeptide moiety can be produced. it can.
- step (6) at least one hydrogen atom in a given substituent of the linker moiety is substituted with an amino acid and / or polypeptide; (8 ′) cleaving the ester bond formed in step (1) with an acid to obtain a desired linker moiety-polypeptide compound comprising an amino acid and / or polypeptide moiety; (9 ′) A sugar chain is added to the amino acid and / or polypeptide portion of the compound.
- a linker moiety having a desired sugar chain, glycosylated amino acid and / or glycosylated polypeptide moiety can be produced.
- the solid phase resin is usually a resin used in solid phase synthesis.
- the solid phase resin is usually a resin used in solid phase synthesis.
- Amino-PEGA resin Merck
- Wang resin Merck
- HMPA- PEGA resin Merck
- 2-chlorotrityl chloride resin Merck
- a linker may be present between the amino-PEGA resin (resin) and the amino acid.
- examples of such a linker include 4-hydroxymethylphenoxyacetic acid (HMPA), 4- (4-hydroxymethyl-3 -Methoxyphenoxy) -butylacetic acid (HMPB) and the like.
- the fat-soluble protecting group examples include 9-fluorenylmethoxycarbonyl (Fmoc) group, t-butyloxycarbonyl (Boc) group, benzyloxycarbonyl group (Z) group, 2,2,2-trichloroethoxycarbonyl ( Troc group, carbonyl-containing group such as allyloxycarbonyl (Alloc) group, acyl group such as acetyl (Ac) group, protecting group such as allyl group, benzyl group, etc. is not.
- Fmoc 9-fluorenylmethoxycarbonyl
- Boc t-butyloxycarbonyl
- Z benzyloxycarbonyl group
- Troc group carbonyl-containing group such as allyloxycarbonyl (Alloc) group
- acyl group such as acetyl (Ac) group
- protecting group such as allyl group, benzyl group, etc. is not.
- the fat-soluble protecting group for example, when introducing the Fmoc group, 9-fluorenylmethyl-N-succinimidyl carbonate and sodium hydrogen carbonate can be added and reacted.
- the reaction may be performed at 0 to 50 ° C., preferably at room temperature, for about 1 to 5 hours.
- amino acid protected with a fat-soluble protecting group those obtained by protecting the above-mentioned amino acid by the above-mentioned method can be used.
- Commercially available products can also be used.
- a known dehydration condensing agent such as 1-mesitylenesulfonyl-3-nitro-1,2,4-triazole (MSNT), dicyclohexylcarbodiimide (DCC), 1,3-diisopropylcarbodiimide (DIC) is used.
- MSNT 1-mesitylenesulfonyl-3-nitro-1,2,4-triazole
- DCC dicyclohexylcarbodiimide
- DIC 1,3-diisopropylcarbodiimide
- the use ratio of the amino acid and the dehydrating condensing agent may be usually 1 to 10 parts by weight, preferably 2 to 5 parts by weight, with respect to the former 1 part by weight.
- the esterification reaction is preferably performed, for example, by placing a resin in a solid phase column, washing the resin with a solvent, and then adding an amino acid solution.
- the cleaning solvent include dimethylformamide (DMF), 2-propanol, dichloromethane, and the like.
- solvents that dissolve amino acids include dimethyl sulfoxide (DMSO), DMF, dichloromethane, and the like.
- the esterification reaction may be carried out at 0 to 50 ° C., preferably at room temperature, for about 10 minutes to 30 hours, preferably for about 15 minutes to 24 hours. After the esterification reaction, it is also preferable to cap the unreacted functional group on the solid phase by acetylation using acetic anhydride or the like.
- the elimination of the lipophilic protecting group can be carried out, for example, by treatment with a base.
- a base include piperidine and morpholine.
- a solvent examples include DMSO, DMF, methanol and the like.
- amidation reaction between a free amino group and a carboxy group in any amino acid / polypeptide in which the amino group nitrogen is protected with a fat-soluble protecting group is preferably performed in the presence of an activator and a solvent.
- activator examples include dicyclohexylcarbodiimide (DCC), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC / HCl), diphenylphosphoryl azide (DPPA), carbonyldiimidazole (CDI).
- DCC dicyclohexylcarbodiimide
- WSC / HCl 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride
- DPPA diphenylphosphoryl azide
- CDI carbonyldiimidazole
- the activator is used in an amount of 1 to 20 equivalents, preferably 1 to 10 equivalents, more preferably 1 to 5 equivalents to any amino acid / polypeptide in which the amino group nitrogen is protected with a fat-soluble protecting group. It is preferable to make it equivalent.
- the reaction proceeds even with the above activator alone, but it is preferable to use an amine as an auxiliary agent.
- an amine for example, diisopropylethylamine (DIPEA), N-ethylmorpholine (NEM), N-methylmorpholine (NMM), N-methylimidazole (NMI), 2,4,6-trimethylpyridine and the like can be used.
- DIPEA diisopropylethylamine
- NEM N-ethylmorpholine
- NMM N-methylmorpholine
- NMI N-methylimidazole
- 2,4,6-trimethylpyridine 2,4,6-trimethylpyridine and the like
- the amount of the adjuvant used is 1 to 20 equivalents, preferably 1 to 10 equivalents, more preferably 1 to 5 equivalents, based on any amino acid / polypeptide in which the amino group nitrogen is protected with a fat-soluble protecting group. Is preferable.
- the solvent examples include DMSO, DMF, and dichloromethane.
- the reaction is carried out at 0 to 50 ° C., preferably at room temperature, for about 10 minutes to 30 hours, preferably about 15 minutes to 24 hours. During this time, it is preferable to acetylate and cap the unreacted amino group on the solid phase using acetic anhydride or the like.
- the elimination of the lipophilic protecting group can be carried out in the same manner as described above.
- the acid include trifluoroacetic acid (TFA) and hydrogen fluoride (HF).
- TSA trifluoroacetic acid
- HF hydrogen fluoride
- a highly reactive cationic species may be generated from the fat-soluble protecting group used for amino acids and the linker on the resin, so a nucleophilic reagent may be added to capture this.
- the nucleophilic reagent include triisopropylsilane (TIS), phenol, thioanisole, ethanedithiol (EDT) and the like.
- the conditions for the condensation reaction between a physiologically active substance are not particularly limited, but may be appropriately selected based on methods well known to those skilled in the art. It's okay. For example, it may cause a unit (for example, a dicarboxylic acid, a diamine, and a sugar chain, a glycosylated amino acid and / or a glycosylated polypeptide) to sequentially act on a physiologically active substance. .
- a dicarboxylic acid is first introduced, then a diamine is introduced into one carboxylic acid of the dicarboxylic acid via an amide bond, and finally a sugar chain or sugar chain is introduced into the other amino group of the diamine via an amide bond. Additional amino acids and / or glycosylated polypeptides may be introduced.
- the other amino group in the diamine is used, for example, to form a substituted or unsubstituted 3- to 7-membered heterocyclic ring, it is used for an amide bond with a glycosylated amino acid and / or a glycosylated polypeptide.
- the amino group can be an amino group derived from a 3-7 membered heterocyclic structure.
- transduction of the said dicarboxylic acid can be performed by making the acid anhydride of dicarboxylic acid react with the free amino group in the said diamine, for example in presence of bases, such as a pyridine, for example.
- the introduction of the diamine can be performed, for example, by condensing the diamine with a free carboxy group in a dicarboxylic acid in the presence of the activator and the auxiliary amine.
- the solvent for the above reaction include DMSO, DMF, and dichloromethane.
- the reaction may be carried out at 0 to 50 ° C., preferably at room temperature, for about 10 minutes to 30 hours, preferably for about 15 minutes to 24 hours.
- Examples of the acid anhydride of the dicarboxylic acid include the following compounds.
- an acid anhydride of a dicarboxylic acid having an aryl ring Is mentioned.
- an acid anhydride of a dicarboxylic acid having a cycloalkyl ring Is mentioned.
- an acid anhydride of a dicarboxylic acid having a cycloalkenyl ring Is mentioned.
- an acid anhydride of a dicarboxylic acid having a heterocyclic ring Is mentioned.
- an acid anhydride of a dicarboxylic acid having bicyclyl Is mentioned.
- R 5A and R 5B together with the carbon atom to which R 5A is bonded, the carbon atom to which R 5B is bonded, are aryl having 5 to 16 carbon atoms, cycloalkenyl having 5 to 16 carbon atoms, and 7 to 13 carbon atoms.
- Y corresponds to, for example, the structural portion of the above-described various acid anhydrides of dicarboxylic acid, excluding C ( ⁇ O) —O—C ( ⁇ O).
- phthalic anhydride when phthalic anhydride is used as a dicarboxylic acid anhydride, the compound of the present invention or a salt thereof, the sugar chain-added linker of the present invention, or a linker (having a structure in which no sugar chain is bonded) is produced.
- the phenyl ring portion surrounded by a dotted line in the following formula that is, the structural portion excluding C ( ⁇ O) —O—C ( ⁇ O) in the phthalic anhydride
- group Y corresponds to the structure of group Y.
- the diamine is not limited, but may be a substituted or unsubstituted ethylenediamine.
- one of the amino groups may be used to form a substituted or unsubstituted 3- to 7-membered heterocyclic ring.
- such a diamine may be a commercially available diamine, or may be synthesized by a method well known to those skilled in the art.
- N- (2-aminoethyl) imidazolidine N- (2-aminoethyl) piperazine: 4- (2-Aminoethyl) -1,4-diazepane: N- (2-aminopropyl) piperazine: 4- (2-Aminoethyl) piperazin-2-one: 1- (2-Aminoethyl) -piperidin-3-ol: 1- (2,5-dimethylpiperazin-1-yl) propan-2-amine:
- the substituted or unsubstituted 3- to 7-membered heterocyclic ring may be the same as the substituted or unsubstituted 3- to 7-membered heterocyclic ring described above in relation to the substituents R 2 and / or R 3. .
- R 2 and / or R 3 in the glycosylated linker moiety represented by the formula (I) in the present invention is an alkyl group having 1 to 16 carbon atoms
- a functional group such as an amino group, a carboxy group, a hydroxy group, or a thiol group, and, for example, a sugar chain, an amino acid, a polypeptide, a glycosylated amino acid, or a glycosylated polypeptide is introduced at the functional group portion.
- the functional group can be introduced at any position on the alkyl group by chemical synthesis according to a method well known to those skilled in the art.
- the amino group is an amide bond
- the carboxy group is an amide bond or an ester bond
- the hydroxy group is an ester bond or an ether bond
- the thiol group is a thioether bond or a thioester bond
- a sugar chain Additional amino acids and / or glycosylated polypeptides can be attached.
- the portion corresponding to R 2 and / or R 3 has an alkyl group having 1 to 16 carbon atoms, and an amino group has been introduced.
- ethylenediamine derivatives examples include the following derivatives (diamine derivatives): 3- (2-Aminoethylamino) propylamine: Tris (2-aminoethyl) amine:
- the moiety corresponding to R 2 and / or R 3 has an alkyl group having 1 to 16 carbon atoms, and a carboxy group is introduced.
- ethylenediamine derivative examples include the following derivatives: [(2-Aminoethyl) amino] acetic acid:
- the moiety corresponding to R 2 and / or R 3 has an alkyl group having 1 to 16 carbon atoms, and a hydroxy group is introduced.
- ethylenediamine derivative examples include the following derivatives: 3- (2-Aminoethylamino) propanol: N, N-bis (2-hydroxyethyl) ethylenediamine:
- a moiety corresponding to R 2 and / or R 3 has an alkyl group having 1 to 16 carbon atoms, and a thiol group is introduced.
- Examples of the ethylenediamine derivative described above include the following derivatives: 2- (2-Aminoethylamino) ethanethiol: Those skilled in the art, for example, in the case where an alkyl group having 1 to 16 carbon atoms is present in the other glycosylated linker or the portion corresponding to R 2 and / or R 3 in the linker, for example, sugar chain, amino acid, poly The introduction of peptides, glycosylated amino acids and / or glycosylated polypeptides is similarly understood.
- R 2 and / or R 3 in the glycosylated linker moiety represented by the formula (I) in the present invention is an aryl group having 5 to 16 carbon atoms
- the aryl group A functional group such as an amino group, a carboxy group, a hydroxy group, or a thiol group is introduced onto the functional group, for example, a sugar chain, an amino acid, a polypeptide, a glycosylated amino acid, or a glycosylated polypeptide. May be introduced.
- the functional group can be introduced at any position on the aryl group by chemical synthesis according to a method well known to those skilled in the art.
- the amino group is an amide bond
- the carboxy group is an amide bond or an ester bond
- the hydroxy group is an ester bond or an ether bond
- the thiol group is a thioether bond or a thioester bond
- a sugar chain Additional amino acids and / or glycosylated polypeptides can be attached.
- the glycosylated linker moiety represented by the formula (I) in the present invention the moiety corresponding to R 2 and / or R 3 has an aryl group having 5 to 16 carbon atoms, and an amino group has been introduced.
- ethylenediamine derivatives examples include the following derivatives: N- (2-aminoethyl) -1,4-benzenediamine: N- (2-aminoethyl) -1,2-benzenediamine: N- (2-aminoethyl) -1,3-benzenediamine:
- the moiety corresponding to R 2 and / or R 3 has an aryl group having 5 to 16 carbon atoms, and a carboxy group is introduced.
- the glycosylated linker moiety represented by the formula (I) in the present invention has an aryl group having 5 to 16 carbon atoms in a portion corresponding to R 2 and / or R 3 and a hydroxy group is introduced.
- ethylenediamine derivative examples include the following derivatives: 4-[(2-Aminoethyl) amino] -phenol: Those skilled in the art will understand, for example, in the case where an aryl group having 5 to 16 carbon atoms is present in other glycosylation linkers or linkers corresponding to R 2 and / or R 3 in the present invention, The introduction of peptides, glycosylated amino acids and / or glycosylated polypeptides is similarly understood.
- R 2 and / or R 3 in the glycosylated linker moiety represented by the formula (I) in the present invention is an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms, or R 2 And when R 3 together with the nitrogen atom to which they are attached form a 3- to 7-membered heterocyclic ring, a thiol group is introduced onto the alkyl group, aryl group or heterocyclic ring.
- a haloacetylated (for example, bromoacetylated) complex type sugar chain derivative (or a haloacetamido complex type sugar chain derivative) or the like can be directly bound, although not limited thereto.
- R 2 and / or R 3 in the glycosylated linker moiety represented by formula (I) in the present invention is an alkyl group having 1 to 16 carbon atoms or an aryl group having 5 to 16 carbon atoms, or R 2 and R 3 together with the nitrogen atom to which they are attached form a 3-7 membered heterocyclic ring and are attached to the glycosylated amino acid or glycosylated poly
- the sugar chain in the peptide is a sugar chain such as a haloacetylated complex sugar chain derivative, it is determined that the sugar chain part can be directly bonded to the glycosylated linker part without using an amino acid part or a polypeptide part. The trader understands naturally.
- the haloacetylated complex type sugar chain derivative (or the haloacetamido complex type sugar chain derivative) is obtained by, for example, converting a hydroxy group bonded to the 1-position carbon of a complex type asparagine-linked sugar chain to —NH— (CH 2 ). a— (CO) —CH 2 X (X is a halogen atom, a is an integer, and is not limited as long as the desired linker function is not inhibited, but preferably represents an integer of 0 to 4). It is a substituted compound.
- At least one hydrogen atom in a given substituent of the linker moiety bound to the physiologically active substance is replaced with a sugar chain, a glycosylated amino acid (the amino acid may be, for example, asparagine) and / or a glycosylated polypeptide (
- the reaction conditions for substitution with a polypeptide are not limited, but may be appropriately selected based on methods well known to those skilled in the art. For example, it may react a sugar chain, a glycosylated amino acid and / or a glycosylated polypeptide in the presence of the activator and the auxiliary amine.
- At least one hydrogen atom in a given substituent of the linker moiety bound to the bioactive substance is replaced with an amino acid (eg, cysteine) and / or a polypeptide moiety (which may be a cysteine residue in the polypeptide).
- an amino acid eg, cysteine
- a polypeptide moiety which may be a cysteine residue in the polypeptide.
- the reaction conditions for substituting by are not limited, but may be appropriately selected based on methods well known to those skilled in the art. For example, it may be carried out by introducing Cys at a position where a sugar chain is to be added, by a solid phase synthesis method, a liquid phase synthesis method or the like.
- the reaction conditions for adding a sugar chain to the substituted amino acid and / or polypeptide are not limited, but may be appropriately selected based on methods well known to those skilled in the art.
- a haloacetylated complex-type sugar chain derivative with a compound containing unprotected Cys obtained above, the sugar chain is reacted with a thiol group of unprotected Cys and bonded to the compound.
- the above reaction is usually performed at 0 to 80 ° C., preferably 10 to 60 ° C., more preferably 15 to 35 ° C. in a phosphate buffer, Tris-HCl buffer, citrate buffer, or a mixed solution thereof. Preferably it is done.
- the reaction time is not limited, but is usually 10 minutes to 24 hours, preferably about 30 minutes to 5 hours. After completion of the reaction, it may be appropriately purified by a known method (for example, HPLC).
- the haloacetylation may be, for example, chloroacetylation, bromoacetylation, iodoacetylation or the like.
- the haloacetylated complex sugar chain derivative means, for example, a compound in which a complex sugar chain such as a double chain complex sugar chain, a three chain complex sugar chain, or a four chain complex sugar chain is haloacetylated. It's okay.
- Methods and embodiments of sugar chain haloacetylation may be referred to, for example, International Publication No. 2005/10053 (US2007060543 (A1)), and are known to those skilled in the art.
- the linker moiety used in the method for producing a compound comprising a glycosylated linker moiety of the present invention and a physiologically active substance moiety or a salt thereof is represented by the aforementioned formula (I ′) (wherein each substituent The base and the wavy line are as defined above.)
- at least one hydrogen atom bonded to a nitrogen atom present in the alkyl group, the aryl group, or the heterocyclic ring is substituted with a glycosylated amino acid or a glycosylated polypeptide. More preferably, the substitution is a linkage at an amino acid or polypeptide portion in the “glycosylated amino acid or glycosylated polypeptide”.
- the linker moiety used in the method for producing a compound containing a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof according to the present invention is represented by the aforementioned formula (I ′), although not limited thereto.
- a linker moiety represented by the following formula (II ′) may be used. [In the formula (II ′), R 4 , Y and the wavy line are respectively as defined above, R 6 ′ is a hydrogen atom. ].
- the hydrogen atom of R 6 ′ of the linker moiety is further substituted with a sugar chain, glycosylated amino acid or glycosylated polypeptide (here, in one embodiment)
- the hydrogen atom of R 6 ′ of the linker moiety is preferably substituted with a glycosylated amino acid or glycosylated polypeptide, and the substitution is not limited, but the “glycosylated amino acid or glycosylated poly (polysaccharide)” It is preferably a bond at an amino acid or polypeptide moiety in the “peptide”).
- the hydrogen atom at R 6 ′ of the linker moiety represented by the formula (II ′) is a glycosylated asparagine (the amino group of the main chain of the asparagine is protected by a protecting group, although not limited thereto). May have a structure of a glycosylated linker moiety represented by the formula (IIIa).
- R 4 , Y and the wavy line are respectively as defined above, R 7A is a —CONH-sugar chain, R 8A is a protecting group such as an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group.
- the protecting group for R 8A may be substituted with a hydrogen atom, amino acid, polypeptide, sugar chain, glycosylated amino acid or glycosylated polypeptide.
- R 8A when R 8A is a glycosylated amino acid or glycosylated polypeptide, the bond to the nitrogen atom of R 8A is the amino acid or polypeptide of the “glycosylated amino acid or glycosylated polypeptide”. A bond at the moiety is preferred.
- the hydrogen atom of R 6 ′ of the linker moiety represented by the formula (II ′) is replaced by a cysteine whose amino group of the main chain is protected by a protecting group. It may be substituted to have the structure of the linker moiety represented by the formula (III ′).
- R 4 , Y and the wavy line are respectively as defined above, R 7 ′ is —SH; R 8 ′ is a protecting group such as an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group.
- the protecting group for R 8 ′ may be further substituted with a hydrogen atom, amino acid, polypeptide, sugar chain, glycosylated amino acid or glycosylated polypeptide.
- R 8 ′ when R 8 ′ is a glycosylated amino acid or glycosylated polypeptide, the bond of R 8 ′ to the nitrogen atom is the amino acid or polypeptide in the “glycosylated amino acid or glycosylated polypeptide”. It is preferably a bond in the peptide part.
- a sugar chain-added linker moiety may be formed by replacing the hydrogen atom in —SH of R 7 ′ with a —CH 2 —CONH-sugar chain.
- the present invention preferably provides a compound or a salt thereof that can be obtained by any of the above-described production methods.
- the compound or salt thereof that can be obtained is not limited to those produced by any of the production methods described above, and those produced by other production methods are also targeted.
- the present invention preferably provides a compound or a salt thereof obtained by any of the above-described production methods (obtained).
- a compound comprising the glycosylated linker moiety of the present invention and the physiologically active substance moiety, regardless of whether or not the physiologically active substance is sparingly soluble by utilizing the glycosylated linker of the present invention.
- the physiologically active substance can be easily dissolved in an aqueous solution or an emulsion prepared from the aqueous solution. After the dissolution, the glycosylated linker moiety is cleaved, whereby an unmodified physiologically active substance can be released.
- the glycosylated linker moiety in the present invention can be cleaved from the compound or salt thereof containing the glycosylated linker moiety of the present invention and a physiologically active substance moiety independently of an enzyme or light.
- the glycosylated linker moiety can be cleaved from the “compound containing a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof” by autohydrolysis by its intramolecular catalysis.
- the cleavage is performed by an enzyme existing in the living body (for example, in the case of an amide bond, an enzyme includes an amidase. In the case of an ester bond, an enzyme includes an esterase). It is not intended to exclude chemical cleavage such as chemical cleavage or light.
- self-cleavage or “autocatalytic cleavage” refers to intramolecular catalysis in a linker moiety in a compound comprising a glycosylated linker moiety of the present invention and a physiologically active substance moiety or a salt thereof. This means that the linkage between the glycosylated linker moiety and the physiologically active substance moiety is cleaved by automatic hydrolysis (hydrolysis that does not require an external factor such as an enzyme or light).
- the compound of the present invention or a salt thereof has a feature that, after being dissolved in an aqueous solution or emulsion, the cleavage of the glycosylated linker moiety is accelerated depending on pH and / or temperature ( pH and / or temperature dependent cleavage).
- the compound of the present invention or a salt thereof and the glycosylated linker of the present invention may be stored, for example, at a low temperature (for example, ⁇ 80 ° C. to 4 ° C.) and / or at a low pH (for example, pH 1 to pH 4).
- the step of preparing a “compound containing a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof” by binding a physiologically active substance to the glycosylated linker moiety is performed at, for example, a low temperature (eg, 0 ° C. to 25 ° C. ) And / or at low pH (eg pH 1 to pH 7).
- a low temperature eg, 0 ° C. to 25 ° C.
- low pH eg pH 1 to pH 7
- the glycosylated linker moiety of the present invention By protecting the N-terminal amino group of the glycosylated amino acid with an acyl group having 1 to 16 carbon atoms, an Fmoc group, a Boc group, a Z group, a Troc group, or an Alloc group, the glycosylated linker moiety of the present invention And a compound comprising a physiologically active substance moiety or a salt thereof and the glycosylated linker of the present invention may be stabilized.
- the compound of the present invention or a salt thereof has a temperature and pH close to physiological conditions (for example, a physiological environment in a mammal's living body or an environment close thereto, such as 35 ° C to 43 ° C, pH 6.8 to 7. 8 etc.).
- physiological conditions for example, a physiological environment in a mammal's living body or an environment close thereto, such as 35 ° C to 43 ° C, pH 6.8 to 7. 8 etc.
- the physiologically active substance can be efficiently dissolved in an aqueous solution or an emulsion prepared from an aqueous solution by using the compound of the present invention or a salt thereof. Therefore, in a preferred embodiment, filter sterilization can be performed even with a physiologically active substance having low water solubility (less soluble) by using the compound of the present invention or a salt thereof. Furthermore, in another preferred embodiment, even a physiologically active substance having low water solubility can be administered to a living body by using the compound of the present invention or a salt thereof.
- the present invention can advantageously reduce the “loss” that can arise from the insolubility of substances in the preparation or administration process of preparations containing expensive physiologically active substances.
- the release time and timing of the active substance can be controlled. For example, it is advantageous for delivery of a physiologically active substance that is desired to exert its effect quickly at a desired site after administration in vivo.
- the compound or salt thereof containing the glycosylated linker moiety and the physiologically active substance moiety of the present invention can provide improved water solubility compared to an unmodified physiologically active substance.
- the improved water solubility is not limited, but is preferably 2 to 1,000,000 times, more preferably 10 to 1,000,000 times, more preferably 100 to More preferably, it is 1,000,000 times.
- a person skilled in the art can determine whether the glycosylated linker moiety of the present invention and the physiologically active substance moiety of the present invention have the required solubility or a salt thereof, or the glycosylated linker of the present invention, depending on the use and purpose of the physiologically active substance. Can be appropriately selected.
- the molar extinction coefficient (specific absorbance) necessary for determining the solubility of the compound or salt thereof containing the glycosylated linker moiety and the physiologically active substance of the present invention or the unmodified physiologically active substance is known to those skilled in the art.
- a solution having a known protein concentration measured by a method such as amino acid composition analysis or nitrogen quantification method is used as a sample, and is determined by UV-visible spectrophotometry (for example, wavelength in the UV-visible region such as 280 nm). Good.
- the composition of the present invention includes one or more other components (active component or inactive component) in addition to one or more compounds of the present invention or a salt thereof.
- active component or inactive component used for an assay system (for example, an in vitro assay system).
- pharmaceutical composition of the present invention is a composition suitable for pharmaceutical use, and dilutes normally used fillers, extenders, binders, moisturizers, disintegrants, surfactants, lubricants and the like. It is formulated in the form of a normal pharmaceutical composition using an agent or excipient.
- Such a pharmaceutical composition examples include, but are not limited to, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories, injections, and the like.
- the pharmaceutical use targeted by the pharmaceutical composition may be intended for a disease or disease involving a physiologically active substance contained in the composition as a physiologically active substance moiety.
- the physiologically active substance is GLP-1 or a derivative thereof
- the intended pharmaceutical use may be diabetes or the like.
- Other medical uses can be similarly understood by those skilled in the art by considering the diseases and types of diseases in which each physiologically active substance is involved.
- the pharmacologically acceptable carrier is not particularly limited. By blending a pharmacologically acceptable carrier, the absorbability and blood concentration of the compound of the present invention or a salt thereof may be affected, resulting in changes in pharmacokinetics.
- the compound of the present invention or a salt thereof and the pharmaceutical composition of the present invention containing the same can also be used as a vaccine.
- a poorly soluble antigen can be dissolved in an aqueous solution or emulsion as the compound of the present invention or a salt thereof, and after cleavage of the glycosylated linker moiety in vivo. Unmodified antigen can be released.
- the compound of the present invention or a salt thereof and a glycosylated linker can be used for development of various vaccines such as peptide vaccines.
- a vaccine means a substance that can generate an immune response when inoculated into an animal.
- a vaccine contains an antigen or is capable of expressing an antigen, which can induce an immune response against the antigen.
- the pharmaceutical composition of the present invention can be used not only for the prevention or treatment of viral infections, bacterial infections (sepsis, etc.), infectious diseases, but also any disease that can be related to the immune response, such as cancer, autoimmune diseases It can also be used for the treatment of (for example, type I diabetes, multiple sclerosis, rheumatoid arthritis, etc.).
- An antigen is a molecule containing one or more epitopes, and may be any one that can induce an antigen-specific immune response by stimulating the host immune system.
- the immune response may be a humoral immune response and / or a cellular immune response.
- As few as 3 to several (eg, 5 or 6) amino acids can be an epitope, but usually one epitope in a protein is 7 to 15 amino acids, eg 8, 9, 10, 12, or 14 Contains amino acids.
- the antigen is preferably a peptide or epitope in one embodiment. When an antigen is used for the treatment of cancer, such a peptide is also referred to as a cancer peptide.
- the pharmaceutical composition of the present invention may be administered to a living body.
- the administration method It administers by the method according to various formulation forms, a patient's age, sex, a disease state, and other conditions.
- the administration method in the case of tablets, pills, liquids, suspensions, emulsions, granules and capsules include oral administration.
- it can be administered intravenously, intramuscularly, intradermally, subcutaneously or intraperitoneally alone or mixed with a normal fluid such as glucose or amino acid.
- a suppository it is administered intrarectally.
- the pharmaceutical composition of the present invention may be subcutaneous, intramuscular, oral, stamped, intradermal and the like.
- the dosage of the pharmaceutical composition of the present invention may be appropriately selected according to the usage, the patient's age, sex, degree of disease, and other conditions.
- the number of administrations may be appropriately selected according to usage, patient age, sex, disease severity, and other conditions, such as 3 times / 1 day, 2 times / 1 day, 1 time / 1 day, Depending on the blood stability, a less frequent administration frequency (for example, once / week, once / month, etc.) may be selected.
- the pharmaceutical composition of the present invention may provide sustained release properties to the physiologically active substance by gradual cleavage of the sugar chain linker moiety.
- the pharmaceutical composition of the present invention may provide rapid action to a physiologically active substance by rapid cleavage of the sugar chain linker moiety.
- the present invention relates to a method for treating a disease, a disease, or a disease targeted by a physiologically active substance in a glycosylated linker, or a compound or a salt thereof including a glycosylated linker moiety and a physiologically active substance moiety. It also relates to the use for the manufacture of a prophylactic medicament.
- the present invention provides a method for treating a disease, a disease or a disease targeted by a physiologically active substance in a glycosylated linker, or a compound or a salt thereof including a glycosylated linker moiety and a physiologically active substance moiety. It also relates to use for prevention.
- the sugar chain-added linker of the present invention has a biodegradable sugar chain added to the linker, thereby reducing adverse effects on the living body compared to the case of adding PEG. As a result, long-term administration to a living body is expected.
- aqueous solution in this specification may be any liquid as long as a substance (for example, acetic acid) is dissolved in water as a solvent, and any aqueous solution known or new to those skilled in the art is targeted.
- a substance for example, acetic acid
- the emulsion in this specification is not limited, but any emulsion prepared from an aqueous solution may be used.
- the emulsion may be, but is not limited to, an oil-in-water (O / W type) emulsion or a water-in-oil (W / O type) emulsion.
- O / W type oil-in-water
- W / O type water-in-oil
- As a method of dispersing and emulsifying in an aqueous solution a method known to those skilled in the art may be used.
- the subject to which the compound of the present invention or a salt thereof or the pharmaceutical composition of the present invention is administered (applied) is not limited, but is an animal (human, non-human mammal (eg, mouse, rat, dog, cat, rabbit). Cattle, horses, sheep, goats, pigs, etc.) or non-mammals (eg fish, reptiles, amphibians or birds)), plants, insects, bacteria, or cells derived from them (including cultured cells), tissues or organs Etc.
- the target may be an artificial environment (for example, an in vitro reaction system).
- the subject in the present invention is a human.
- the compound or salt thereof comprising a glycosyl linker moiety and a physiologically active substance moiety of the present invention may consist essentially of a physiologically active substance moiety and a glycosylated linker moiety ( In other words, it may have other components in a manner that does not affect the basic and essential constitution of the present invention), or it may consist only of a physiologically active substance moiety and a glycosylated linker moiety. Good.
- first, second, etc. are used to represent various elements, it is understood that these elements should not be limited by those terms. These terms are only used to distinguish one element from another, for example, the first element is referred to as the second element, and similarly, the second element is the first element. Can be made without departing from the scope of the present invention.
- any numerical value used to indicate the component content or numerical range is interpreted as including the meaning of the term “about” unless otherwise specified.
- “10 times” is understood to mean “about 10 times” unless otherwise specified.
- Chemerin 9 having a short chain length was selected.
- Chemerin 9 (9 residues, sequence: YFPGQFAFS) corresponds to amino acid residues 4 to 12 in SEQ ID NO: 31 (18 amino acid residues) in the sequence listing of US Patent Publication 2003/096299.
- chemerin 9 has ChemR23 agonist activity, which is a G protein-coupled receptor, it has potential as a therapeutic and / or prophylactic agent for immune diseases, inflammatory diseases, and diabetes.
- it is known that in vivo it is very unstable because it undergoes degradation by proteolytic enzymes Japanese Patent Laid-Open No. 2010-229093.
- the production method, reaction conditions, temperature, and the like are known and will be apparent to those skilled in the art, but chemerin 9 may be synthesized according to the method described in the above document.
- Amino-PEGA resin (manufactured by Merck) (200 ⁇ mol) was placed in a solid phase synthesis column and washed with DMF. Add DMF (5.0 mL) solution containing HMPB (121.2 mg, 0.504 mmol), TBTU (161.7 mg, 0.504 mmol), and N-ethylmorpholine (57.3 ⁇ L, 0.495 mmol) at room temperature. Shake for 3 hours.
- the Fmoc group in a part (70 ⁇ mol) thereof was removed by treatment with 20% piperidine in DMF, and a resin (compound) in which chemerin 9 protected with tBu and Trt was bound 12) (SEQ ID NO: 2) was obtained.
- a resin compound in which chemerin 9 protected with tBu and Trt was bound 12
- SEQ ID NO: 2 a resin (compound) in which chemerin 9 protected with tBu and Trt was bound 12)
- TFA water: triisopropylsilane: ethanedithiol (volume parts, 90: 2.5: 5: 2.5, respectively) was added to the resin (compound 15), and shaken at room temperature for 3 hours. Cooled diethyl ether was added to the filtrate to obtain the compound as a precipitate.
- the cutting behavior was tracked as follows. Lyophilized glycosylated (Asn (Asialo) type) linker-chemerin 9 conjugate (Compound 1) was dissolved in PBS solution (37 ° C., pH 7.4, 350 ⁇ L) and then allowed to stand at 37 ° C. for incubation. did. Thereafter, a PBS solution (28 ⁇ L) in which the glycosylated (Asn (asialo) type) linker-chemerin 9 conjugate (compound 1) was dissolved was sampled at regular time intervals, and a 0.5% TFA aqueous solution was added to the sampled solution. After adding (28 ⁇ L), the solution was frozen.
- ESI-MS (m / z ) calcd for C 81 H 104 N 16 O 22 S [M + 2H] 2+ 843.4, found 843.4.
- ESI-MS (m / z) calcd for C 172 H 237 N 21 O 80 S [M + 3H] 3+ 1303.8, [M + 4H] 4+ 978.1, found 1308.8, 978.1.
- the Fmoc group of the resin (compound 15) (15 ⁇ mol) in which the linker moiety was bonded to tmel and protected Tmel and protected Tmer was removed by treatment with 20% piperidine in DMF. After washing with DMF, DMF solution (375 ⁇ L) containing acetic acid (4.3 ⁇ L), HOBt (10.1 mg, 75 ⁇ mol), and DIC (11.0 ⁇ L, 71 ⁇ mol) was added, and the mixture was shaken at room temperature for 1 hour to condense. The operation was performed. After washing with DMF, this condensation operation was repeated once.
- Example 9> Synthesis of sugar chain addition (Asn (asialo) -tetrachlorophthaloyl type) linker-chemerin 9 conjugate (compound 10)) After synthesizing a glycosylated (Fmoc-Asn (Asialo) type) linker-chemerin 9 conjugate (Compound 7) as described in Example 1, the glycosylation (Asn (Asialo) was synthesized as described in Example 2.
- Asn (asialo) type (1) represents a glycosylated (Asn (asialo) type) linker-chemerin 9 conjugate (compound 1)
- Cys (GlcNAc) type (4) represents glycosylation (Cys (GlcNAc) type) linker-chemerin 9 conjugate (compound 4)
- Cys (asialo) type (5) represents a glycosylated (Cys (asialo) type) linker-chemerin 9 conjugate (compound 5)
- Cys (disialo) type (6) represents a glycosylated (Cys (disialo) type) linker-chemerin 9 conjugate (compound 6)
- Fmoc-Asn (asialo) type (7) represents
- the Fmoc-Asn (Asialo) type (7) in which the N-terminus of asparagine added to the sugar chain is protected with the Fmoc group is compared with the Asn (Asialo) type (1) in which the N-terminus of the asparagine is not protected.
- the cleavage time was slow at both pH 4.0 and pH 7.4.
- the Fmoc-Cys (disialo) type (8) in which the N-terminus of the cysteine added to the sugar chain is protected with the Fmoc group is the Cys (disialo) type (6) in which the N-terminus of the cysteine is not protected.
- the half-life of Asn (Asialo) -tetrachlorophthaloyl type (10) was 15.3 minutes (about 0.25 hours) in PBS (37 ° C., pH 7.4).
- the half-life of Asn (Asialo) -tetrachlorophthaloyl type (10) is only about one-fifth compared with the half-life of Asn (Asialo) type (1) in which the phthaloyl group is not substituted with a chlorine atom. It was.
- the present inventor has found that the substitution of a phthaloyl group with a tetrachlorophthaloyl group in the sugar chain addition linker part speeds up the autocatalytic cleavage of the sugar chain addition linker part about 5 times. Without intending to be bound by theory, this is because the electron density of the carbonyl carbon bonded to the peptide is changed by substituting the hydrogen atom on the aromatic ring with an electron-attracting chlorine atom in the phthaloyl group. It is thought that it decreased and became more susceptible to nucleophilic attack by nitrogen. A person skilled in the art will understand that by utilizing the structural characteristics of such a compound, it can also be applied to a physiologically active substance that wants to exhibit its activity quickly after administration in vivo.
- the half-life of Asn (asialo) -tetrachlorophthaloyl type (10) in the aqueous solution was 15.3 minutes (about 0.25 hours) in PBS (37 ° C., pH 7.4), while 4.5 hours in acetate buffer (25 ° C., pH 4.0). Due to the difference in half-life, a compound containing a glycosylated linker moiety and a physiologically active substance moiety of the present invention is prepared at pH 4.0 and room temperature (for example, 25 ° C.) and then in vivo (for example, pH 7.4, for example, It is understood that an unmodified physiologically active substance can be rapidly and controllably released by administration at 37 ° C.).
- glycosylated linker moiety in the present invention self-cleaves from a compound containing a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof not only in an aqueous solution but also in an emulsion
- a compound containing a glycosylated linker moiety and a physiologically active substance moiety or a salt thereof can be applied to the development of various vaccines such as peptide vaccines.
- the stability of a compound containing a glycosylated linker moiety of the present invention and a physiologically active substance moiety or a salt thereof in an emulsion prepared from an aqueous solution was compared with that of an acetate buffer as follows.
- a lyophilized glycosylated (Asn (asialo) type) linker-chemerin 9 conjugate (compound 1) is dissolved in 0.1 M acetic acid buffer (pH 4.0, 25 ° C., 175 ⁇ L), and then a mineral oil system. 175 ⁇ L of MONTANIDE ISA 206 VG (manufactured by SEPPIC) as an adjuvant was added to the acetate buffer. The mixture was then vortexed vigorously to form an emulsion.
- lyophilized glycosylated (Asn (Asialo) type) linker-chemerin 9 conjugate (Compound 1) was dissolved in 0.1 M acetate buffer (25 ° C., pH 4.0, 350 ⁇ L), Incubation was allowed to stand at 37 ° C. Thereafter, 28 ⁇ L of an acetic acid buffer solution of a glycosylated (Asn (Asialo) type) linker-chemerin 9 conjugate (Compound 1) was injected at regular time intervals and subjected to HPLC analysis.
- those skilled in the art can use the bioactive substance derivative having a glycosylated linker moiety in the present invention to remove an unmodified bioactive substance at the same rate as in an aqueous solution even in an emulsion prepared from the aqueous solution. Understand that can be released with. That is, it was revealed that the glycosylated linker moiety in the present invention can be applied to use of a physiologically active substance as a vaccine.
- Example 12 Synthesis of Glycosylation (Asn (Asialo)) Linker-HER2 8-16 Conjugate (Compound 11), Cleavage Evaluation of Glycosylation Linker Part, and Solubility Evaluation)
- the physiologically active substance derivative having a glycosylated linker moiety in the present invention can be used in the form of an emulsion, it can be used for the development of various vaccines. Therefore, the present inventor created, as an example, a conjugate of HER2 8-16 and a glycosylated linker that can also be used as a tumor antigen peptide.
- HER2 8-16 (sequence: RWGLLLALL) is a residue of 8 to 16 amino acids in the amino acid sequence of HER2 / neu protein, which is one of HER (Human Epidermal Growth Factor Receptor) family.
- HER2 8-16 also referred to as code HE1, has a binding ability to HLA-A24, which is one of HLA (Human Leukocyte Antigen), and cytotoxic T cells by antigen presentation via HLA Since it is possible to induce (CTL), it has been identified as a tumor vaccine candidate peptide (see International Publication No. 2005/007694 pamphlet, etc.).
- Amino-PEGA resin 200 ⁇ mol was placed in a solid phase synthesis column and washed with DMF. Add DMF (5.0 mL) solution containing HMPB (120.2 mg, 0.500 mmol), TBTU (160.6 mg, 0.500 mmol), and N-ethylmorpholine (57.3 ⁇ L, 0.495 mmol) at room temperature. Shake for 3 hours.
- the Fmoc group was removed by treatment with 20% piperidine in DMF for 15 minutes. After washing with DMF, a protected HER2 8-16 peptide in a state bound to a resin represented by the following formula (21) by a peptide solid phase synthesis method by the Fmoc method using a Prelude (trademark) peptide synthesizer (SEQ ID NO: 16) was synthesized. The condensation reaction was performed in DMF using HCTU as the condensing agent.
- the Fmoc group in a part (50 ⁇ mol) of the obtained resin (Compound 21) was removed by treatment with 20% piperidine in DMF for 20 minutes to obtain a resin having a protected peptide bound thereto. .
- phthalic anhydride phthalic anhydride
- dichloromethane 1.5 mL
- pyridine 90 ⁇ L
- the cutting behavior was tracked in the same manner as described in Example 3. That is, the lyophilized glycosylated (Asn (Asialo) type) linker-HER2 8-16 conjugate (Compound 11) was dissolved in PBS (pH 7.4) or 0.1 M acetate buffer (pH 4.0). Then, it left still and incubated at 25 degreeC or 37 degreeC. Thereafter, a fixed amount of PBS solution or 0.1 M acetate buffer in which the glycosylated (Asn (Asialo)) linker-HER2 8-16 conjugate (Compound 11) is dissolved is injected at regular intervals. HPLC analysis was performed.
- Glycosylation linker-HER2 8-16 conjugate (Compound 11) and HER2 8-16 peptide were taken in different microtubes in the amount of about 3.5 mg and 3.5 mg, respectively. 30 ⁇ L of 0.1% TFA aqueous solution was added to each microtube. These microtubes were shaken at 25 ° C. for 15 minutes and then centrifuged at 25 ° C. and 16100 ⁇ g for 10 minutes. Next, the absorbance at 280 nm of the supernatant was measured in these microtubes, and the concentration of the glycosylated linker-HER2 8-16 conjugate (compound 11) and HER2 8-16 peptide was determined from the obtained values. Each was calculated and solubility was determined.
- the molar extinction coefficient at 280 nm of the glycosylated linker-HER2 8-16 conjugate (Compound 11) was determined by the following method. That is, the compound 11 solution was dispensed into 5 tubes in equal amounts, and after freeze-drying, amino acid composition analysis was performed using 3 of the tubes to determine the sample content. Also, 1 mL of 0.1% TFA aqueous solution was added to one of the five tubes, and the absorbance at 280 nm of the glycosylated linker-HER2 8-16 conjugate (Compound 11) at this time was measured. . The absorbance at 280 nm was determined by dividing by the concentration determined by amino acid composition analysis.
- the molar absorption coefficient ⁇ M at 280 nm of the glycosylated linker-HER2 8-16 conjugate was 5922.
- the molar extinction coefficient ⁇ M at 280 nm of the HER2 8-16 peptide was calculated using the following formula (CN Path et al., Prot. Sci., 1995, 4, 2411-2423). page).
- ⁇ M Trp ⁇ 5500 + Tyr ⁇ 1490 + Cystein ⁇ 125 [A 280 / mol / cm]
- Trp represents the number of tryptophan residues
- Tyr represents the number of tyrosine residues
- Cystein represents the number of disulfide bonds. Since the HER2 8-16 peptide (amino acid sequence: RWGLLLALL) contains one tryptophan residue, the molar extinction coefficient ⁇ M at 280 nm was 5500.
- the solubility of the HER2 8-16 peptide to which the glycosylated linker was not bound in 0.1% TFA aqueous solution was 0.21 mg / mL (2.0 ⁇ 10 2 ⁇ M)). At this time, precipitation of the HER2 8-16 peptide could be visually confirmed in the microtube.
- the solubility of the glycosylated (Asn (Asialo) type) linker-HER2 8-16 conjugate (Compound 11) in 0.1% TFA aqueous solution was confirmed to be 100 mg / mL or more.
- a compound containing a glycosylated linker moiety of the present invention and a physiologically active substance moiety or a salt thereof can significantly improve the solubility in an aqueous solution or emulsion as compared with an unmodified physiologically active substance.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩であって、
前記化合物は、下記式(A)で表わされ、
R1-X (A)
ここで、
R1は、糖鎖付加リンカー部分を意味し、
R1は、下記式(I)で表わされ、
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、Xへの結合部分を示す。]
Xは、生理活性物質部分を意味し、
前記生理活性物質は、少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有しており、
XのR1との結合は、当該少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基における結合である、
化合物またはその塩を提供することによって、達成される。
前記R1は、下記式(I)で表わされる、
[式(I)中、
R2およびR3は、それらが結合している窒素原子と一緒になって3~7員の複素環を形成しており、
ここで、前記複素環は、アジリジン、アゼチジン、ピロリン、ピロール、イミダゾール、イミダゾリン、ピラゾール、ピラゾリン、イソオキサゾリン、チアゾリン、イソチアゾリン、チアジアゾリン、ピロリジン、イミダゾリジン、ピラゾリジン、オキサゾリジン、イソオキサゾリジン、チアゾリジン、イソチアゾリジン、チアジアゾリジン、ピペラジン、ピペリジン、モルホリン、チオモルホリン、チアジン、テトラゾール、トリアゾール、トリアゾリジン、テトラゾリジン、アゼパン、ジアゼパン、アゼピンおよびホモピペラジンからなる群から選択され、
前記複素環における少なくとも1つの水素原子は、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、当該置換は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合であり、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、前記Xへの結合部分を示す。]
ことが好ましい。
前記R1は、下記式(II)で表わされる、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリールを形成するか、あるいは、R5A、R5Bは、いずれも水素原子であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、シクロヘキシルまたはノルボルニルを形成し、
R6は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドであり、
波線は、前記Xへの結合部分を示す。]
ことが好ましい。
前記生理活性物質は、ペプチド部分を有しており、
前記Xの前記R1との結合は、
(1)前記生理活性物質の前記ペプチド部分のN末端のアミノ基におけるアミド結合、
(2)前記生理活性物質の前記ペプチド部分のセリン残基、スレオニン残基またはチロシン残基の側鎖に存在するヒドロキシ基におけるエステル結合(但し、前記生理活性物質の前記ペプチド部分が、セリン残基、スレオニン残基またはチロシン残基を有する場合に限る)、
(3)前記生理活性物質の前記ペプチド部分のアスパラギン酸残基またはグルタミン酸残基の側鎖に存在するカルボキシ基における酸無水物結合(但し、前記生理活性物質の前記ペプチド部分が、アスパラギン酸残基またはグルタミン酸残基を有する場合に限る)、
(4)前記生理活性物質の前記ペプチド部分のリシン残基、アスパラギン残基、アルギニン残基、ヒスチジン残基またはトリプトファン残基の側鎖に存在するアミノ基におけるアミド結合(但し、前記生理活性物質の前記ペプチド部分が、リシン残基、アスパラギン残基、アルギニン残基、ヒスチジン残基またはトリプトファン残基を有する場合に限る)、
(5)前記生理活性物質の前記ペプチド部分のシステイン残基の側鎖に存在するチオール基におけるチオエステル結合(但し、前記生理活性物質の前記ペプチド部分が、システイン残基を有する場合に限る)、または、
(6)前記生理活性物質の前記ペプチド部分のC末端のカルボキシ基における酸無水物結合、
である、
ことが好ましい。
前記R1は、下記式(III)で表わされ、
[式(III)中、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリールを形成するか、あるいは、R5A、R5Bは、いずれも水素原子であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、シクロヘキシルまたはノルボルニルを形成し、
R7は、-S-CH2-CONH-糖鎖または-CONH-糖鎖であり、
R8は、水素原子、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等のカルバメート系保護基、糖鎖、アミノ酸、ポリペプチド、糖鎖付加アミノ酸、または糖鎖付加ポリペプチドであり、
波線は、Xへの結合部分を示す。]
前記生理活性物質は、少なくとも1つのアミノ基を有しており、
前記Xの前記R1との結合は、当該少なくとも1つのアミノ基における結合である、
ことが好ましい。
前記R1は、下記式(IV)で表わされ、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
R7は、-S-CH2-CONH-糖鎖または-CONH-糖鎖であり、
R8は、水素原子、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等のカルバメート系保護基、糖鎖、アミノ酸、ポリペプチド、糖鎖付加アミノ酸または糖鎖付加ポリペプチドであり、
R9は、それぞれ独立に、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基またはアミノ基であり、
波線は、Xへの結合部分を示す。]
前記生理活性物質は、少なくとも1つのアミノ基を有しており、
前記Xの前記R1との結合は、当該少なくとも1つのアミノ基における結合である、
ことが好ましい。
前記式(I)、(II)、(III)または(IV)における4つの前記R4は、いずれも水素原子である
ことが好ましい。
前記式(IV)における少なくとも1つの前記R9は、ハロゲンである、
ことが好ましい。
前記式(IV)における4つの前記R9は、いずれも塩素である、
ことが好ましい。
前記「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」において、糖鎖は、アミノ酸またはポリペプチドにおける、AsnまたはCysに結合している、
ことが好ましい。
前記「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」において、糖鎖は、アミノ酸またはポリペプチドと、リンカーを介することなく結合している、
ことが好ましい。
前記「糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチド」における糖鎖は、4個以上の糖残基からなる、
ことが好ましい。
前記「糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチド」における糖鎖は、2本鎖複合型糖鎖、3本鎖複合型糖鎖、または4本鎖複合型糖鎖である、
ことが好ましい。
前記糖鎖が、ジシアロ糖鎖、モノシアロ糖鎖、アシアロ糖鎖、ジグルクナック糖鎖およびジマンノース糖鎖からなる群から選択される2本鎖複合型糖鎖である、
ことが好ましい。
前記「糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチド」における糖鎖が、下記式:
[式中、R10およびR11は、同一または異なって、
で表される糖鎖である、
ことが好ましい。
前記生理活性物質は、低分子生理活性物質または生体高分子である、
ことが好ましい。
前記生体高分子は、タンパク質、ポリペプチド、ポリヌクレオチド、およびペプチド核酸からなる群より選択される、
ことが好ましい。
無修飾の生理活性物質と比較して、向上した水溶性を有する、
ことが好ましい。
前記向上した水溶性が、モル濃度において、前記「無修飾の生理活性物質」と比較して、10~1,000,000倍である、
ことが好ましい。
前記糖鎖付加リンカー部分がpHおよび/または温度に依存して自己触媒的に切断される、
ことが好ましい。
前記化合物又はその塩における糖鎖は、実質的に均一である、
組成物を提供する。
(I)前記化合物またはその塩、および
(II)薬理学的に許容される担体
を含む、
医薬組成物を提供する。
前記生理活性物質は、対象に投与後に速やかに活性を発揮する、
ことが好ましい。
ワクチン接種に用いられる、
ことが好ましい。
糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩の製造方法であって、
ここで、前記生理活性物質は、少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有するペプチド部分を含んでおり、
以下のステップ、
(a)固相合成法により、樹脂上に前記ペプチド部分を合成するステップと、
(b)ステップ(a)で合成された前記ペプチド部分における前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」に、下記式(I’)で表わされるリンカー部分を結合させるステップと、
[式(I’)中、
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、前記ペプチド部分の前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」との結合部分を示す。]
(c)ステップ(b)により、前記ペプチド部分の前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」に結合された前記リンカー部分のR2またはR3における前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子を、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換するステップ
を含む、
製造方法を提供する。
糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩の製造方法であって、
ここで、前記生理活性物質は、少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有するペプチド部分を含んでおり、
前記ペプチド部分における前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」に、下記式(I’’)で表わされる糖鎖付加リンカーを脱水縮合により結合させる製造方法を提供する。
[式(I’’)中、
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成する。]
前記いずれかの製造方法により得られうる、化合物またはその塩を提供する。
前記いずれかの製造方法により得られた、化合物またはその塩を提供する。
少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有する生理活性物質との結合に用いてもよい、糖鎖付加リンカーであって、
前記糖鎖付加リンカーは、下記式(B)で表され、
R1-L (B)
ここで、
R1は、糖鎖付加リンカー部分を意味し、
R1は、下記式(I)で表わされ、
[式(I)中、
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、Lへの結合部分を示す。]
Lは、脱離基を意味する、
糖鎖付加リンカーを提供する。
-NH-(CH2)a-(CO)-CH2-
(式中、aは整数であり、目的とするリンカー機能を阻害しない限り限定されるものではないが、好ましくは0~4の整数を示す。);
C1~10ポリメチレン;
-CH2-R-;
(式中、Rは、置換または非置換のアルキル、置換または非置換のアルケニル、置換または非置換のアルキニル、置換または非置換のアリール、置換または非置換の炭素環基、置換または非置換の複素環基を含む群より選択される基から水素原子が1つ脱離して生ずる基である。)
-(CO)-(CH2)a-(CO)-
(式中、aは整数であり、目的とするリンカー機能を阻害しない限り限定されるものではないが、好ましくは0~4の整数を示す。)
等を挙げることができる。
さらに、例えば、これらのポリラクトサミン構造またはシアリルポリラクトサミン構造を有する糖鎖の非還元末端から1つ又は複数の糖を失った糖鎖も挙げることができる。
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成する。限定はされないが、好ましい一実施態様において、R2およびR3は、それらが結合している窒素原子と一緒になって、3~7員の複素環を形成する。
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基である。
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成してよい。
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリールを形成するか、あるいは、R5A、R5Bは、いずれも水素原子であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、シクロヘキシルまたはノルボルニルを形成してよい。
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基である。
R5C、R5Dが、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキルを形成する場合、炭素数4~16のシクロアルキルは、置換または非置換のシクロアルキルであってよい。非置換のシクロアルキルの例としては、限定されないが、シクロブチル、シクロペンチル、シクロヘキシル、シクロヘプチル、シクロオクチル、シクロノニル、シクロデシル、シクロウンデシル、シクロドデシル、シクロトリデシル、シクロテトラデシル、シクロペンタデシル、またはシクロヘキサデシルを挙げることができる。シクロアルキルの1つまたは複数の水素原子が置換されている場合の置換基の例としては、それぞれ独立に、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基(例えば、メトキシ、エトキシ、プロポキシ、ブトキシ等)、アミノ基、ヒドロキシ基、チオール基、カルボキシ基、ハロゲン原子(例えば、フッ素、塩素、臭素、ヨウ素)、または炭素数1~4のハロゲン化アルキル基(例えば塩化メチル基)を挙げることができる。
R8は、水素原子、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等のカルバメート系保護基、あるいは、アミノ酸、ポリペプチド、糖鎖、糖鎖付加アミノ酸、または糖鎖付加ポリペプチドである。特定の一態様において、R8は、水素原子、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基であってよい。R8Aは、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等の保護基である。R8’は、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等の保護基である。
R9は、それぞれ独立に、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基またはアミノ基である。
同様に、好ましい別の実施態様において、本発明における糖鎖付加リンカー、糖鎖付加リンカー部分、またはリンカー部分において、R5A、R5Bが、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成する場合、あるいは、R5C、R5Dが、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成する場合、これらの環上に存在する少なくとも1つの水素原子が、独立に、ハロゲン、シアノ基、ニトロ基、メシル基(メタンスルホニル基)、トシル基(p-トルエンスルホニル基)または炭素数1~3のアシル基で置換されていてよい。
R2またはR3が水素原子である場合(R2およびR3の両方が、同時に、水素原子とはならない)、かかる水素原子の部分で、糖鎖付加アミノ酸または糖鎖付加ポリペプチドは置換されていてよく;または
R2および/またはR3が炭素数1~16のアルキル基、または炭素数5~16のアリール基であるか、あるいはR2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成している場合、前記アルキル基、前記アリール基、または、前記複素環に結合している少なくとも1つの水素原子の部分で、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドは置換されていてよい。
例えば、前記R2がメチル基の場合、当該メチル基(-CH3)における少なくとも1つの水素原子が、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されていてよい。あるいは、例えば、前記R2および前記R3はそれらが結合している窒素原子と一緒になってピペラジンを形成する場合、当該ピペラジンの環構造上の窒素原子に結合した水素原子が、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されていてよい。
好ましくは、前記アルキル基、前記アリール基、または、前記複素環に存在する窒素原子に結合している少なくとも1つの水素原子が糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドで置換されている。さらに好ましくは、前記アルキル基、前記アリール基、または、前記複素環に存在する窒素原子に結合している少なくとも1つの水素原子が糖鎖付加アミノ酸または糖鎖付加ポリペプチドで置換されており、いっそう好ましくは、当該置換は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合である。
R6の糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドが前記式(II)中のピペラジンの環構造上の窒素原子に結合している。一態様において、R6は、糖鎖付加アミノ酸または糖鎖付加ポリペプチドであるのが好ましく、かかる場合、限定はされないが、R6の窒素原子との結合は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合であることが好ましい。
R7が-S-CH2-CONH-糖鎖または-CONH-糖鎖を採用することにより、前記式(III)または前記式(IV)で表される本発明における糖鎖付加リンカー部分は、糖鎖構造を含む。また、前記糖鎖付加リンカー部分がさらに糖鎖を含む場合、R8は糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドであって、前記式(III)または前記式(IV)中のR8が結合している窒素原子に結合していてよい。
限定はされないが、例えば、水素原子、あるいは、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等の保護基であるR8を、R8が結合している窒素原子由来のアミノ基の求核性を利用して、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドでさらに置換してもよい。限定はされないが、置換されたR8が糖鎖付加アミノ酸または糖鎖付加ポリペプチドである場合、当該置換は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合であるのが好ましい。もちろん、まず、水素原子、あるいは、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等の保護基であるR8をアミノ酸またはポリペプチドで置換した後に、置換したアミノ酸またはポリペプチドに、当業者に周知の方法で、さらに糖鎖を付加してもよい。
(I)N末端にアミノ酸に由来するアミノ基を有するか、
(II)側鎖にヒドロキシ基を有するセリン残基、スレオニン残基またはチロシン残基を含むか、
(III)側鎖にカルボキシ基を有するアスパラギン酸残基またはグルタミン酸残基を含むか、
(IV)側鎖にアミノ基を有するリシン残基、アスパラギン残基、アルギニン残基、ヒスチジン残基またはトリプトファン残基を含むか、
(V)側鎖にチオール基を有するシステイン残基を含むか、または、
(VI)C末端にアミノ酸に由来するカルボキシ基を有する
ことが好ましい。アスパラギン酸はD-アスパラギン酸であってもよい。また、グルタミン酸はD-グルタミン酸であってもよい。他の人工アミノ酸も同様に採用されてよい。
かかる実施態様において、生理活性物質部分と糖鎖付加リンカー部分との結合は、
(1)前記生理活性物質のN末端のアミノ基におけるアミド結合、
(2)前記生理活性物質のセリン残基、スレオニン残基またはチロシン残基の側鎖に存在するヒドロキシ基におけるエステル結合(但し、前記生理活性物質が、セリン残基、スレオニン残基またはチロシン残基を有する場合に限る)、
(3)前記生理活性物質のアスパラギン酸残基またはグルタミン酸残基の側鎖に存在するカルボキシ基(具体的には、-COOH基中の-OH部分)における酸無水物結合(但し、前記生理活性物質が、アスパラギン酸残基またはグルタミン酸残基を有する場合に限る)、
(4)前記生理活性物質のリシン残基、アスパラギン残基、アルギニン残基、ヒスチジン残基またはトリプトファン残基の側鎖に存在するアミノ基におけるアミド結合(但し、前記生理活性物質が、リシン残基、アスパラギン残基、アルギニン残基、ヒスチジン残基またはトリプトファン残基を有する場合に限る)、
(5)前記生理活性物質のシステイン残基の側鎖に存在するチオール基におけるチオエステル結合(但し、前記生理活性物質が、システイン残基を有する場合に限る)、または、
(6)前記生理活性物質のC末端のカルボキシ基における酸無水物結合、
であることが好ましい。
前記(1)、(4)の場合、生理活性物質部分と糖鎖付加リンカー部分は、結合により-NH-部分を介してリンクし、
前記(2)、(3)、(6)の場合、生理活性物質部分と糖鎖付加リンカー部分は、結合により-O-部分を介してリンクし、
前記(5)の場合、生理活性物質部分と糖鎖付加リンカー部分は、結合により-S-部分を介してリンクする。
R1-L (B)
ここで、
R1は、糖鎖付加リンカー部分を意味し、その定義は上述のとおりであり、
Lは、脱離基を意味する。
ここで、好ましくは、前記アルキル基、前記アリール基、または、前記複素環に存在する窒素原子に結合している少なくとも1つの水素原子が糖鎖付加アミノ酸または糖鎖付加ポリペプチドで置換されており、いっそう好ましくは、当該置換は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合である。
(A)適当な樹脂に、生理活性物質を固定するステップと、
(B)当該生理活性物質が有する少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基において、リンカーをアミド結合、エステル結合、チオエステル結合または酸無水物結合により結合させるステップと、
(C)次いで、糖鎖、糖鎖付加アミノ酸及び/または糖鎖付加ポリペプチドをリンカーに結合させるステップと
を含む工程によって合成してもよい。
(B’)当該生理活性物質が有する少なくとも1つの遊離のアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基の部分で、第1のリンカー部分(ジカルボン酸無水物(例えばフタル酸無水物))をアミド結合、エステル結合、チオエステル結合または酸無水物結合により縮合させ、さらに、当該第1のリンカー部分における遊離のカルボキシ基に、第2のリンカー部分(ジアミン(例えばN-(2-アミノエチル)ピペラジン))における遊離のアミノ基を縮合させることにより、所望のリンカー部分を有する生理活性物質を得てもよい。当業者は、反応条件、反応させるリンカーの一部を構成する化合物等を適宜選択して、生理活性物質に連続して縮合させることにより、所望のリンカー部分を有する生理活性物質を合成することができる。
(2)工程(1)で得られたエステルの脂溶性保護基を脱離して遊離アミノ基を形成させ、
(3)上記遊離アミノ基と、脂溶性保護基でアミノ基が保護された別のアミノ酸のカルボキシ基とをアミド化反応させ、
(4)工程(3)の後、脂溶性保護基を脱離して遊離アミノ基を形成させ、
(5)工程(3)及び(4)の工程を必要に応じて繰り返すことにより、所望の数のアミノ酸が連結したポリペプチドを得ることができる。
(6)目的の構造を有するリンカーを、樹脂に結合した前記ポリペプチドの遊離アミノ基の部分でアミド結合、エステル結合、チオエステル結合または酸無水物結合させ、
(7)前記リンカー部分の所定の置換基における少なくとも1つの水素原子を糖鎖、糖鎖付加アミノ酸および/または糖鎖付加ポリペプチドによって置換させ、
(8)工程(1)で形成されたエステル結合を酸で切断する。
(7’)前記リンカー部分の所定の置換基における少なくとも1つの水素原子をアミノ酸および/またはポリペプチドによって置換させ、
(8’)工程(1)で形成されたエステル結合を酸で切断して、所望の、アミノ酸及び/またはポリペプチド部分を備えたリンカー部分-ポリペプチドの化合物を得て、
(9’)前記化合物のアミノ酸及び/またはポリペプチド部分に糖鎖を付加させる。
R5A、R5Bが、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成する場合、あるいは、
R5C、R5Dが、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成する場合、
Yの構造は、例えば、上述の、具体的に示した多様なジカルボン酸の酸無水物における、C(=O)-O-C(=O)を除いた構造部分に相当する。例えば、ジカルボン酸無水物としてフタル酸無水物を用いて、本発明の化合物またはその塩、あるいは本発明の糖鎖付加リンカー、あるいはリンカー(糖鎖が結合していない構造を有する)を製造する場合、フタル酸無水物のうち、下記式において点線で囲ったフェニル環部分(すなわち、フタル酸無水物のうち、C(=O)-O-C(=O)を除いた構造部分)が、置換基Yの構造に相当する。
N-(2-アミノエチル)イミダゾリジン:
例えば、本発明における式(I)で表される糖鎖付加リンカー部分におけるR2および/またはR3に相当する部分で炭素数1~16のアルキル基を有し、アミノ基を導入された、前述のエチレンジアミン誘導体として、以下の誘導体(ジアミン誘導体)が例示される:
3-(2-アミノエチルアミノ)プロピルアミン:
[(2-アミノエチル)アミノ]酢酸:
3-(2-アミノエチルアミノ)プロパノール:
2-(2-アミノエチルアミノ)エタンチオール:
例えば、本発明における式(I)で表される糖鎖付加リンカー部分におけるR2および/またはR3に相当する部分で炭素数5~16のアリール基を有し、アミノ基を導入された、前述のエチレンジアミン誘導体として、以下の誘導体が例示される:
N-(2-アミノエチル)-1,4-ベンゼンジアミン:
4-[(2-アミノエチル)アミノ]-安息香酸:
4-[(2-アミノエチル)アミノ]-フェノール:
ここで、好ましくは、前記アルキル基、前記アリール基、または、前記複素環に存在する窒素原子に結合している少なくとも1つの水素原子が糖鎖付加アミノ酸または糖鎖付加ポリペプチドで置換されており、いっそう好ましくは、当該置換は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合である。
[式(II’)中、
R4、Yおよび波線は、それぞれ、上記において規定したとおりであり、
R6’は、水素原子である。]。
かかる場合、糖鎖付加リンカー部分を得るために、さらに、前記リンカー部分のR6’の水素原子を、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換する(ここで、一態様において、前記リンカー部分のR6’の水素原子を、糖鎖付加アミノ酸または糖鎖付加ポリペプチドで置換するのが好ましく、当該置換は、限定はされないが、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合であるのが好ましい。)。
[式(IIIa)中、
R4、Yおよび波線は、それぞれ、上記において規定したとおりであり、
R7Aは、-CONH-糖鎖であり、
R8Aは、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等の保護基である。)
さらに、前記R8Aの保護基を、水素原子、アミノ酸、ポリペプチド、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドで置換してもよい。一態様において、R8Aが糖鎖付加アミノ酸または糖鎖付加ポリペプチドであるとき、R8Aの窒素原子との結合は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合であるのが好ましい。
[式(III’)中、
R4、Yおよび波線は、それぞれ、上記において規定したとおりであり、
R7’は、-SHであり、
R8’は、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、またはAlloc基等の保護基である。)
また、前記R7’の-SHにおける水素原子を、-CH2-CONH-糖鎖で置換することにより、糖鎖付加リンカー部分を形成してよい。
Ac:アセチル(基)
AcOH:酢酸
Alloc基:アリルオキシカルボニル基
Asn:アスパラギン
Boc:tert-ブチルオキシカルボニル基
Cys:システイン
DIC:ジイソプロピルカルボジイミド
DIPEA:N,N-ジイソプロピルエチルアミン
DMF:N,N-ジメチルホルムアミド
DMSO:ジメチルスルホキシド
DTT:ジチオトレイトール
ESI-MS:エレクトロスプレーイオン化(ElectroSpray Ionization)質量分析
Fmoc(基):9-フルオレニルメチルオキシカルボニル(基)
GlcNAc:N-アセチルグルコサミン
HCTU:O-(6-Chloro-1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate
HMPB:4-ヒドロキシメチル-3-メトキシフェノキシ酪酸
HOBt:1-ヒドロキシベンゾトリアゾール
HPLC:高速液体クロマトグラフィー
H2O:水
Leu:ロイシンまたはロイシン残基
ln2:loge2
MSNT:1-(メシチレン-2-スルホニル)-3-ニトロ-1,2,4-トリアゾール(1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole)
PBS:リン酸緩衝生理食塩水
Pbf:2,2,4,6,7-ペンタメチルジヒドロベンゾフラン-5-スルホニル
tBu:tert-ブチル基
TBTU:O-(1H-ベンゾトリアゾール-1-イル)N,N,N’,N’-テトラメチルウロニウム(O-(1H-Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium)
TFA:トリフルオロ酢酸
Trt:トリチル基
(糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)の合成および糖鎖付加リンカー部分の切断評価)
生理活性物質の溶解性をさらに高めることができるリンカーを開発する目的で、水溶性の高い糖鎖をリンカーに付加した、糖鎖付加リンカーとペプチドとからなる新規化合物の合成を試みた。糖鎖としては、アシアロ糖鎖を用い、ペプチドとしてはケメリン9(Chemerin9)を用いた。アシアロ糖鎖付加リンカーとペプチドとからなる化合物(糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1(配列番号6))を、後述のように合成した。
糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)を合成するために、まず、糖鎖付加(Fmoc-Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物7)(配列番号5)を、以下のように合成した。
ESI-MS:(m/z)calcd for C149H201N19O64 [M+3H]3+ 1094.4、[M+4H]4+ 821.1、found 1094.4、821.1。
(糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)の合成)
ESI-MS:(m/z)calcd for C134H191N19O62 [M+3H]3+ 1020.4、[M+4H]4+ 765.6、found 1020.4、765.6。
(糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)の糖鎖付加リンカー部分の、水溶液中での切断評価)
(a.糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)の自己切断による無修飾ケメリン9の遊離生成)
続いて、上記のように得られた糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)における、糖鎖が付加したリンカー部分の、水溶液における自己触媒的な切断挙動を追跡した。以下に、その反応を示す。
凍結乾燥した糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)をPBS溶液(37℃、pH7.4、350μL)に溶解させた後、37℃で静置させてインキュベーションした。その後、一定の時間間隔で、糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)が溶解したPBS溶液(28μL)をサンプリングし、サンプリングした溶液に0.5%TFA水溶液(28μL)を加えた後、この溶液を凍結させた。得られた溶液をHPLC分析の直前に溶解させ、50μLをインジェクションして、HPLC[カラム:SHISEIDO CAPCELL PAK C18 UG-120(5μm)、φ4.6x250mm、流速:0.7mL/分、溶離液A:0.1%TFA水 溶離液B:0.09%TFA/10%水/90%アセトニトリル、グラジエントA:B=77:23→50:50(20分) 直線濃度勾配溶出]分析を行った。化合物の検出はダイオードアレイ検出器を用い、検出波長は220nmに設定した。HPLCクロマトグラムおよびESI-MSの解析から、時間経過とともに糖鎖付加リンカー部分の切断が進行し、無修飾のケメリン9(化合物3)(配列番号1)が遊離することを確認した(図1の矢印3で示されるピーク)。試験開始6時間後には、糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)はほとんど存在せず、無修飾のケメリン9(化合物3)が多く存在した。
6時間後、反応液のHPLC[カラム:SHISEIDO CAPCELL PAK C18 UG-120(5μm)、φ4.6x250mm、流速:0.7mL/分、溶離液A:0.1%TFA水 溶離液B:0.09%TFA/10%水/90%アセトニトリル、グラジエントA:B=95:5→95:5(8分) 次いでA:B=95:5→5:95(20分) 直線濃度勾配溶出]分析を行った。その結果、保持時間9.6分で糖鎖付加リンカー部分(化合物2)のピークが確認された。
化合物2のESI-MS:(m/z)calcd for C80H127N9O50[M+2H]2+ 1007.9、[M+3H]3+ 672.3、found 1007.9、672.2。
t1/2=ln2/k(kは直線プロットの傾き)
に代入することにより、出発物質(糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1))の消失半減期t1/2を算出した。消失半減期は、1.2時間であった。
次に、様々な温度(4℃、25℃、37℃)およびpH(pH4.0、pH7.4)条件下で、糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)における糖鎖付加リンカー部分の自己触媒的切断を観察した。
さらに、同じpHでの半減期を比較すると、温度が高いほど、糖鎖付加リンカー部分の切断が速いことを見出した(Entry 1、2、3の比較(pH4.0)、Entry 4、5、6の比較(pH7.4))。
これらの結果から、(i)温度、(ii)pHが高いほど、糖鎖付加リンカー部分の切断が促進されることを本発明者は発見した。
(糖鎖付加(Cys(GlcNAc)型)リンカー-ケメリン9コンジュゲート(化合物4)の合成)
ESI-MS:(m/z)calcd for C86H98N14O18S [M+2H]2+ 824.4、found 824.4。
ESI-MS:(m/z)calcd for C71H88N14O16S [M+2H]2+ 713.3、found 713.3。
ESI-MS:(m/z)calcd for C81H104N16O22S [M+2H]2+ 843.4、found 843.4。
(糖鎖付加(Cys(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物5)の合成)
実施例4における糖鎖付加(Cys(GlcNAc)型)リンカー-ケメリン9コンジュゲート(化合物4)の合成で用いたGlcNAcと2-ブロモアセトアミドとの脱水縮合物(化合物18)の代わりに、下記化学式:
ESI-MS:(m/z)calcd for C135H193N19O62S [M+2H]2+ 1553.1、[M+3H]3+ 1035.7、found 1553.2、1035.8。
(糖鎖付加(Cys(ジシアロ)型)リンカー-ケメリン9コンジュゲート(化合物6)の合成)
実施例4における糖鎖付加(Cys(GlcNAc)型)リンカー-ケメリン9コンジュゲート(化合物4)の合成で用いたGlcNAcと2-ブロモアセトアミドとの脱水縮合物(化合物18)の代わりに、下記化学式:
ESI-MS:(m/z)calcd for C157H227N21O78S [M+3H]3+ 1229.8、[M+4H]4+ 922.6、found 1229.8、922.6。
(糖鎖付加(Fmoc-Cys(ジシアロ)型)リンカー-ケメリン9コンジュゲート(化合物8)の合成)
実施例4の糖鎖付加(Cys(GlcNAc)型)リンカー-ケメリン9コンジュゲート(化合物4)の合成過程で得られた化合物16(0.4mg、0.24μmol)、および実施例6の糖鎖付加(Cys(ジシアロ)型)リンカー-ケメリン9コンジュゲート(化合物6)の合成においても用いたジシアロ糖鎖と2-ブロモアセトアミドとの脱水縮合物(化合物20)(0.9mg、0.38μmol)を7M グアニジン塩酸塩を含む0.2Mリン酸緩衝液(pH7.4、56μL)に溶解し、室温で2.5時間反応させた。反応溶液をHPLC[カラム:SHISEIDO CAPCELL PAK C18 UG-120(5μm)、φ4.6x250mm、流速:0.7mL/分、溶離液A:0.1%TFA水 溶離液B:0.09%TFA/10%水/90%アセトニトリル、グラジエントA:B=60:40→40:60(20分) 直線濃度勾配溶出]を用いて精製し、糖鎖付加(Fmoc-Cys(ジシアロ)型)リンカー-ケメリン9コンジュゲート(化合物8)(配列番号12)(0.9 mg、0.23 μmol、収率96%)を得た。
ESI-MS:(m/z)calcd for C172H237N21O80S [M+3H]3+ 1303.8、[M+4H]4+ 978.1、found 1308.8、978.1。
(糖鎖付加(Ac-Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物9)の合成)
ESI-MS:(m/z)calcd for C136H193N19O63 [M+2H]2+ 1551.1、[M+3H]3+ 1034.4、found 1551.1、1034.4。
(糖鎖付加(Asn(アシアロ)-テトラクロロフタロイル型)リンカー-ケメリン9コンジュゲート(化合物10)の合成)
実施例1に記載のように糖鎖付加(Fmoc-Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物7)を合成した後に、実施例2に記載のように糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)を合成する過程において、フタル酸無水物の代わりにテトラクロロフタル酸無水物を用いることにより、糖鎖付加(Asn(アシアロ)-テトラクロロフタロイル型)リンカー-ケメリン9コンジュゲート(化合物10)(配列番号14)を得た。
ESI-MS:(m/z)calcd for C134H187Cl4N19O62 [M+2H]2+ 1598.0、[M+3H]3+ 1065.7、found 1598.0、1065.7。
合成した糖鎖付加(Asn(アシアロ)-テトラクロロフタロイル型)リンカー-ケメリン9コンジュゲート(化合物10)の化学式を以下に示す。
式中、Rは以下の化学式を表す。
(合成した様々な糖鎖付加リンカー-ケメリン9コンジュゲートの切断評価)
上記実施例において合成した糖鎖付加リンカー-ケメリン9コンジュゲートの模式的構造を以下に示す。
Asn(asialo)型(1)は、糖鎖付加(Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物1)を表し、
Cys(GlcNAc)型(4)は、糖鎖付加(Cys(GlcNAc)型)リンカー-ケメリン9コンジュゲート(化合物4)を表し、
Cys(asialo)型(5)は、糖鎖付加(Cys(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物5)を表し、
Cys(disialo)型(6)は、糖鎖付加(Cys(ジシアロ)型)リンカー-ケメリン9コンジュゲート(化合物6)を表し、
Fmoc-Asn(asialo)型(7)は、糖鎖付加(Fmoc-Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物7)を表し、
Fmoc-Cys(disialo)型(8)は、糖鎖付加(Fmoc-Cys(ジシアロ)型)リンカー-ケメリン9コンジュゲート(化合物8)を表し、
Ac-Asn(asialo)型(9)は、糖鎖付加(Ac-Asn(アシアロ)型)リンカー-ケメリン9コンジュゲート(化合物9)を表し、
Asn(asialo)-テトラクロロフタロイル型(10)は、糖鎖付加(Asn(アシアロ)-テトラクロロフタロイル型)リンカー-ケメリン9コンジュゲート(化合物10)を表し、
(糖鎖付加リンカー-ケメリン9コンジュゲートの糖鎖付加リンカー部分の、エマルション中での切断評価)
抗原液をエマルションと混合させてワクチンとして生体に投与した場合、抗原が、ワクチン注射部位に残存する効果と、徐放効果とを期待することができる。そこで、本発明における糖鎖付加リンカー部分が水溶液のみならずエマルションにおいても、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩から自己切断するかを検討することにより、本発明の糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩が、ペプチドワクチン等の様々なワクチンの開発に応用できるかを検討した。水溶液から調製するエマルション中での、本発明の糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩の安定性を、以下のように、酢酸緩衝液の場合と比較した。
(糖鎖付加(Asn(アシアロ)型)リンカー-HER28-16コンジュゲート(化合物11)の合成、糖鎖付加リンカー部分の切断評価、および溶解度評価)
上述のように、本発明における糖鎖付加リンカー部分を有する生理活性物質誘導体は、エマルションの形態でも使用できることから、様々なワクチンの開発に利用できる。そこで、本発明者は、例示として、腫瘍抗原ペプチドとしても使用可能なHER28-16と糖鎖付加リンカーとのコンジュゲートを作成した。ここで、HER28-16(配列:RWGLLLALL)は、HER(ヒト上皮増殖因子受容体:Human Epidermal Growth Factor Receptor)ファミリーの1つであるHER2/neuタンパク質のアミノ酸配列のうち、8~16アミノ酸残基に相当するペプチドである。HER28-16は、コードHE1とも呼ばれ、HLA(ヒト白血球抗原分子:Human Leukocyte Antigen)の一つであるHLA-A24に結合能を有し、HLAを介した抗原提示により細胞傷害性T細胞(CTL)を誘導することが可能であることから、腫瘍ワクチン候補ペプチドとして同定されている(国際公開第2005/007694号パンフレット等を参照)。
本発明者は、以下の模式的構造を有する、アシアロ糖鎖付加リンカーとペプチドとからなる化合物(糖鎖付加(Asn(アシアロ)型)リンカー-HER28-16コンジュゲート(化合物11))を合成した。
ESI-MS:(m/z)calcd for C132H212N22O59 [M+2H]2+ 1525.7、[M+3H]3+ 1017.5、[M+4H]4+ 763.4、found 1525.7、1017.5、763.4。
続いて、得られた糖鎖付加(Asn(アシアロ)型)リンカー-HER28-16コンジュゲート(化合物11)における、糖鎖が付加したリンカー部分の、水溶液における自己触媒的な切断挙動を追跡した。
したがって、当業者であれば、表5~7の結果をも併せて鑑みることにより、本発明における糖鎖付加リンカー部分を有する生理活性物質は、温度および/またはpHに依存して、糖鎖付加リンカー部分が切断されることによって、無修飾の生理活性物質を生成させることが可能であることを理解する。
本発明における糖鎖付加リンカー部分を有する生理活性物質誘導体を用いた場合の、水溶性向上の効果を評価した。一例として、生理活性物質としてHER28-16を用いた。
ここで、糖鎖付加リンカー-HER28-16コンジュゲート(化合物11)の280nmにおけるモル吸光係数は、以下の方法で求めた。すなわち、化合物11の溶液を5本のチューブに等量ずつ分注し、凍結乾燥後、そのうちのチューブ3本を用いてアミノ酸組成分析を行うことでサンプル含量を求めた。また、前記5本のうちの1本のチューブに1mLの0.1%TFA水溶液を添加し、このときの糖鎖付加リンカー-HER28-16コンジュゲート(化合物11)の280nmの吸光度を測定した。この280nmの吸光度を、アミノ酸組成分析で求めた濃度で割ることにより求めた。その結果、糖鎖付加リンカー-HER28-16コンジュゲート(化合物11)の280nmにおけるモル吸光係数εMは5922となった。
HER28-16ペプチド(配列番号15)の280nmにおけるモル吸光係数εMは、以下の式を用いて算出した(C.N.Pace et al.,Prot.Sci.,1995, 4,2411-2423頁)。
εM = Trp×5500+Tyr×1490+Cystine×125[A280/mol/cm]
ここで、Trpはトリプトファン残基の数、Tyrはチロシン残基の数、Cystineはジスルフィド結合の数を表す。HER28-16ペプチド(アミノ酸配列:RWGLLLALL)はトリプトファン残基を1残基含むことから、280nmにおけるモル吸光係数εMは5500となった。
Claims (28)
- 糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩であって、
前記化合物は、下記式(A)で表わされ、
R1-X (A)
ここで、
R1は、糖鎖付加リンカー部分を意味し、
R1は、下記式(I)で表わされ、
[式(I)中、
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、Xへの結合部分を示す。]
Xは、生理活性物質部分を意味し、
前記生理活性物質は、少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有しており、
XのR1との結合は、当該少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基における結合である、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記R1は、下記式(I)で表わされる、
R2およびR3は、それらが結合している窒素原子と一緒になって3~7員の複素環を形成しており、
ここで、前記複素環は、アジリジン、アゼチジン、ピロリン、ピロール、イミダゾール、イミダゾリン、ピラゾール、ピラゾリン、イソオキサゾリン、チアゾリン、イソチアゾリン、チアジアゾリン、ピロリジン、イミダゾリジン、ピラゾリジン、オキサゾリジン、イソオキサゾリジン、チアゾリジン、イソチアゾリジン、チアジアゾリジン、ピペラジン、ピペリジン、モルホリン、チオモルホリン、チアジン、テトラゾール、トリアゾール、トリアゾリジン、テトラゾリジン、アゼパン、ジアゼパン、アゼピンおよびホモピペラジンからなる群から選択され、
前記複素環における少なくとも1つの水素原子は、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、当該置換は、当該「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」におけるアミノ酸またはポリペプチドの部分における結合であり、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、前記Xへの結合部分を示す。]
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記R1は、下記式(II)で表わされる、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリールを形成するか、あるいは、R5A、R5Bは、いずれも水素原子であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、シクロヘキシルまたはノルボルニルを形成し、
R6は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドであり、
波線は、前記Xへの結合部分を示す。]
化合物またはその塩。 - 請求項1~3のいずれか1項に記載の化合物またはその塩であって、
前記生理活性物質は、ペプチド部分を有しており、
前記Xの前記R1との結合は、
(1)前記生理活性物質の前記ペプチド部分のN末端のアミノ基におけるアミド結合、
(2)前記生理活性物質の前記ペプチド部分のセリン残基、スレオニン残基またはチロシン残基の側鎖に存在するヒドロキシ基におけるエステル結合(但し、前記生理活性物質の前記ペプチド部分が、セリン残基、スレオニン残基またはチロシン残基を有する場合に限る)、
(3)前記生理活性物質の前記ペプチド部分のアスパラギン酸残基またはグルタミン酸残基の側鎖に存在するカルボキシ基における酸無水物結合(但し、前記生理活性物質の前記ペプチド部分が、アスパラギン酸残基またはグルタミン酸残基を有する場合に限る)、
(4)前記生理活性物質の前記ペプチド部分のリシン残基、アスパラギン残基、アルギニン残基、ヒスチジン残基またはトリプトファン残基の側鎖に存在するアミノ基におけるアミド結合(但し、前記生理活性物質の前記ペプチド部分が、リシン残基、アスパラギン残基、アルギニン残基、ヒスチジン残基またはトリプトファン残基を有する場合に限る)、
(5)前記生理活性物質の前記ペプチド部分のシステイン残基の側鎖に存在するチオール基におけるチオエステル結合(但し、前記生理活性物質の前記ペプチド部分が、システイン残基を有する場合に限る)、
または、
(6)前記生理活性物質の前記ペプチド部分のC末端のカルボキシ基における酸無水物結合、
である、化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記R1は、下記式(III)で表わされ、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリールを形成するか、あるいは、R5A、R5Bは、いずれも水素原子であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、シクロヘキシルまたはノルボルニルを形成し、
R7は、-S-CH2-CONH-糖鎖または-CONH-糖鎖であり、
R8は、水素原子、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、Alloc基、カルバメート系保護基、糖鎖、アミノ酸、ポリペプチド、糖鎖付加アミノ酸、または糖鎖付加ポリペプチドであり、
波線は、Xへの結合部分を示す。]
前記生理活性物質は、少なくとも1つのアミノ基を有しており、
前記Xの前記R1との結合は、当該少なくとも1つのアミノ基における結合である、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記R1は、下記式(IV)で表わされ、
R4は、それぞれ独立し
て、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
R7は、-S-CH2-CONH-糖鎖または-CONH-糖鎖であり、
R8は、水素原子、炭素数1~16のアシル基、Fmoc基、Boc基、Z基、Troc基、Alloc基、カルバメート系保護基、糖鎖、アミノ酸、ポリペプチド、糖鎖付加アミノ酸または糖鎖付加ポリペプチドであり、
R9は、それぞれ独立に、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基またはアミノ基であり、
波線は、Xへの結合部分を示す。]
前記生理活性物質は、少なくとも1つのアミノ基を有しており、
前記Xの前記R1との結合は、当該少なくとも1つのアミノ基における結合である、
化合物またはその塩。 - 請求項6に記載の化合物またはその塩であって、
4つの前記R4は、いずれも水素原子である、
化合物またはその塩。 - 請求項6または7に記載の化合物またはその塩であって、
少なくとも1つの前記R9は、ハロゲンである、
化合物またはその塩。 - 請求項6または7に記載の化合物またはその塩であって、
4つの前記R9は、いずれも塩素である、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」において、糖鎖は、アミノ酸またはポリペプチドにおける、AsnまたはCysに結合している、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記「糖鎖付加アミノ酸または糖鎖付加ポリペプチド」において、糖鎖は、アミノ酸またはポリペプチドと、リンカーを介することなく結合している、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記「糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチド」における糖鎖は、4個以上の糖残基からなる、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記「糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチド」における糖鎖は、2本鎖複合型糖鎖、3本鎖複合型糖鎖、または4本鎖複合型糖鎖である、
化合物またはその塩。 - 請求項13に記載の化合物またはその塩であって、
前記糖鎖が、ジシアロ糖鎖、モノシアロ糖鎖、アシアロ糖鎖、ジグルクナック糖鎖およびジマンノース糖鎖からなる群から選択される2本鎖複合型糖鎖である、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記生理活性物質は、低分子生理活性物質または生体高分子である、
化合物またはその塩。 - 請求項16に記載の化合物またはその塩であって、
前記生体高分子は、タンパク質、ポリペプチド、ポリヌクレオチド、およびペプチド核酸からなる群より選択される、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
無修飾の生理活性物質と比較して、向上した水溶性を有する、
化合物またはその塩。 - 請求項18に記載の化合物またはその塩であって、
前記向上した水溶性が、モル濃度において、前記「無修飾の生理活性物質」と比較して、10~1,000,000倍である、
化合物またはその塩。 - 請求項1に記載の化合物またはその塩であって、
前記糖鎖付加リンカー部分がpHおよび/または温度に依存して自己触媒的に切断される、
化合物またはその塩。 - 請求項1~20のいずれか1項に記載の化合物またはその塩を含む組成物であって、
前記化合物又はその塩における糖鎖は、実質的に均一である、
組成物。 - 医薬組成物であって、
(I)請求項1~20のいずれか1項に記載の化合物またはその塩、および
(II)薬理学的に許容される担体
を含む、
医薬組成物。 - 請求項22に記載の医薬組成物であって、
前記生理活性物質は、対象に投与後に速やかに活性を発揮する、
医薬組成物。 - 請求項22または23に記載の医薬組成物であって、
ワクチン接種に用いられる、
医薬組成物。 - 糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩の製造方法であって、
ここで、前記生理活性物質は、少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有するペプチド部分を含んでおり、
以下のステップ、
(a)固相合成法により、樹脂上に前記ペプチド部分を合成するステップと、
(b)ステップ(a)で合成された前記ペプチド部分における前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」に、下記式(I’)で表わされるリンカー部分を結合させるステップと、
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、前記ペプチド部分の前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」との結合部分を示す。]
(c)ステップ(b)により、前記ペプチド部分の前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」に結合された前記リンカー部分のR2またはR3における前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子を、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換するステップ
を含む、
製造方法。 - 糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩の製造方法であって、
ここで、前記生理活性物質は、少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有するペプチド部分を含んでおり、
前記ペプチド部分における前記「アミノ基、ヒドロキシ基、チオール基、またはカルボキシ基」に、下記式(I’’)で表わされる糖鎖付加リンカーを脱水縮合により結合させる製造方法。
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成する。] - 請求項25または26に記載の製造方法により得られうる、化合物またはその塩。
- 少なくとも1つのアミノ基、ヒドロキシ基、チオール基、またはカルボキシ基を有する生理活性物質との結合用の、糖鎖付加リンカーであって、
前記糖鎖付加リンカーは、下記式(B)で表され、
R1-L (B)
ここで、
R1は、糖鎖付加リンカー部分を意味し、
R1は、下記式(I)で表わされ、
R2およびR3は、それぞれ独立して、水素原子、炭素数1~16のアルキル基、または、炭素数5~16のアリール基であり(ただし、R2およびR3の両方が、同時に、水素原子とはならない)、または、R2およびR3はそれらが結合している窒素原子と一緒になって、3~7員の複素環を形成し、
前記アルキル基、前記アリール基、または前記複素環における少なくとも1つの水素原子は、糖鎖、糖鎖付加アミノ酸または糖鎖付加ポリペプチドによって置換されており、
R4は、それぞれ独立して、水素原子、炭素数1~16のアルキル基または炭素数5~16のアリール基であり、
Yは、
ここで、
R5A、R5Bは、R5Aが結合する炭素原子、R5Bが結合する炭素原子と一緒になって、炭素数5~16のアリール、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、炭素数6~14のキノン、または5~10員の複素環を形成するか、あるいは、R5A、R5Bは、それぞれ独立して、水素原子、ハロゲン、シアノ基、炭素数1~4のアルキル基、炭素数1~4のアルコキシ基、ニトロ基、メシル基、トシル基、炭素数1~3のアシル基、ヒドロキシ基、カルボキシ基、アミノ基、置換または非置換のフェニル基、ベンジル基であり、
R5C、R5Dは、R5Cが結合する炭素原子、R5Dが結合する炭素原子と一緒になって、炭素数4~16のシクロアルキル、炭素数5~16のシクロアルケニル、炭素数7~13のビシクリル、炭素数9~14のトリシクリル、または5~10員の複素環を形成し、
波線は、Lへの結合部分を示す。]
Lは、脱離基を意味する、
糖鎖付加リンカー。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014548498A JP6211533B2 (ja) | 2012-11-22 | 2013-10-30 | 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法 |
US14/646,295 US9708413B2 (en) | 2012-11-22 | 2013-10-30 | Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof |
DK13857593.1T DK2924053T3 (da) | 2012-11-22 | 2013-10-30 | Glycosyleret linker, forbindelse, der indeholder glycosyleret linker-del og fysiologisk aktiv stofdel eller salt deraf, og fremgangsmåder til fremstilling af forbindelsen eller saltet deraf |
KR1020157015751A KR102227918B1 (ko) | 2012-11-22 | 2013-10-30 | 당쇄 부가 링커, 당쇄 부가 링커 부분과 생리 활성 물질 부분을 함유하는 화합물 또는 그의 염, 및 이들의 제조 방법 |
CN201380070699.2A CN104918962B (zh) | 2012-11-22 | 2013-10-30 | 糖链加成连接基团、含有糖链加成连接基团部分与生理活性物质部分的化合物或其盐、及其制造方法 |
EP13857593.1A EP2924053B1 (en) | 2012-11-22 | 2013-10-30 | Glycosylated linker, compound containing glycosylated linker moiety and physiologically active substance moiety or salt thereof, and methods for producing said compound or salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012256947 | 2012-11-22 | ||
JP2012-256947 | 2012-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014080730A1 true WO2014080730A1 (ja) | 2014-05-30 |
Family
ID=50775917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/079408 WO2014080730A1 (ja) | 2012-11-22 | 2013-10-30 | 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9708413B2 (ja) |
EP (1) | EP2924053B1 (ja) |
JP (1) | JP6211533B2 (ja) |
KR (1) | KR102227918B1 (ja) |
CN (1) | CN104918962B (ja) |
DK (1) | DK2924053T3 (ja) |
TW (1) | TWI634127B (ja) |
WO (1) | WO2014080730A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019182015A1 (ja) * | 2018-03-22 | 2019-09-26 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
JP2020152680A (ja) * | 2019-03-20 | 2020-09-24 | 国立大学法人東北大学 | 新規オピオイドペプチド、その糖鎖付加体及びそれらを含む医薬組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI660741B (zh) | 2015-11-03 | 2019-06-01 | 財團法人工業技術研究院 | 抗體藥物複合物及其製造方法 |
CN113501889A (zh) * | 2021-07-06 | 2021-10-15 | 郑州大学 | 一种三七多糖阳离子衍生物的制备方法及其应用 |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0476001A (ja) * | 1990-07-19 | 1992-03-10 | Shizuoka Univ | 機能化高分子の合成方法 |
JPH0539306A (ja) * | 1990-12-14 | 1993-02-19 | D D S Kenkyusho:Kk | ヒアルロン酸およびコンドロイチン誘導体 |
JPH0680705A (ja) * | 1992-09-02 | 1994-03-22 | D D S Kenkyusho:Kk | ヘパリン誘導体 |
JP2001509144A (ja) * | 1996-12-16 | 2001-07-10 | デ・シュタート・デア・ネーダーランデン、フェルテゲンウールディクト・ドール・デ・ミニスター・バン・ベルツィン、フォルクスゲゾンドハイド・エン・カルツール | 多糖類をタンパクに結合する方法 |
JP2001302695A (ja) | 2000-04-20 | 2001-10-31 | Asahi Kasei Corp | Gln結合型糖鎖付加カルシトニン誘導体 |
WO2003008431A1 (fr) | 2001-06-19 | 2003-01-30 | Otsuka Chemical Co.,Ltd. | Methode de production d'un derive d'asparagine de chaines des sucres |
US20030096299A1 (en) | 2001-07-09 | 2003-05-22 | Valerie Wittamer | Natural ligand of G protein coupled receptor ChemR23 and uses thereof |
WO2004005330A1 (ja) | 2002-07-05 | 2004-01-15 | Otsuka Chemical Co., Ltd. | 糖鎖アスパラギンを有する糖ペプチドの製造法及び該糖ペプチド |
WO2004008431A1 (en) | 2000-04-28 | 2004-01-22 | Labarbera Anthony L | System for generating percussion sounds from stringed instruments |
WO2004058824A1 (ja) | 2002-12-26 | 2004-07-15 | Otsuka Chemical Co., Ltd. | 3分岐型糖鎖アスパラギン誘導体、該糖鎖アスパラギン、該糖鎖およびそれらの製造方法 |
WO2004058984A1 (ja) | 2002-12-24 | 2004-07-15 | Otsuka Chemical Co., Ltd. | 糖鎖アスパラギン誘導体、糖鎖アスパラギンおよび糖鎖ならびにそれらの製造法 |
WO2004070046A1 (ja) | 2003-02-04 | 2004-08-19 | Otsuka Chemical Co., Ltd. | 糖鎖アスパラギン誘導体の製造方法 |
WO2005007694A1 (ja) | 2003-07-16 | 2005-01-27 | Green Peptide Co., Ltd. | HER2/neuペプチドおよびその治療上の用途 |
WO2005010053A1 (ja) | 2003-07-28 | 2005-02-03 | Otsuka Chemical Co., Ltd. | アミノ化複合型糖鎖誘導体及びその製造方法 |
WO2005095331A1 (ja) | 2004-03-31 | 2005-10-13 | Shionogi & Co., Ltd. | 糖鎖-ペプチド結合剤 |
WO2006095775A1 (ja) * | 2005-03-08 | 2006-09-14 | Chugai Seiyaku Kabushiki Kaisha | 水溶性ヒアルロン酸修飾物とglp-1アナログの結合体 |
WO2007011055A1 (ja) | 2005-07-19 | 2007-01-25 | Otsuka Chemical Co., Ltd. | 糖鎖誘導体の製造方法、構造解析方法、及び糖鎖誘導体 |
JP2007501870A (ja) * | 2003-08-08 | 2007-02-01 | フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒドロキシアルキルデンプンとg−csfの複合体 |
JP2007528354A (ja) | 2003-04-08 | 2007-10-11 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的peg化薬物 |
JP2007530569A (ja) | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | 化学修飾タンパク質組成物及び方法 |
WO2008155900A1 (ja) * | 2007-06-19 | 2008-12-24 | Otsuka Chemical Co., Ltd. | 糖鎖付加glp-1ペプチド |
WO2009095479A2 (en) | 2008-02-01 | 2009-08-06 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
JP2009242372A (ja) | 2008-03-11 | 2009-10-22 | Yokohama City Univ | 均一な糖鎖構造を有するエリスロポエチン誘導体 |
WO2009153960A1 (ja) | 2008-06-17 | 2009-12-23 | 大塚化学株式会社 | 糖鎖付加glp-1ペプチド |
WO2010021126A1 (ja) | 2008-08-19 | 2010-02-25 | 大塚化学株式会社 | 糖タンパク質の製造方法及びスクリーニング方法 |
JP2010229093A (ja) | 2009-03-27 | 2010-10-14 | Banyu Pharmaceut Co Ltd | 新規ChemerinRアゴニスト |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005005436A2 (en) | 2003-07-11 | 2005-01-20 | Theravance, Inc. | Cross-linked glycopeptide-cephalosporin antibiotics |
CN1832762B (zh) * | 2003-08-08 | 2012-09-05 | 弗雷泽纽斯卡比德国有限公司 | 羟烷基淀粉与g-csf的偶联物 |
CN1310898C (zh) | 2004-01-19 | 2007-04-18 | 中国人民解放军军事医学科学院毒物药物研究所 | 紫杉醇水溶性衍生物 |
BR112012011467A2 (pt) * | 2009-10-30 | 2019-09-24 | Otsuka Chemical Co Ltd | forma glicosilada de análogo ao glp-1 antigênico. |
-
2013
- 2013-10-30 CN CN201380070699.2A patent/CN104918962B/zh active Active
- 2013-10-30 WO PCT/JP2013/079408 patent/WO2014080730A1/ja active Application Filing
- 2013-10-30 DK DK13857593.1T patent/DK2924053T3/da active
- 2013-10-30 JP JP2014548498A patent/JP6211533B2/ja active Active
- 2013-10-30 KR KR1020157015751A patent/KR102227918B1/ko active IP Right Grant
- 2013-10-30 US US14/646,295 patent/US9708413B2/en active Active
- 2013-10-30 EP EP13857593.1A patent/EP2924053B1/en active Active
- 2013-11-20 TW TW102142224A patent/TWI634127B/zh active
Patent Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0476001A (ja) * | 1990-07-19 | 1992-03-10 | Shizuoka Univ | 機能化高分子の合成方法 |
JPH0539306A (ja) * | 1990-12-14 | 1993-02-19 | D D S Kenkyusho:Kk | ヒアルロン酸およびコンドロイチン誘導体 |
JPH0680705A (ja) * | 1992-09-02 | 1994-03-22 | D D S Kenkyusho:Kk | ヘパリン誘導体 |
JP2001509144A (ja) * | 1996-12-16 | 2001-07-10 | デ・シュタート・デア・ネーダーランデン、フェルテゲンウールディクト・ドール・デ・ミニスター・バン・ベルツィン、フォルクスゲゾンドハイド・エン・カルツール | 多糖類をタンパクに結合する方法 |
JP2001302695A (ja) | 2000-04-20 | 2001-10-31 | Asahi Kasei Corp | Gln結合型糖鎖付加カルシトニン誘導体 |
WO2004008431A1 (en) | 2000-04-28 | 2004-01-22 | Labarbera Anthony L | System for generating percussion sounds from stringed instruments |
WO2003008431A1 (fr) | 2001-06-19 | 2003-01-30 | Otsuka Chemical Co.,Ltd. | Methode de production d'un derive d'asparagine de chaines des sucres |
US20030096299A1 (en) | 2001-07-09 | 2003-05-22 | Valerie Wittamer | Natural ligand of G protein coupled receptor ChemR23 and uses thereof |
WO2004005330A1 (ja) | 2002-07-05 | 2004-01-15 | Otsuka Chemical Co., Ltd. | 糖鎖アスパラギンを有する糖ペプチドの製造法及び該糖ペプチド |
WO2004058984A1 (ja) | 2002-12-24 | 2004-07-15 | Otsuka Chemical Co., Ltd. | 糖鎖アスパラギン誘導体、糖鎖アスパラギンおよび糖鎖ならびにそれらの製造法 |
WO2004058824A1 (ja) | 2002-12-26 | 2004-07-15 | Otsuka Chemical Co., Ltd. | 3分岐型糖鎖アスパラギン誘導体、該糖鎖アスパラギン、該糖鎖およびそれらの製造方法 |
WO2004070046A1 (ja) | 2003-02-04 | 2004-08-19 | Otsuka Chemical Co., Ltd. | 糖鎖アスパラギン誘導体の製造方法 |
JP2007528354A (ja) | 2003-04-08 | 2007-10-11 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的peg化薬物 |
WO2005007694A1 (ja) | 2003-07-16 | 2005-01-27 | Green Peptide Co., Ltd. | HER2/neuペプチドおよびその治療上の用途 |
US20070060543A1 (en) | 2003-07-28 | 2007-03-15 | Yasuhiro Kajihara | Aminated complex-type sugar chain derivatives and process for the production thereof |
WO2005010053A1 (ja) | 2003-07-28 | 2005-02-03 | Otsuka Chemical Co., Ltd. | アミノ化複合型糖鎖誘導体及びその製造方法 |
JP2007501870A (ja) * | 2003-08-08 | 2007-02-01 | フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒドロキシアルキルデンプンとg−csfの複合体 |
JP2007530569A (ja) | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | 化学修飾タンパク質組成物及び方法 |
WO2005095331A1 (ja) | 2004-03-31 | 2005-10-13 | Shionogi & Co., Ltd. | 糖鎖-ペプチド結合剤 |
WO2006095775A1 (ja) * | 2005-03-08 | 2006-09-14 | Chugai Seiyaku Kabushiki Kaisha | 水溶性ヒアルロン酸修飾物とglp-1アナログの結合体 |
WO2007011055A1 (ja) | 2005-07-19 | 2007-01-25 | Otsuka Chemical Co., Ltd. | 糖鎖誘導体の製造方法、構造解析方法、及び糖鎖誘導体 |
WO2008155900A1 (ja) * | 2007-06-19 | 2008-12-24 | Otsuka Chemical Co., Ltd. | 糖鎖付加glp-1ペプチド |
WO2009095479A2 (en) | 2008-02-01 | 2009-08-06 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
JP2011510954A (ja) * | 2008-02-01 | 2011-04-07 | アセンディス ファーマ エーエス | 自己切断可能なリンカーを含むプロドラッグ |
JP2009242372A (ja) | 2008-03-11 | 2009-10-22 | Yokohama City Univ | 均一な糖鎖構造を有するエリスロポエチン誘導体 |
WO2009153960A1 (ja) | 2008-06-17 | 2009-12-23 | 大塚化学株式会社 | 糖鎖付加glp-1ペプチド |
WO2010021126A1 (ja) | 2008-08-19 | 2010-02-25 | 大塚化学株式会社 | 糖タンパク質の製造方法及びスクリーニング方法 |
JP2010229093A (ja) | 2009-03-27 | 2010-10-14 | Banyu Pharmaceut Co Ltd | 新規ChemerinRアゴニスト |
Non-Patent Citations (7)
Title |
---|
BARRY BYRNE ET AL., DRUG DISCOVERY TODAY, vol. 12, 2007, pages 319 - 326 |
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1526, 2001, pages 242 - 248 |
BIOCONJUGATE CHEM., vol. 18, 2007, pages 1869 - 1878 |
C.N. PACE ET AL., PROT. SCI., vol. 4, 1995, pages 2411 - 2423 |
CHEM. PHARM. BULL., vol. 56, 2008, pages 1515 - 1520 |
FEBS LETTERS, vol. 50, no. 3, February 1975 (1975-02-01) |
See also references of EP2924053A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019182015A1 (ja) * | 2018-03-22 | 2019-09-26 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
JPWO2019182015A1 (ja) * | 2018-03-22 | 2021-03-11 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
JP7404228B2 (ja) | 2018-03-22 | 2023-12-25 | 持田製薬株式会社 | 非ステロイド性抗炎症性化合物結合アルギン酸誘導体 |
JP2020152680A (ja) * | 2019-03-20 | 2020-09-24 | 国立大学法人東北大学 | 新規オピオイドペプチド、その糖鎖付加体及びそれらを含む医薬組成物 |
JP7437578B2 (ja) | 2019-03-20 | 2024-02-26 | 国立大学法人東北大学 | 新規オピオイドペプチド、その糖鎖付加体及びそれらを含む医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN104918962B (zh) | 2017-12-19 |
KR102227918B1 (ko) | 2021-03-15 |
KR20150102003A (ko) | 2015-09-04 |
JP6211533B2 (ja) | 2017-10-11 |
EP2924053A4 (en) | 2016-08-24 |
US9708413B2 (en) | 2017-07-18 |
CN104918962A (zh) | 2015-09-16 |
TWI634127B (zh) | 2018-09-01 |
JPWO2014080730A1 (ja) | 2017-01-05 |
DK2924053T3 (da) | 2020-12-14 |
US20150299337A1 (en) | 2015-10-22 |
EP2924053A1 (en) | 2015-09-30 |
TW201427999A (zh) | 2014-07-16 |
EP2924053B1 (en) | 2020-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6684396B2 (ja) | インスリン抵抗性のための改善されたペプチドの調合薬 | |
JP6883912B2 (ja) | 改善されたペプチド製剤 | |
RU2676324C2 (ru) | Пролекарство, содержащее саморасщепляемый линкер | |
ES2590679T3 (es) | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre | |
JP6219308B2 (ja) | 糖鎖付加リンカー、糖鎖付加リンカーと生理活性物質とを含む化合物またはその塩、及びそれらの製造方法 | |
KR101324828B1 (ko) | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 | |
JP6211533B2 (ja) | 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法 | |
ES2856055T3 (es) | Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre | |
CN113264994A (zh) | 针对胰岛素抵抗的改良肽药物 | |
US10053499B2 (en) | Polypeptide having sialylated sugar chains attached thereto | |
RU2798085C2 (ru) | Пролекарство, содержащее саморасщепляемый линкер | |
RU2798085C9 (ru) | Пролекарство, содержащее саморасщепляемый линкер | |
KR20070017494A (ko) | 펩티드의 트랜스글루타미나아제 매개된 접합 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13857593 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014548498 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14646295 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013857593 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157015751 Country of ref document: KR Kind code of ref document: A |